Appendix A: Peer reviewed literature search strategies

Four peer reviewed literature databases were searched in this exercise: Medline, EMBASE, PubMed and Biomed Central.

Listed below are the different literature and search strategies and terminologies used for each of the different databases. Because different databases use different terminologies and require searching in different ways it was necessary to develop search strategies for each database.

These searches were developed in close consultation with a specialist drug and alcohol archivist and with a generalist university librarian with expertise across all the databases searched.

A.1 Medline Search Strategy

A.1.1 Medline search terms

'key-words' in regular type, 'MESH' (Medical subject heading) terms in **bold**

Search 1. Injecting Drug Use
IDU OR IDUs OR "injecting drug" OR "intravenous drug" OR "intravenous substance" OR "injecting substance" OR **exp substance abuse, intravenous/**

Search 2. Drugs and drug use
heroin OR cocaine OR amphetamine$ OR methamphetamine$ OR opioid$ OR opium OR opiate OR drug abuse OR drug use$ OR drug misuse OR drug dependenc$ OR substance abuse OR substance use$ OR substance misuse OR substance dependenc$ OR addict$ .mp. [mp=title, original title, abstract, name of substance word, subject heading word]OR **exp designer drugs/ or exp street drugs/ or exp Cocaine/ or exp crack cocaine/ or exp amphetamines/ or exp amphetamine/ or exp methamphetamine/ or exp Opium/ or exp Heroin/ or exp substance-related disorders/ or exp amphetamine-related disorders/ or exp cocaine-related disorders/ or exp opioid-related disorders/ or exp heroin dependence/ or exp morphine dependence/ or exp psychoses, substance-induced/**

Search 3. HIV/AIDS
(HIV or AIDS).mp. or HIV/aids or "Human Immunodeficiency Virus".mp. or "Human Immune Deficiency Virus".mp. or "Acquired Immunodeficiency Syndrome".mp. or "Acquired Immune Deficiency Syndrome".mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp HIV/ or exp HIV-1/ or exp HIV-2/ or exp HIV infections/ or exp acquired immunodeficiency syndrome/ or HIV seropositivity/ or exp HIV seroprevalence/ or exp AIDS serodiagnosis/**

Search 4. Epidemiology

"prevalence" OR "incidence" OR "epidemiolog$" OR "data collection" Or "Survey" OR "surveillance" OR "screening" OR "seroprevalence" OR "cohort" OR "population study" OR "population sample" OR "population survey" OR "population surveillance" OR "community sample" OR "RAR" OR "rapid assessment" OR "situation$ assessment" OR "statistics" **or exp epidemiologic methods/ or exp contact tracing/ or exp data collection/ or exp health surveys/ or exp health care surveys/ or exp interviews[1]/ or exp narration/ or exp questionnaires/ or exp records[2]/ or exp registries/ or exp disease notification/ or exp sentinel surveillance/ or exp epidemiologic studies/ or exp cohort studies/ or exp longitudinal studies/ or exp follow-up studies/ or exp prospective studies/ or exp cross-sectional studies/ or exp seroepidemiologic studies/ or exp hiv seroprevalence/ or exp sampling studies/ or exp focus groups/ or exp delphi technique/**

Search 5. South East Asia

(south east asia or borneo or brunei darussalam or cambodia or east timor or indonesia or laos or mekong valley or myanmar or philippines or singapore or thailand or vietnam).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp asia, southeastern/ or exp borneo/ or exp brunei/ or exp cambodia/ or exp east timor/ or exp indonesia/ or exp laos/ or exp malaysia/ or exp mekong valley/ or exp myanmar/ or exp philippines/ or exp singapore/ or exp thailand/ or exp vietnam/**

Search 6. Middle East

(middle east or afghanistan or bahrain or iran or iraq or israel or jordan or kuwait or lebanon or oman or qatar or saudi arabia or syria or turkey or united arab emirates or yemen).mp. [mp=title, original title, abstract, name of substance word, subject heading word] **or exp middle east/ or exp afghanistan/ or exp bahrain/ or exp iran/ or exp iraq/ or exp israel/ or exp jordan/ or exp kuwait/ or exp lebanon/ or exp oman/ or exp qatar/ or exp saudi arabia/ or exp syria/ or exp turkey/ or exp united arab emirates/ or exp yemen/**

Search 7. Eastern Europe

(eastern europe or albania or estonia or latvia or lithuania or bosnia or herzegovina or bulgaria or belarus or byelarus or croatia or czech republic or hungary or macedonia or montenegro or serbia or moldova or poland or romania or russia or russian or slovakia or slovenia or ukraine or yugoslavia).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp europe, eastern/ or exp albania/ or exp baltic states/ or exp estonia/ or exp latvia/ or exp lithuania/ or exp bosnia-herzegovina/ or exp bulgaria/ or exp byelarus/ or exp croatia/ or exp czech republic/ or exp hungary/ or exp "macedonia (republic)"/ or exp moldova/ or exp poland/ or exp romania/ or exp russia/ or exp bashkiria/ or exp dagestan/ or exp moscow/ or exp siberia/ or exp slovakia/ or exp slovenia/ or exp ukraine/ or exp yugoslavia/**

Search 8. Central Asia

(central asia or kazakhstan or kyrgzstan or tajikstan or turkmenistan or uzbekistan).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp asia, central/ or exp kazakhstan/ or exp kyrgyzstan/ or exp tajikistan/ or exp turkmenistan/ or exp uzbekistan/**

---

[1] Note: Medline has recently expanded the MESH term for *interviews*. *Interview, psychological* is now the recommended MESH term.

[2] Note: Medline has recently expanded the MESH term for *records*. *Medical records* is now the recommended MESH term.

Search 9. Oceania

(oceania or australia or "new zealand" or "pacific islands" or melanesia or fiji or "new Caledonia" or "papua new guinea" or vanuatu or Micronesia or guam or palau or polynesia or hawaii or pitcairn island or samoa or tonga).mp. [mp=title, original title, abstract] or **exp oceania/ or exp australasia/ or exp australia/ or exp pacific islands/ or exp melanesia/ or exp fiji/ or exp new caledonia/ or exp papua new guinea/ or exp vanuatu/ or exp micronesia/ or exp guam/ or exp palau/ or exp new zealand/ or exp polynesia/ or exp hawaii/ or exp pitcairn island/ or exp samoa/ or exp tonga/**

Search 10. East Asia

(far east or east asia or china or japan or north korea or south korea or mongolia or taiwan).mp. [mp=title, original title, abstract] or **exp far east/ or exp china/ or exp hong kong/ or exp tibet/ or exp japan/ or exp tokyo/ or exp korea/ or exp macao/ or exp mongolia/ or exp taiwan/**

Search 11. Europe

(europe or andorra or austria or belgium or finland or france or germany or gibraltar or great britain or united kingdom or channel islands or england or hebrides or northern ireland or scotland or wales or greece or iceland or ireland or italy or sicily or liechtenstein or luxembourg or monaco or netherlands or portugal or san marino or spain or switzerland or vatican city).mp. [mp=title, original title, abstract] or **exp europe/ or exp andorra/ or exp austria/ or exp belgium/ or exp finland/ or exp france/ or exp paris/ or exp germany/ or exp berlin/ or exp germany, east/ or exp germany, west/ or exp gibraltar/ or exp great britain/ or exp channel islands/ or exp england/ or exp london/ or exp hebrides/ or exp northern ireland/ or exp scotland/ or exp wales/ or exp greece/ or exp iceland/ or exp ireland/ or exp italy/ or exp rome/ or exp sicily/ or exp liechtenstein/ or exp luxembourg/ or exp mediterranean region/ or exp mediterranean islands/ or exp cyprus/ or exp malta/ or exp monaco/ or exp netherlands/ or exp portugal/ or exp san marino/ or exp spain/ or exp switzerland/ or exp transcaucasia/ or exp vatican city/**

Search 12. Transcaucasia

(transcaucasia or armenia or azerbaijan or georgia republic).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp transcaucasia/ or exp armenia/ or exp azerbaijan/ or exp "georgia (republic)"/**

Search 13. Sub-Saharan Africa

(sub-saharan africa, or sub sahar$ africa or central or cameroon or central african republic or chad or congo or " democratic republic of the congo" or equatorial guinea or gabon or eastern africa or burundi or djibouti or eritrea or ethiopia or kenya or rwanda or somalia or sudan or tanzania or uganda or south$ africa or angola or botswana or lesotho or malawi or mozambique or namibia or south africa or swaziland or zambia or zimbabwe or africa, western or benin or burkina faso or cote d'ivoire or gambia or ghana or guinea or guinea-bissau or liberia or mali or mauritania or niger or nigeria or senegal or sierra leone or togo or tuvalu or uganda or zambia or Zimbabwe).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp "africa south of the sahara"/ or exp africa, central/ or exp cameroon/ or exp central african republic/ or exp chad/ or exp congo/ or exp "democratic republic of the congo"/ or exp equatorial guinea/ or exp gabon/ or exp africa, eastern/ or exp burundi/ or exp djibouti/ or exp eritrea/ or exp ethiopia/ or exp kenya/ or exp rwanda/ or exp somalia/ or exp sudan/ or exp tanzania/ or exp uganda/ or exp africa, southern/ or exp angola/ or exp botswana/ or exp lesotho/ or exp malawi/ or exp mozambique/ or exp namibia/ or exp south africa/ or exp swaziland/ or exp zambia/ or exp zimbabwe/ or exp africa, western/ or exp benin/ or exp burkina faso/ or exp cote d'ivoire/ or exp gambia/ or exp ghana/ or exp guinea/ or exp guinea-bissau/ or exp liberia/ or exp mali/ or exp mauritania/ or exp niger/ or exp nigeria/ or exp senegal/ or exp sierra leone/ or exp togo/ or exp tuvalu/ or exp uganda/ or exp zambia/ or exp zimbabwe/**

Search 14. Western Asia

("western asia" OR bangladesh OR bhutan OR india OR nepal OR pakistan OR "sri lanka").mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp asia, western/ or exp bangladesh/ or exp bhutan/ or exp india/ or exp sikkim/ or exp nepal/ or exp pakistan/ or exp sri lanka/**

Search 15. Scandinavia

(scandinavia OR denmark OR norway OR sweden).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp scandinavia/ or exp denmark/ or exp norway/ or exp svalbard/ or exp sweden/**

Search 16. Mediterranean

(mediterranean OR cyprus OR malta OR sicily).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp mediterranean region/ or exp mediterranean islands/ or exp cyprus/ or exp malta/ or exp sicily/**

Search 17. Caribbean

(caribbean OR antigua OR barbuda OR bahamas OR barbados OR cuba OR "dominican republic" OR grenada OR guadeloupe OR haiti OR jamaica OR martinique OR "netherland antilles" OR "puerto rico" OR "saint kitts" OR nevis OR "saint lucia" OR "saint vincent" OR "the grenadines" OR "saint vincent and the grenadines" OR trinidad OR tobago OR "virgin islands").mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp caribbean region/ or exp west indies/ or exp antigua/ or exp bahamas/ or exp barbados/ or exp cuba/ or exp dominica/ or exp dominican republic/ or exp grenada/ or exp guadeloupe/ or exp haiti/ or exp jamaica/ or exp martinique/ or exp netherlands antilles/ or exp puerto rico/ or exp "saint kitts and nevis"/ or exp saint lucia/ or exp "saint vincent and the grenadines"/ or exp "trinidad and tobago"/ or exp "virgin islands of the united states"/**

Search 18. South America

("south america" OR argentina OR bolivia OR brazil OR chile OR columbia OR

ecuador OR "french guiana" OR guyana OR paraguay OR peru OR suriname OR uraguay OR venezuela).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp south america/ or exp argentina/ or exp bolivia/ or exp brazil/ or exp chile/ or exp colombia/ or exp ecuador/ or exp french guiana/ or exp guyana/ or exp paraguay/ or exp peru/ or exp suriname/ or exp uruguay/ or exp venezuela/**

Search 19. Central America

("central america" OR bellize OR "costa rica" OR ecuador OR "el salvador" OR guatemala OR honduras OR nicaragua OR panama).mp. [mp=title, original title, abstract] or **exp central america/ or exp belize/ or exp costa rica/ or exp el salvador/ or exp guatemala/ or exp honduras/ or exp nicaragua/ or exp panama/ or exp panama canal zone/**

Search 20. North America

("north america" OR canada OR greenland OR mexico OR "united states").mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp north america/ or exp canada/ or exp alberta/ or exp british columbia/ or exp manitoba/ or exp new brunswick/ or exp newfoundland/ or exp northwest territories/ or exp nova scotia/ or exp nunavut/ or exp ontario/ or exp prince edward island/ or exp quebec/ or exp saskatchewan/ or exp yukon territory/ or exp greenland/ or exp mexico/ or exp united states/ or exp appalachian region/ or exp alabama/ or exp georgia/ or exp kentucky/ or exp maryland/ or exp new york/ or exp north carolina/ or exp ohio/ or exp pennsylvania/ or exp south carolina/ or exp tennessee/ or exp virginia/ or exp west virginia/ or exp great lakes region/ or exp illinois/ or exp chicago/ or exp indiana/ or exp michigan/ or exp minnesota/ or exp new york city/ or exp wisconsin/ or exp mid-atlantic region/ or exp delaware/ or exp "district of columbia"/ or exp baltimore/ or exp new jersey/ or exp philadelphia/ or exp midwestern united states/ or exp iowa/ or exp kansas/ or exp missouri/ or exp nebraska/ or exp north dakota/ or exp oklahoma/ or exp south dakota/ or exp new england/ or exp connecticut/ or exp maine/ or exp massachusetts/ or exp boston/ or exp new hampshire/ or exp rhode island/ or exp vermont/ or exp northwestern united states/ or exp idaho/ or exp montana/ or exp oregon/ or exp washington/ or exp wyoming/ or exp pacific states/ or exp alaska/ or exp california/ or exp los angeles/ or exp san francisco/ or exp hawaii/ or exp southeastern united states/ or exp arkansas/ or exp florida/ or exp louisiana/ or exp mississippi/ or exp southwestern united states/ or exp arizona/ or exp colorado/ or exp nevada/ or exp new mexico/ or exp texas/ or exp utah/ or exp south america/**

Search 21. Northern Africa

("northern africa" or "north africa" or algeria or egypt or libya or morocco or tunisia).mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp africa, northern/ or exp algeria/ or exp egypt/ or exp libya/ or exp morocco/ or exp tunisia/**

Search 22. Atlantic Islands

("atlantic islands" OR azores OR bermuda OR "falkland islands").mp. [mp=title, original title, abstract, name of substance word, subject heading word] or **exp atlantic islands/ or exp azores/ or exp bermuda/ or exp falkland islands/**

Search 23. Pacific Islands

("pacific islands" OR fiji OR "french polynesia" OR guam OR hawaii OR kiribati OR "marshall islands" OR micronesia OR "federated states or micronesia" OR nauru OR "new calidonia" OR palau OR "papua new guinea" OR samoa OR "solomon islands" OR tonga OR vanuatu).mp. [mp=title, original title, abstract] or **exp pacific islands/ or**

exp melanesia/ or exp fiji/ or exp new caledonia/ or exp papua new guinea/ or exp vanuatu/ or exp micronesia/ or exp guam/ or exp palau/ or exp polynesia/ or exp hawaii/ or exp pitcairn island/ or exp samoa/ or exp american samoa/ or exp "independent state of samoa"/ or exp tonga/

Search 24. Indian Ocean Islands

("indian ocean islands" OR comoros OR madagasca OR maldives OR mauritius OR reunion OR seychelles).mp. [mp=title, original title, abstract] or **exp indian ocean islands/ or exp comoros/ or exp madagascar/ or exp mauritius/ or exp reunion/ or exp seychelles/**

A.1.2 Medline search strategies:

Injecting drug use epidemiology

Combine (Search 1. Injecting Drug Use) AND (Search [Region: searches 5-24]) individually for each region

- **If search result greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

OR

- **If search result is less than 200 references →** also perform the following:
  Combine (Search 2) and (Search [Region])
- **If this search result is greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

HIV among IDU epidemiology

Combine (Search 3. HIV/AIDS) AND (Search [Region: searches 5-24]) individually for each region

- **If search result greater than 1000 references →** limit by combining this search result AND ((Search 1. Injecting drug use) OR (Search 2. Drugs and drug use))
  If search result still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)
  If search result still greater than 1000 references → limit to 2002- 2007 only

A.2 EMBASE Global Search Strategy

A.2.1 EMBASE search terms

'key words' in lowercase, EMTREE terms in **bold**

Search 1. Injecting Drug Use
IDU OR IDUs OR "injecting drug" OR "intravenous drug" OR "intravenous substance" OR "injecting substance"
exp intravenous drug abuse/

Search 2. Drug use
heroin OR cocaine OR amphetamine$ OR methamphetamine$ OR opioid$ OR opium OR opiate OR drug abuse OR drug use$ OR drug misuse OR drug dependenc$ OR substance abuse OR substance use$ OR substance misuse OR substance dependenc$ OR addict$
exp substance abuse/ or exp drug abuse/ or exp analgesic agent abuse/ or exp drug abuse pattern/ or exp drug misuse/ or exp drug traffic/ or exp multiple drug abuse/ or exp addiction/ or exp drug dependence/ or exp cocaine dependence/ or narcotic dependence/ or exp heroin dependence/ or exp morphine addiction/ or exp opiate addiction/

Search 3. HIV/AIDS
HIV OR AIDS OR HIV/AIDS OR "Human Immunodeficiency Virus" OR "Acquired Immunodeficiency Syndrome" OR "Acquired Immune Deficiency Syndrome"
exp human immunodeficiency virus/ or exp human immunodeficiency virus 1/ or exp human immunodeficiency virus 2/ or exp acquired immune deficiency syndrome/ or exp aids related complex/ or exp acquired immune deficiency syndrome/ or exp aids related complex/ or exp Human Immunodeficiency Virus Infection/ or exp human immunodeficiency virus prevalence/

Search 4. Epidemiology
"prevalence" OR "incidence" OR "epidemiolog$" OR "data collection" Or "Survey" OR "surveillance" OR "screening" OR "seroprevalence" OR "cohort" OR "population study" OR "population sample" OR "population survey" OR "population surveillance" OR "community sample" OR "RAR" OR "rapid assessment" OR "situation$ assessment" OR "statistics"
exp community assessment/ or exp health survey/ or exp infection rate/ or exp mandatory reporting/ or exp seroepidemiology/ or human immunodeficiency virus prevalence/ or seroprevalence/ or exp biostatistics/ or exp health statistics/ or exp epidemiology/ or exp incidence/ or exp morbidity/ or exp mortality/ or exp prevalence/ or exp epidemiological data/ or exp comorbidity/ or exp disease registry/ or exp geographic distribution/ or exp infection rate/ or exp seasonal variation/ or exp survival/ or exp action research/ or exp feasibility study/ or exp field study/ or exp observational study/ or exp panel study/ or exp pilot study/ or exp prevention study/ or exp trend study/ or exp case finding/ or exp cohort analysis/ or exp exploratory research/ or exp multimethod study/ or exp naturalistic inquiry/ or exp qualitative research/ or exp quantitative study/ or exp sample size/ or exp secondary analysis/ or exp technique/ or exp triangulation/ or exp "medical record review"/ or exp semi structured interview/ or exp structured interview/ or exp unstructured interview/ or exp observational method/ or exp questionnaire/ or exp open ended questionnaire/ or exp structured questionnaire/ or exp model/

Search 5. Africa
"africa" OR "sub-saharan africa" OR angola OR benin OR botswana OR " burkina faso" OR burundi OR cameroon OR "cape verde" OR "central african republic" OR "chad"

OR comoros OR congo OR "republic of the congo" OR "cote d'Ivoire" OR "democratic republic of the congo" OR djibouti OR dominica or "equatorial guinea" OR eritrea OR ethiopia OR gabon OR gambia OR ghana OR guinea OR "guinea-bissau" OR kenya OR lesotho OR liberia OR libya OR madagascar OR malawi OR mali OR mauritania OR mozambique OR namibia OR niger OR nigeria OR rwanda OR "san tome and principe" OR senegal OR serbia OR "sierra leone" OR somalia OR "south africa" OR sudan OR swaziland OR tanzania OR togo OR tuvalu OR uganda OR zambia OR zimbabwe OR "northern africa" OR algeria OR egypt OR libya OR morocco OR Tunisia OR "western sahara"
exp africa/ or exp "africa south of the sahara"/ or exp angola/ or exp benin/ or exp botswana/ or exp burkina faso/ or exp burundi/ or exp cameroon/ or exp cape verde/ or exp central africa/ or exp central african republic/ or exp chad/ or exp comoros/ or exp congo/ or exp cote d'ivoire/ or exp democratic republic congo/ or exp djibouti/ or exp equatorial guinea/ or exp eritrea/ or exp ethiopia/ or exp gabon/ or exp gambia/ or exp ghana/ or exp guinea/ or exp guinea-bissau/ or exp kenya/ or exp lesotho/ or exp liberia/ or exp madagascar/ or exp malawi/ or exp mali/ or exp mayotte/ or exp mozambique/ or exp namibia/ or exp niger/ or exp nigeria/ or exp rwanda/ or exp senegal/ or exp sierra leone/ or exp somalia/ or exp south africa/ or exp sudan/ or exp swaziland/ or exp tanzania/ or exp togo/ or exp uganda/ or exp zambia/ or exp zimbabwe/ or exp north africa/ or exp algeria/ or exp egypt/ or exp libyan arab jamahiriya/ or exp mauritania/ or exp morocco/ or exp tunisia/ or exp western sahara

Search 6. Asia
asia OR "far east" OR china OR japan OR "north korea" OR "south korea" OR mongolia OR taiwan "south east asia" OR borneo OR "brunei darussalam" OR cambodia OR "east timor" OR indonesia OR laos OR "mekong valley" OR myanmar OR philippines OR singapore OR thailand OR Vietnam OR "central asia" OR kazakhstan OR kyrgzstan or tajikstan OR turkmenistan OR uzbekistan OR "south asia" OR "afghanistan" or bangladesh OR bhutan OR india OR nepal OR pakistan OR "sri lanka" OR "middle east" OR bahrain OR iran OR iraq OR israel OR jordan OR kuwait OR lebanon OR oman OR qatar OR "saudi arabia" OR syria OR turkey OR "united arab emirates" OR yemen OR "south asia" OR "afghanistan" or bangladesh OR bhutan OR india OR nepal OR pakistan OR "sri lanka"
exp asia/ or exp kazakhstan/ or exp kyrgyzstan/ or exp tajikistan/ or exp turkmenistan/ or exp uzbekistan/ or exp far east/ or exp china/ or exp japan/ or exp macao/ or exp mongolia/ or exp philippines/ or exp taiwan/ or exp southeast asia/ or exp borneo/ or exp brunei darussalam/ or exp cambodia/ or exp hong kong/ or exp indonesia/ or exp laos/ or exp malaysia/ or exp myanmar/ or exp papua new guinea/ or exp singapore/ or exp thailand/ or exp timor-leste/ or exp viet nam/ or exp korea/ or exp north korea/ or exp south korea/ or exp middle east/ or exp bahrain/ or exp cyprus/ or exp dubai/ or exp iran/ or exp iraq/ or exp israel/ or exp jordan/ or exp kuwait/ or exp lebanon/ or exp oman/ or exp palestine/ or exp qatar/ or exp saudi arabia/ or exp syrian arab republic/ or exp "turkey (republic)"/ or exp united arab emirates/ or exp yemen/ or exp south asia/ or exp afghanistan/ or exp bangladesh/ or exp bhutan/ or exp india/ or exp nepal/ or exp pakistan/ or exp sikkim/ or exp sri lanka/

Search 7. Australia and New Zealand
australia OR "new zealand"
exp "australia and new zealand"/ or exp australia/ or exp new zealand/

Search 8. Eastern Europe
"eastern europe" OR albania OR armenia OR azerbaijan OR "georgia republic" OR estonia OR latvia OR lithuania OR bosnia OR herzegovina OR bulgaria OR belarus OR byelarus OR croatia OR "czech republic" OR hungary OR macedonia OR montenegro

OR moldova OR “poland” OR romania OR russia OR russian OR slovakia OR slovenia OR ukraine OR yugoslavia
exp eastern europe/ or exp albania/ or exp armenia/ or exp azerbaijan/ or exp belarus/ or exp "bosnia and herzegovina"/ or exp bulgaria/ or exp croatia/ or exp czech republic/ or exp "georgia (republic)"/ or exp hungary/ or exp "macedonia (republic)"/ or exp moldova/ or exp poland/ or exp romania/ or exp russian federation/ or exp slovakia/ or exp slovenia/ or exp ukraine/ or exp yugoslavia/ or exp baltic states/ or exp estonia/ or exp latvia/ or exp lithuania/

Search 9. Western Europe
“western europe” OR andorra OR austria OR belgium OR finland OR france OR germany OR gibralta OR “great britain” OR greece OR iceland OR ireland OR italy OR liechtenstein OR luxembourg OR monaco OR netherlands OR portugal OR “san marino” OR spain OR Switzerland OR “united kingdom” OR scandinavia OR denmark OR norway OR sweden OR “vatican city” OR cyprus OR malta OR sicily
exp western europe/ or exp austria/ or exp belgium/ or exp benelux/ or exp france/ or exp ireland/ or exp liechtenstein/ or exp luxembourg/ or exp monaco/ or exp netherlands/ or exp switzerland/ or exp united kingdom/ or exp germany/ or exp german democratic republic/ or exp german federal republic/ or exp scandinavia/ or exp denmark/ or exp faroe islands/ or exp finland/ or exp greenland/ or exp iceland/ or exp norway/ or exp "svalbard and jan mayen"/ or exp sweden/ or exp southern europe/ or exp andorra/ or exp gibraltar/ or exp greece/ or exp italy/ or exp malta/ or exp portugal/ or exp san marino/ or exp spain/ or exp vatican city state/

Search 10. “Atlantic islands”
“atlantic islands” OR azores OR bermuda OR “falkland islands”
exp atlantic ocean/ or exp atlantic islands/ or exp bermuda/ or exp bouvet island/ or exp "falkland islands (malvinas)"/ or exp greenland/ or exp iceland/ or exp saint helena/ or exp "saint pierre and miquelon"/ or exp "sao tome and principe"/ or exp "south georgia and the south sandwich islands"/

Search 11. “Indian Ocean Islands”
“indian ocean islands” OR comoros OR madagasca OR maldives OR mauritius OR reunion OR seychelles
exp indian ocean/ or exp british indian ocean territory/ or exp christmas island/ or exp "cocos (keeling) islands"/ or exp french southern territories/ or exp "heard island and mcdonald islands"/ or exp maldives/ or exp mauritius/ or exp reunion/ or exp seychelles/

Search 12. Pacific Islands
"pacific islands" OR fiji OR "french polynesia" OR guam OR hawaii OR kiribati OR "marshall islands" OR micronesia OR "federated states or micronesia" OR nauru OR "new calidonia" OR palau OR "papua new guinea" OR samoa OR "solomon islands" OR tonga OR vanuatu
oceanic regions/ or exp pacific ocean/ or exp pacific islands/ or exp cook islands/ or exp "federated states of micronesia"/ or exp fiji/ or exp french polynesia/ or exp guam/ or exp indonesia/ or exp kiribati/ or exp marshall islands/ or exp melanesia/ or exp nauru/ or exp new caledonia/ or exp niue/ or exp norfolk island/ or exp northern mariana islands/ or exp palau/ or exp papua new guinea/ or exp philippines/ or exp pitcairn/ or exp polynesia/ or exp solomon islands/ or exp timor-leste/ or exp tokelau/ or exp tonga/ or exp tuvalu/ or exp united states minor outlying islands/ or exp vanuatu/ or exp "wallis and futuna"/ or exp samoan islands/ or exp american samoa/ or exp samoa/

Search 13. Caribbean Islands
caribbean OR antigua OR barbuda OR bahamas OR barbados OR cuba OR "dominican republic" OR grenada OR guadeloupe OR haiti OR jamaica OR martinique OR "netherland antilles" OR "puerto rico" OR "saint kitts" OR nevis OR "saint lucia" OR "saint vincent" OR "the grenadines" OR "saint vincent and the grenadines" OR trinidad OR tobago OR "virgin islands"
exp caribbean islands/ or exp "anguilla (country)"/ or exp "antigua and barbuda"/ or exp aruba/ or exp bahamas/ or exp barbados/ or exp cayman islands/ or exp cuba/ or exp dominica/ or exp dominican republic/ or exp grenada/ or exp guadeloupe/ or exp haiti/ or exp jamaica/ or exp martinique/ or exp montserrat/ or exp netherlands antilles/ or exp puerto rico/ or exp "saint kitts and nevis"/ or exp saint lucia/ or exp "saint vincent and the grenadines"/ or exp "trinidad and tobago"/ or exp "turks and caicos islands"/ or exp "virgin islands (british)"/ or exp "virgin islands (u.s.)"/

Search 14. North America
"north america" OR canada OR greenland OR mexico OR "united states"
exp north america/ or exp canada/ or exp mexico/ or exp united states/

Search 15. South and Central America
"south and central america" OR "central america" OR bellize OR "costa rica" OR ecuador OR "el salvador" OR guatemala OR honduras OR nicaragua OR panama OR "south america" OR argentina OR bolivia OR brazil OR chile OR columbia OR ecuador OR "french guiana" OR guyana OR paraguay OR peru OR suriname OR uraguay OR venezuela"
exp "south and central america"/ or exp central america/ or exp belize/ or exp costa rica/ or exp el salvador/ or exp guatemala/ or exp honduras/ or exp nicaragua/ or exp panama/ or exp south america/ or exp argentina/ or exp aruba/ or exp bolivia/ or exp brazil/ or exp chile/ or exp colombia/ or exp ecuador/ or exp french guiana/ or exp guyana/ or exp netherlands antilles/ or exp paraguay/ or exp peru/ or exp suriname/ or exp uruguay/ or exp venezuela/

A.2.2 EMBASE search strategies

Injecting drug use epidemiology

Combine (Search 1. Injecting Drug Use) AND (Search [Region: searches 5-15]) individually for each region

- **If search result greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

OR

- **If search result is less than 200 references →** also perform the following:
  Combine (Search 2. Drug use) and (Search [Region])
- **If this search result is greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

HIV among IDU epidemiology

Combine (Search 3. HIV/AIDS) AND (Search [Region: searches 5-15]) individually for each region

- **If search result greater than 1000 references →** limit by combining this search result AND ((Search 1. Injecting drug use) OR (Search 2. Drug use))
  If search result still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)
  If search result still greater than 1000 references → limit to 2002- 2007 only

A.3 BioMed Central Global Search Strategy

A.3.1 BioMed Central search terms

Search 1. Injecting Drug Use
IDU OR IDUs OR "injecting drug" OR "intravenous drug" OR "intravenous substance" OR "injecting substance"

Search 2. Drug use
heroin OR cocaine OR amphetamine* OR methamphetamine* OR opioid* OR opium OR opiate OR drug abuse OR drug use* OR drug misuse OR drug dependenc* OR substance abuse OR substance use* OR substance misuse OR substance dependenc* OR addict*

Search 3. HIV/AIDS
HIV OR AIDS OR HIV/AIDS OR "Human Immunodeficiency Virus" OR "Acquired Immunodeficiency Syndrome" OR "Acquired Immune Deficiency Syndrome"

Search 4. Epidemiology
"prevalence" OR "incidence" OR "epidemiolog*" OR "data collection" Or "Survey" OR "surveillance" OR "screening" OR "seroprevalence" OR "cohort" OR "population study" OR "population sample" OR "population survey" OR "population surveillance" OR "community sample" OR "RAR" OR "rapid assessment" OR "situation* assessment" OR "statistics"

Search 5. Africa
"africa" OR "sub-saharan africa" OR angola OR benin OR botswana OR " burkina faso" OR burundi OR cameroon OR "cape verde" OR "central african republic" OR "chad" OR comoros OR congo OR "republic of the congo" OR "cote d'lvoire" OR "democratic republic of the congo" OR djibouti OR dominica or "equatorial guinea" OR eritrea OR ethiopia OR gabon OR gambia OR ghana OR guinea OR "guinea-bissau" OR kenya OR lesotho OR liberia OR libya OR madagascar OR malawi OR mali OR mauritania OR mozambique OR namibia OR niger OR nigeria OR rwanda OR "san tome and principe" OR senegal OR serbia OR "sierra leone" OR somalia OR "south africa" OR sudan OR swaziland OR tanzania OR togo OR tuvalu OR uganda OR zambia OR zimbabwe OR "northern africa" OR algeria OR egypt OR libya OR morocco OR Tunisia OR "western sahara"

Search 6. Asia
asia OR "far east" OR china OR japan OR "north korea" OR "south korea" OR mongolia OR taiwan "south east asia" OR borneo OR "brunei darussalam" OR cambodia OR "east timor" OR indonesia OR laos OR "mekong valley" OR myanmar OR philippines OR singapore OR thailand OR Vietnam OR "central asia" OR kazakhstan OR kyrgzstan or tajikstan OR turkmenistan OR uzbekistan OR "south asia" OR "afghanistan" or bangladesh OR bhutan OR india OR nepal OR pakistan OR "sri lanka" OR "middle east" OR bahrain OR iran OR iraq OR israel OR jordan OR kuwait OR lebanon OR oman OR qatar OR "saudi arabia" OR syria OR turkey OR "united arab emirates" OR yemen OR "south asia" OR "afghanistan" or bangladesh OR bhutan OR india OR nepal OR pakistan OR "sri lanka"

Search 7. Australia and New Zealand
australia OR "new zealand"

Search 8. Eastern Europe
"eastern europe" OR albania OR armenia OR azerbaijan OR "georgia republic" OR estonia OR latvia OR lithuania OR bosnia OR herzegovina OR bulgaria OR belarus OR byelarus OR croatia OR "czech republic" OR hungary OR macedonia OR montenegro OR moldova OR "poland" OR romania OR russia OR russian OR slovakia OR slovenia OR ukraine OR yugoslavia

Search 9. Western Europe
"western europe" OR andorra OR austria OR belgium OR finland OR france OR germany OR gibralta OR "great britain" OR greece OR iceland OR ireland OR italy OR liechtenstein OR luxembourg OR monaco OR netherlands OR portugal OR "san marino" OR spain OR Switzerland OR "united kingdom" OR scandinavia OR denmark OR norway OR sweden OR "vatican city" OR cyprus OR malta OR sicily

Search 10. "Atlantic islands"
"atlantic islands" OR azores OR bermuda OR "falkland islands"

Search 11. "Indian Ocean Islands"
"indian ocean islands" OR comoros OR madagasca OR maldives OR mauritius OR reunion OR seychelles

Search 12. Pacific Islands
"pacific islands" OR fiji OR "french polynesia" OR guam OR hawaii OR kiribati OR "marshall islands" OR micronesia OR "federated states or micronesia" OR nauru OR "new calidonia" OR palau OR "papua new guinea" OR samoa OR "solomon islands" OR tonga OR vanuatu

Search 13. Caribbean Islands
caribbean OR antigua OR barbuda OR bahamas OR barbados OR cuba OR "dominican republic" OR grenada OR guadeloupe OR haiti OR jamaica OR martinique OR "netherland antilles" OR "puerto rico" OR "saint kitts" OR nevis OR "saint lucia" OR "saint vincent" OR "the grenadines" OR "saint vincent and the grenadines" OR trinidad OR tobago OR "virgin islands"

Search 14. North America
"north america" OR canada OR greenland OR mexico OR "united states"

Search 15. South and Central America
"south and central america" OR "central america" OR bellize OR "costa rica" OR ecuador OR "el salvador" OR guatemala OR honduras OR nicaragua OR panama OR "south america" OR argentina OR bolivia OR brazil OR chile OR columbia OR ecuador OR "french guiana" OR guyana OR paraguay OR peru OR suriname OR uraguay OR venezuela"

A.3.2 BioMed Central search strategies

Injecting drug use epidemiology

Combine (Search 1. Injecting Drug Use) AND (Search [Region: searches 5-15]) individually for each region

- **If search result greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

OR

- **If search result is less than 200 references →** also perform the following:
  Combine (Search 2. Drug use) and (Search [Region])
- **If this search result is greater than 1000 references →** limit to 2002- 2007 only.
  If still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)

HIV among IDU epidemiology

Combine (Search 3. HIV/AIDS) AND (Search [Region: searches 5-15]) individually for each region

- **If search result greater than 1000 references →** limit by combining this search result AND ((Search 1. Injecting drug use) OR (Search 2. Drug use))
  If search result still greater than 1000 references → limit by combining this search result AND (Search 4. Epidemiology)
  If search result still greater than 1000 references → limit to 2002- 2007 only

A.4 PubMed Search Strategy

A.4.1 PubMed search terms

'key-words' in lowercase, 'MESH' terms in **bold**

Search 1. Injecting Drug Use
IDU OR IDUs OR "injecting drug" OR "intravenous drug" OR "intravenous substance" OR "injecting substance" OR "**exp substance abuse, intravenous" [MH]**

Search 2. Drugs and drug use
heroin OR cocaine OR amphetamine* OR methamphetamine* OR opioid* OR opium OR opiate* OR "drug abuse" OR "drug use" OR "drug user" OR "drug users" OR "drug misuse" OR "drug dependent" OR "drug dependence" OR OR "drug dependency" OR "substance abuse" OR "substance use" OR "substance user" OR "substance users" OR "substance misuse" OR "substance dependence" OR "substance dependency" OR "substance dependent" OR addict* OR "**designer drugs" [MH] OR "street drugs" [MH] OR Cocaine [MH] OR "crack cocaine" [MH] OR amphetamines [MH] OR amphetamine [MH] OR methamphetamine [MH] OR Opium [MH] OR Heroin [MH] OR "substance-related disorders" [MH] OR "amphetamine-related disorders" [MH] OR "cocaine-related disorders" [MH] OR "opioid-related disorders" [MH] OR "heroin dependence" [MH] OR "morphine dependence" [MH] OR "psychoses, substance-induced" [MH]**

Search 3. HIV/AIDS
HIV OR AIDS OR HIV/AIDS OR "Human Immunodeficiency Virus" OR "Human Immune Deficiency Virus" OR "Acquired Immunodeficiency Syndrome" OR "Acquired Immune Deficiency Syndrome" OR **HIV [MH] OR HIV-1 [MH] OR HIV-2 [MH] OR "HIV infections" [MH] OR "acquired immunodeficiency syndrome" [MH] OR "HIV seropositivity" [MH] OR "HIV seroprevalence" [MH] OR "AIDS serodiagnosis" [MH]**

Search 4. Epidemiology
prevalence OR incidence OR epidemiolog* OR "data collection" Or survey OR surveillance OR screening OR seroprevalence OR cohort OR "population study" OR "population sample" OR "population survey" OR "population surveillance" OR "community sample" OR "RAR" OR "rapid assessment" OR "situation assessment" OR "situational assessment" OR statistics OR **epidemiologic methods [MH] OR contact tracing [MH] OR data collection [MH] OR health surveys [MH] OR health care surveys [MH] OR interviews [MH] OR narration [MH] OR questionnaires [MH] OR records [MH] OR registries [MH] OR disease notification [MH] OR sentinel surveillance [MH] OR epidemiologic studies [MH] OR cohort studies [MH] OR longitudinal studies [MH] OR follow-up studies [MH] OR prospective studies [MH] OR cross-sectional studies [MH] OR seroepidemiologic studies [MH] OR hiv seroprevalence [MH] OR sampling studies [MH] OR focus groups [MH] OR delphi technique [MH]**

A.4.2 PubMed search strategies

IDU epidemiology
1. IDU a) limit: Epidemiology b) limit: 2002 Or if need to expand: c) **'Drugs and drug use'** d) limit: Epidemiology e) limit: 2002

HIV among IDU epidemiology
2. HIV/AIDS a) limit: (IDU **OR** 'Drug use') [play with this] b) limit: Epidemiology c) limit: 2002

Appendix B: Grey literature and online database searches

A wide range of online databases and websites were searched for additional information to that collected in the peer reviewed literature. These databases are crucial sources of information on the epidemiology of injecting drug use and HIV among injecting drug users because so much of the work in this area appear to be published only in the form of reports. In total, 44 online resource and database websites were searched. In addition, 14 surveillance system websites; 9 regional harm reduction websites; 3 prison databases, and 33 country-specific drug control agencies and ministry of health websites were searched for relevant data.

The following search terms were used (both as acronyms and expanded as full terms):

1. IDU/s
2. HIV, AIDS, HIV/AIDS
3. Heroin, Cocaine, Amphetamine, Methamphetamine, Opioid
4. OST, MMT, Methadone, Buprenorphine
5. HCV
6. HIV + HCV
7. HIV + TB
8. Harm Reduction
9. HIV + Prison
10. NSP, SEP,
11. ART, HAART
12. Condom Program
13. Targeted Info,
14. VCT
15. HAV +/or HBV + IDU

B.1 Online resources, libraries and databases

1. Alcohol and Drug Council of Australia (ADCA) National Resource Centre:
http://www.adca.org.au/content/view/19/57/

2. Australian Drug Foundation - Drug Info Clearinghouse library
http://www.druginfo.adf.org.au/browse.asp?containerid=library

3. Australasian Society of HIV Medicine
http://theconsortium.nchsr.arts.unsw.edu.au/home.htm

4. Caribbean Drug Information Network (CARIDIN) CAREC/CARIFORUM/EU Drug Abuse Epidemiological & Surveillance System Project
http://www.carec.org/projects/caridin_daess/caridin_daess.htm

5. CINAHL
http://www.cinahl.com/

6. Drug Policy Alliance
http://www.drugpolicy.org/library/

7. Drugscope UK
http://www.drugscope.org.uk/

8. ELISAD Europe
http://www.addictionsinfo.eu/

9. Health on the net 'HON'
http://www.hon.ch/

10. Global Health (via UNSW Sirus)

11. Grey Net
http://www.greynet.org/

12. Science Accelerator
http://www.scienceaccelerator.gov/

13. High Wire Press at Standford University
http://highwire.stanford.edu/

14. LILACS & MEDICARB databases (Latin American and Caribbean of Health Sciences Information System)
http://www.bireme.br/php/index.php?lang=en

15. Lindesmith Library
http://library.soros.org/lindesmith.html

16. National Prevention Information Network (formerly CDC AIDS clearinghouse)
http://www.cdcnpin.org/scripts/index.asp

17. New York Academy of Medicine
http://www.nyam.org/library/

18. Project CORK
http://www.projectcork.org/database_search/index.html

19. SAMHDA (Substance Abuse and Mental Health Data Archive)
http://www.icpsr.umich.edu/SAMHDA/

20. Schaffer Library of Drug Policy:
http://www.druglibrary.org/schaffer/index.htm

21. SCOPUS
http://www.info.scopus.com/

22. Web of Science
http://scientific.thomson.com/products/wos/

23. Human Rights Watch:
http://www.hrw.org

24. PAIS International – access via UNSW library resource list

25. Virtual Health Science Library: EMIAC
http://www.virtualhealthlibrary.org/php/index.php?lang=en

26. BiblioLine:
http://biblioline.nisc.com/scripts/login.dll?noip

27. ISI Proceedings – access via UNSW library resource list

28. MEDCARIB[1]
http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&base=MedCarib&lang=i&form=F

29. The AIDS Education Global information System (AEGiS):
http://www.aegis.com/

30. The Consortium for Social and Policy Research on HIV, Hepatitis C and related diseases:
http://nchsr.arts.unsw.edu.au/Clearinghouse/search.htm

31. hivpolicy.org
http://www.hivpolicy.org/

32. SEA-AIDS eForums
http://www.healthdev.org/eforums/sea-aids/

33. Beckley Foundation
http://www.internationaldrugpolicy.net/

34. The International Treatment Preparedness Coalition (ITPC)
http://www.aidstreatmentaccess.org

35. Thomas Land Health Publishers
http://thomasland.metapress.com/app/home/main.asp

36. Asia Development Bank
http://www.adb.org/

37. World Bank AIDS Economics
http://www.worldbank.org/aidsecon/

38. AVERT
http://www.avert.org/

39. APAIC
http://www.apaic.org/librarynew.html

40. IAS-AIDS conference proceedings
http://www.iasociety.org/

41. IHRA-Conference Proceedings (via IHRA)

[1] Note: can be accessed through Virtual Health Library portal

42. Asia Foundation
http://www.asiafoundation.org/

43. WHO regional office for the Eastern Mediterranean: Library and Information database
http://www.emro.who.int/cgi-bin/wxis.exe/iah/?IsisScript=iah/iah.xic&base=emcat&lang=i

44. China AIDS
http://www.china-aids.org/english/

45. Cranstoun Drug Services
http://www.cranstoun.org/index.htm

B.2 Surveillance Systems

1. CARDIN: Caribbean Drug Information Network
http://www.carec.org/projects/caridin_daess/caridin_daess.htm

2. ACCORD: ASEAN and China Cooperative Operations in Response to Dangerous Drugs
http://www.accordplan.net/

3. NATRESA: National Agency for the Treatment and Rehabilitation of Substance Abusers
http://www.gov.mu/portal/site/natresa/

4. Southern African Development Community (SADC) Epidemiology Network on Drug Use (SENDU)
http://www.sadc.int/

5. SIDUC: Inter-American Drug Use Data System
http://www.cicad.oas.org/en/default.asp

6. CICAD OID: The Inter-American Observatory on Drugs
http://www.cicad.oas.org/OID/

7. APAIC: Asian Pacific ATS Information Centre
http://www.apaic.org/
-Regional ATS trends: http://www.apaic.org/TRENDS/Philippinesnew.html

8. CEWG: Community Epidemiology Work Group
http://www.drugabuse.gov/about/organization/CEWG/CEWGHome.html

9. DAWN: Drug Abuse Warning Network (US)
http://dawninfo.samhsa.gov/

10. Australian Illicit Drug Reporting System (IDRS)
http://ndarc.med.unsw.edu.au/NDARCWeb.nsf/page/IDRSa

11. Australian National Centre in HIV Epidemiology and Clinical Research (NCHECR)
http://www.nchecr.unsw.edu.au/

12. CDC Centre for Disease Control (US – Atlanta)
http://www.cdc.gov/

14. European Monitoring Centre on Drugs and Drug Addiction (EMCDDA)
http://www.emcdda.europa.eu/

B.3 National Government Drug Agencies, Ministries of Health and related

Many government websites were searched. These included:

1. Andorra: Ministry of Health and Welfare
http://www.salutibenestar.ad

2. Armenia: National Centre for AIDS Prevention
http://www.armaids.am

3. Austria: Federal Ministry for Health & Women
http://www.bmgf.gv.at

4. Belgium: Scientific Institute of Public Health
http://www.iph.fgov.be

5. Cyprus: Ministry of Health
http://www.moh.gov.cy

6. Czech Republic: National Institute of Public Health
http://www.szu.cz

7. Denmark: Statens Serum Institute
http://www.ssi.dk

8. Estonia: Health Protection Inspectorate
http://www.tervisekaitse.ee/?lang=3

9. Finland: National Public Health Institute
http://www.ktl.fi

10. France: Institut de veille sanitaire
http://www.invs.sante.fr

11. Georgia: AIDS & Clinical Immunology Research Centre
http://aids.gol.ge

12. Germany: Robert Koch-Institut
http://www.rki.de

13. Greece: Hellenic Centre for Disease Prevention and Control
http://www.keel.org.gr

14. Iceland: Directorate of Health
http://www.landlaeknir.is/

15. Indonesia: Departemen Keseatan
http://www.depkes.go.id/en/index_en.htm

16. Ireland: Health Protection Surveillance Centre
http://www.ndsc.ie

17. Israel: Ministry of Health
http://www.health.gov.il

18. Italy: Istituto Superiore di Sanità
http://www.iss.it

19. Latvia: AIDS Prevention Centre
http://www.aids-latvija.lv/

20. Lithuania: AIDS Centre
http://www.aids.lt

21. Luxembourg: Direction de la Santé
http://www.ms.etat.lu

22. Malta: Department of Public Health
http://www.sahha.gov.mt/pages.aspx

23. Netherlands: National Institute for Public Health & the Environment
http://www.rivm.nl

24. Norway: Institute of Public Health
http://www.fhi.no

25. Poland: National Institute of Hygiene
http://www.medstat.waw.pl

26. Portugal: National Institute of Health Dr Ricardo Jorge
http://www.insarj.pt

Romania: Matei Bals Institute of Infectious Diseases, Bucharest
http://www.ms.ro

27. Spain: Instituto de Salud "Carlos III"
http://www.isciii.es

28. Sweden: Institute for Infectious Disease Control
http://www.smittskyddsinstitutet.se

29. Switzerland: Federal Office of Public Health
http://www.bag.admin.ch

30. Thailand: Office of the Narcotics Control Board (ONCB)
http://www.oncb.go.th/

31. Turkey: Ministry of Health
http://www.saglik.gov.tr

32. United Kingdom: Health Protection Agency
& Health Protection Scotland, Glasgow
http://www.hpa.org.uk & http://www.hps.scot.nhs.uk

33. Viet Nam: Ministry of Health
http://www.moh.gov.vn/homebyt/en/portal/index.jsp

B.4 Regional Harm Reduction Networks

1. Soros IHRD program
http://www.soros.org/initiatives/health/focus/ihrd

2. Asian Harm Reduction Network
http://www.ahrn.net

3. Canadian Harm Reduction Network
http://www.canadianharmreduction.com/

4. Central and Eastern European and Central Asian Harm Reduction Network
http://www.ceehrn.org/

5. CHRC - Caribbean Harm Reduction Coalition
www.caribbeanharmreductioncoalition.htmlplanet.com

6. HRC – The Harm Reduction Coalition (USA)
www.harmreduction.org

7. Reduc – The Brazilian Harm Reduction Network
www.reduc.org.br

8. UKHRA – The UK Harm Reduction Alliance
www.ukhra.org

B.5 Prison databases

1. International Centre for Prison Studies – Kings College
http://www.kcl.ac.uk/schools/law/research/icps

2. ENDIPP[2] - European Network on Drugs and Infections Prevention in Prison
http://www.endipp.net/index.php?option=com_content&task=view&id=32&Itemid=49

[2] Note: the ENDIPP website has been discontinued as of early 2008

Appendix C: Email request for additional data

In January 2008, an email was sent worldwide requesting further data to:

a. known email lists (including the Asian Harm Reduction Network, EHRN, IYNHR, NHRN, Stijn Goossens, HRC, ADCA UPDATE, International Harm Reduction Association, CHRC, Correlation-ENSIH),
b. Reference Group members,
c. WHO, UNAIDS and UNODC Headquarters staff, and
d. Contacts of researchers in the Secretariat team.

This request resulted in 62 responses containing data from people and resulted in the identification of reports that provided data for countries across all regions worldwide.

The email text read:

"URGENT REQUEST
Reference Group to the UN on HIV and IDU

We are looking for data from around the world on the number of injecting drug users and HIV prevalence among IDUs.

Do you have data from your country?

The Reference Group to the United Nations on HIV and injecting drug use advises UNODC, UNAIDS and WHO on injecting drug use and on effective approaches to HIV prevention and care for IDUs to help guide strategies for scaling up these activities.

See www.idurefgroup.unsw.edu.au for more information about the work of the Reference Group, the international experts who currently make up the group and the Secretariat which is currently based at the National Drug and Alcohol Centre in Australia.

One of our major activities is to report on the global extent of IDU and HIV.

We are in the process of updating estimates for every country around the world on:

1. ***the number of people who inject drugs in each country***
2. ***the prevalence of HIV among these injecting drug users***

Many of you may be familiar with the estimates that were released several years ago by the previous Reference Group.

Producing these estimates is difficult because in many countries there are no data measuring the extent of injecting drug use or HIV among injecting drug users. In other countries data may exist, but are not widely available.

So far we have conducted a very large search of the peer-reviewed literature and have tried to gather as much *grey* literature (such as NGO and government reports) as possible. However we know that there will be some material that our search would have missed.

Below is a list of countries that we do not currently have sufficient data on. This lack of data means we will be unable to make direct estimates on the size of the IDU population or the prevalence of HIV among IDUs for these countries.

Do you have any information on these countries that may be of use to us?

Any assistance you are able to provide will be acknowledged in the reports of the Reference Group. We have only a limited amount of time in which to complete this work. Because of this we will only be able consider material that is sent to us ***before Friday 15 February 2008."***

More data is needed for the following countries:

Eastern Europe and Central Asia:
Bosnia and Herzegovina, Georgia, Lithuania

South Asia:
Bhutan, Maldives, Sri Lanka

East and South East Asia
Brunei Darussalam, Democratic People's Republic of Korea, Japan, Lao People's Democratic Republic, Mongolia, Republic of Korea, Singapore, The Taiwan Provence of China, Timor Leste

Caribbean
Antigua and Barbuda, Bahamas, Barbados, Cuba, Dominica, Dominican Republic, Grenada, Haiti, Jamaica, Saint Kitts and Nevis, Saint Lucia, Saint Vincent & Grenadines, Trinidad and Tobago

South America
Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Guyana, Honduras, Nicaragua, Panama, Paraguay, Peru, Suriname, Uruguay, Venezuela

Oceania and the Pacific
American Samoa, Federated States of Micronesia, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Nauru, New Caledonia, Palau, Papua New Guinea, Samoa, Solomon Islands, Tonga, Tuvalu, Vanuatu

Western Europe

Albania, Andorra, Belgium, Iceland, Italy, Finland, France, Liechtenstein, Monaco, Montenegro, San Marino, Serbia, Spain, Switzerland, The Former Yugoslav Republic of Macedonia

Middle East and North Africa
Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libyan Arab Jamahiriya, Morocco, Occupied Palestinian Territories, Oman, Qatar, Saudi Arabia, Sudan, Syrian Arab Republic, Tunisia, Turkey, United Arab Emirates, Yemen

Sub-Saharan Africa
Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Côte d'Ivoire, Democratic Republic of the Congo, Djibouti, Equatorial Guinea, Eritrea, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Namibia, Niger, Nigeria, Republic of the Congo, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, Swaziland, Togo, Uganda, Zambia, Zimbabwe

If you have any information you can share with us or you have any further questions please send an email to: **IDUreferencegroup@med.unsw.edu.au**

We would greatly appreciate any help you can offer us.

I look forward to hearing from you.

Regards,

Bradley Mathers.

Dr Bradley Mathers
Coordinator, Secretariat of the Reference Group to the UN on HIV and IDU
National Drug and Alcohol Research Centre
University of New South Wales
Sydney, Australia
Web: http://www.idurefgroup.unsw.edu.au

Appendix D: Source references for estimates used

Table 2 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Europe

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Eastern Europe									
Armenia	--	(1)	--	--	(1)	--	(1, 2)	(1, 2)	(2)
Azerbaijan	--	(3, 4)	--	--	(3, 4)	--	(5)	(5)	(5)
Belarus	--	(6)	--	--	(6)	--	--	(6)	--
Bosnia & Herzegovina	--	(7)	--	--	--	--	--	(8)	--
Bulgaria	(9)	(9)	(9)	(9)	(9)	(9)	--	(10)	--
Croatia	--	(8)	--	--	--	--	--	(10)	--
Czech Republic	(11)	(11)	(11)	(11)	(11)	(11)	(10)	(10)	(10)
Estonia	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Georgia	(12)	(12, 13)	(13)	(12)	(12, 13)	(13)	(12)	(12, 13)	(13)
Hungary	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Latvia	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Lithuania	--	(14)	--	--	(14)	--	--	(10)	--
Moldova	--	(8)	--	--	(8)	--	--	(15)	--
Poland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Romania	--	(16, 17)	--	--	--	--	--	(10)	--
Russian Federation	--	(3)	--	--	(3)	--	(18)	(18)	(18)
Slovakia	(11)	(11)	(11)	(11)	(11)	(11)	--	(10, 19, 20)	--
Ukraine	(21)	(21)	(21)	--	--	--	--	(22)	--
Western Europe:									
Albania	--	(23)	--	--	--	--	--	(10)	--
Andorra	--	(23)	--	--	--	--	--	(10)	--
Austria	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Belgium	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
Denmark	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Finland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
France	--	(10)	--	--	(10)	--	--	(10)	--
Germany	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Greece	(11)	(11)	(11)	(11)	(11)	(11)	(10)	(10)	(10)
Iceland	--	(23)	--	--	--	--	--	(23)	--
Ireland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
Italy	--	(10)	--	--	(10)	--	--	(24)	--
Liechtenstein	--	--	--	--	--	--	--	--	--
Luxembourg	--	(10, 25)	--	--	(10, 25)	--	--	(10)	--
Macedonia FYR	--	(23)	--	--	--	--	--	(23)	--
Malta	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--

Monaco	--	(23)	--	--	--	--	--	(23)	--
Montenegro	--	(23)	--	--	--	--	--	(23)	--
Netherlands	(10)	(10)	(10)	(10)	(10)	(10)	--	(26)	--
Norway	(10, 27)	(10, 27)	(10, 27)	(10, 27)	(10, 27)	(10, 27)	--	(10)	
Portugal	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)	(10)
San Marino	--	(23)	--	--	--	--	--	(23)	--
Serbia	--	(23)	--	--	--	--	--	(23)	--
Slovenia	--	(10)	--	--	(10)	--	--	(10)	--
Spain	--	(10)	--	--	(10)	--	--	(10)	--
Sweden	--	(10)	--	--	(10)	--	--	(10)	--
Switzerland	(10)	(10)	(10)	(10)	(10)	(10)	--	(10)	--
United Kingdom	(11)	(11)	(11)	(11)	(11)	(11)	(24, 28)	(24, 28)	(24, 28)

Table 3 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Asia

	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
East and South East Asia:									
Brunei Darussalam	--	(29)	--	--	--	--	--	(30)	--
Cambodia	(31)	(31)	(31)	(31)	(31)	(31)	(31)		
China	(32)	(32)	(32)	(32)	(32)	(32)	(32)		
DPR Korea	--	--	--	--	--	--	--	--	--
Indonesia	(33)	(33)	(33)	(33)	(33)	(33)	(33)	(33)	(33)
Japan	--	(34)	--	--	(34)	--	--	(34)	--
Lao PDR	--	(35-37)	--	--	--	--	--	(38)	--
Malaysia	(39)	(39)	(39)	(39)	(39)	(39)	--	(40)	--
Mongolia	--	(41)	--	--	--	--	--	(41)	--
Myanmar	(42)	(42) (43)	(42)	(42)	(42)	(42)	(42)	(42)	(42)
Republic of Korea	--	(44)	--	--	--	--	--	(44)	--
Philippines	--	(45-47)	--	--	--	--	--	(45)	--
Singapore	--	(34)	--	--	--	--	--	(30)	--
Taiwan province of China	--	(48)	--	--	--	--	(48)	(48, 49)	(49)
Thailand	--	(50-52)	--	--	(50-52)	--	--	(53)	--
Timor Leste	--	(54)	--	--	--	--	--	--	--
Viet Nam	--	(55)	--	--	(55)	--	--	(56)	--
South Asia:									
Afghanistan	(57)	(57)	(57)	(57)	(57)	(57)	(58)	(58)	(58)
Bangladesh	(59)	(60, 61)	(59, 60)	(60)	(60)	(60)	(61)	(61)	(61)
Bhutan	--	(62)	--	--	--	--	--	--	--
India	(63)	(63)	(63)	(63)	(63)	(63)	--	(64)	--
Iran, Islamic Republic	--	(65)	--	--	(65)	--	(66)	(66)	(66)
Maldives	--	(67)	--	--	--	--	--	--	--
Nepal	(68)	(68)	(68)	(68)	(68)	(68)	--	(68)	--
Pakistan	(69)	(69)	(69)	(69)	(69)	(69)	(69, 70)	(69, 70)	(69, 70)
Sri Lanka	--	(44, 71, 72)	--	--	--	--	--	(72)	--
Central Asia:									
Kazakhstan	--	--	--	--	(3, 73, 74)	--	(73, 74)	--	(73, 74)
Kyrgyzstan	--	--	--	--	(73, 74)	--	(73, 74)	--	(73, 74)
Tajikistan	--	--	--	--	(73, 74)	--	(73, 74)	--	(73, 74)
Turkmenistan	--	(3)	--	--	--	--	--	(3)	--
Uzbekistan	--	(3, 73, 74)	--	--	(3, 73, 74)	--	(73-75)	--	(73, 74, 76)

Table 4 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Americas

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Antigua & Barbuda	--	(77)	--	--	--	--	--	(77)	--
Bahamas	--	(30, 77)	--	--	--	--	--	(30)	--
Barbados	--	(77)	--	--	--	--	--	(78)	--
Bermuda	--	(30)	--	--	--	--	--	--	--
Commonwealth of Puerto Rico	--	(79)	--	--	(79)	--	--	(80)	--
Cuba	--	--	--	--	--	--	--	(81)	--
Dominica	--	(77, 82)	--	--	--	--	--	(77)	--
Dominican Republic	--	(30)	--	--	--	--	--	(30)	--
Grenada	--	(77)	--	--	--	--	--	(77)	--
Haiti	--	(77, 82, 83)	--	--	--	--	--	(77, 84, 85)	--
Jamaica	--	(77)	--	--	--	--	--	(77, 86-88)	--
Saint Kitts & Nevis	--	(82)	--	--	--	--	--	(77)	--
Saint Lucia	--	(82)	--	--	--	--	--	(77)	--
Saint Vincent & Grenadines	--	(77)	--	--	--	--	--	(77)	--
Trinidad & Tobago	--	(89)	--	--	--	--	--	(77)	--
Latin America:									
Argentina	(90)	(90, 91)	(91)	(90)	(90, 91)	(91)	(91) (92)	(91, 92)	(91, 92)
Belize	--	(93)	--	--	--	--	--	(77, 93, 94)	--
Bolivia	--	(94)	--	--	--	--	--	(94)	--
Brazil	--	(95)	--	--	(95)	--	(90, 96-98)	(90, 96-98)	(90, 96-98)
Chile	--	(99)	--	--	(99)	--	--	(100, 101)	--
Colombia	--	(96)	--	--	--	--	(96)	(96)	(96)
Costa Rica	--	(30)	--	--	--	--	--	(30)	--
Ecuador	--	(30)	--	--	--	--	--	(30)	--
El Salvador	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Guatemala	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Guyana	--	(103)	--	--	--	--	--	--	--
Honduras	--	(104)	--	--	--	--	--	(94, 102, 104)	--
Mexico	--	(90, 105)	--	--	--	--	(106) (107)	(106)	(106, 107)
Nicaragua	--	(30)	--	--	--	--	--	(96)	--
Panama	--	(94, 102)	--	--	--	--	--	(94, 102)	--
Paraguay	--	(108, 109)	--	--	--	--	(108, 109)	(108, 109)	(108, 109)
Peru	--	(96)	--	--	--	--	--	(96)	--
Suriname	--	(30)	--	--	--	--	--	(110)	--
Uruguay	--	(111)	--	--	--	--	--	(90, 112)	--
Venezuela	--	(30)	--	--	--	--	--	(30)	--
Canada and the US:									
Canada	(113)	(113)	(113)	(113)	(113)	(113)	(114)	(114)	(114)
United States	(79)	(79)	(79)	(79)	(79)	(79)	(79, 115)	(79, 115)	(79, 115)

Table 5 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Oceania

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Pacific Island States and Territories:									
American Samoa	--	--	--	--	--	--	--	--	--
Micronesia (Federated States of)	--	(116)	--	--	--	--	--	(116)	--
Fiji	--	(117)	--	--	--	--	--	(117, 118)	--
French Polynesia	--	(117)	--	--	--	--	--	(30)	--
Guam	--	(30)	--	--	--	--	--	(30)	--
Kiribati	--	(117, 119)	--	--	--	--	--	(117)	--
Marshall Islands	--	--	--	--	--	--	--	--	--
Nauru	--	--	--	--	--	--	--	--	--
New Caledonia	--	(30)	--	--	--	--	--	(30)	--
Palau	--	--	--	--	--	--	--	--	--
Papua New Guinea	--	(120, 121)	--	--	--	--	--	(122)	--
Samoa	--	(117)	--	--	--	--	--	(117)	--
Solomon Islands	--	(117)	--	--	--	--	--	(117)	--
Tonga	--	(117)	--	--	--	--	--	(117)	--
Tuvalu	--	--	--	--	--	--	--	--	--
Vanuatu	--	(117)	--	--	--	--	--	--	--
Australasia:									
Australia	(123)	(123)	(123)	(123)	(123)	(123)	--	(124)	--
New Zealand				(125)	(125)	(125)	--	(125)	--

Table 6 (D): Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Middle East and Africa

Countries and territories	IDU prevalence (%)			2007 IDU population			HIV prevalence (%)		
	Lower	Mid	Upper	Lower	Mid	Upper	Lower	Mid	Upper
Middle East and North Africa:									
Algeria	--	(126, 127)	--	--	--	--	--	(111, 127, 128)	--
Bahrain	--	(129)	--	--	--	--	(129)	(129)	(129)
Cyprus	(11)	(11)	(11)	(11)	(11)	(11)	--	(130)	--
Egypt	--	(128, 131-134)	--	--	--	--	(135)	(135)	(135)
Iraq		(30)					--	--	--
Israel	--	(136)	--	--	--	--	(136) (137)	(136)	(136)
Jordan	--	(128, 138, 139)	--	--	--	--	--	(129, 138)	--
Kuwait	--	(128, 129)	--	--	--	--	--	(129)	--
Lebanon	--	(140)	--	--	--	--	--	(128, 140)	--
Libyan Arab Jamahiriya	--	(132)	--	--	(132)	--	--	(141)	--
Morocco	--	(141, 142)	--	--	--	--	--	(141)	--
Occupied Palestinian Territories	--	(132)	--	--	--	--	--	(128)	--
Oman	--	(128)	--	--	--	--	(128)	(128, 141)	(141)
Qatar	--	(30, 132)	--	--	--	--	--	(30, 132)	--
Saudi Arabia	--	(128, 143)	--	--	--	--	--	(128)	--
Sudan	--	(30)	--	--	--	--	--	(128)	--
Syrian Arab Republic	--	(132)	--	--	--	--	--	(128)	--
Tunisia	--	(128, 132, 144)	--	--	--	--	--	(144)	--
Turkey	--	(10)	--	--	--	--	(145)	(10, 145)	(10)
United Arab Emirates	--	(132)	--	--	--	--	--	--	--
Yemen	--	(132)	--	--	--	--	--	--	--
Sub-Saharan Africa:									
Angola	--	--	--	--	--	--	--	--	--
Benin	--	--	--	--	--	--	--	--	--
Botswana	--	--	--	--	--	--	--	--	--
Burkina Faso	--	--	--	--	--	--	--	--	--
Burundi	--	--	--	--	--	--	--	--	--
Cameroon	--	--	--	--	--	--	--	--	--
Cape Verde	--	--	--	--	--	--	--	--	--
Central African Republic	--	--	--	--	--	--	--	--	--
Chad	--	--	--	--	--	--	--	--	--
Comoros	--	--	--	--	--	--	--	--	--
Cote d'Ivoire	--	(30)	--	--	--	--	--	--	--
Democratic Republic of the Congo	--	--	--	--	--	--	--	--	--
Djibouti	--	(30)	--	--	--	--	--	(30)	--
Equatorial Guinea	--	--	--	--	--	--	--	--	--
Eritrea	--	--	--	--	--	--	--	--	--
Ethiopia	--	--	--	--	--	--	--	--	--

Gabon	--	(30)	--	--	--	--	--	--	--
Gambia	--	--	--	--	--	--	--	--	--
Ghana	--	(30)	--	--	--	--	--	--	--
Guinea	--	--	--	--	--	--	--	--	--
Guinea-Bissau	--	--	--	--	--	--	--	--	--
Kenya	(146)	(146)	(147)	(146) (148)	(146)	(147) (148)	(149)	(149, 150)	(150)
Lesotho	--	--	--	--	--	--	--	--	--
Liberia	--	--	--	--	--	--	--	--	--
Madagascar	--	--	--	--	--	--	--	--	--
Malawi	--	(151)	--	--	--	--	--	--	--
Mali	--	--	--	--	--	--	--	--	--
Mauritania	--	--	--	--	--	--	--	--	--
Mauritius	(152, 153)	(152, 153)	(152, 153)	(152, 153)	(152, 153)	(152, 153)	--	(152, 153)	--
Mozambique	--	--	--	--	--	--	--	--	--
Namibia	--	--	--	--	--	--	--	--	--
Niger	--	--	--	--	--	--	--	--	--
Nigeria	--	(154, 155)	--	--	--	--	(154) (155)	(154)	(154, 155)
Republic of the Congo	--	--	--	--	--	--	--	--	--
Rwanda	--	--	--	--	--	--	--	--	--
Sao Tome & Principe	--	--	--	--	--	--	--	--	--
Senegal	--	(30)	--	--	--	--	--	--	--
Seychelles	--	--	--	--	--	--	--	--	--
Sierra Leone	--	--	--	--	--	--	--	--	--
Somalia	--	--	--	--	--	--	--	--	--
South Africa	--	(156)	--	--	(156)	--	(157)	(157, 158)	(158)
Swaziland	--	--	--	--	--	--	--	--	--
Togo	--	--	--	--	--	--	--	--	--
Uganda	--	(30)	--	--	--	--	--	--	--
United Republic of Tanzania	--	(131, 159-162)	--	--	--	--	--	(159, 160, 163)	--
Zambia	--	(30)	--	--	--	--	--	--	--
Zimbabwe	--	--	--	--	--	--	--	--	--

References

1. Markosyan KM, Kocharyan A, Potosyan A. Meeting the challenge of injection drug use and HIV in Armenia. Health & Human Rights. 2006;9(1):128-51.
2. Republic of Armenia. HIV/AIDS Epidemic in the Republic of Armenia. In: National Centre for AIDS Prevention, editor.; 2007.
3. AIDS Projects Management Group. Measuring Coverage of HIV Prevention and Care for Injecting Drug Users: Draft Final Report. Sydney: AIDS Project Management Group,; 2007.
4. Nasibov R. Rapid assessment of situation on intravenous drug use related HIV/AIDS in Azerbaijan. The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro; 2005.
5. World Health Organization. Regional Office for Europe. HIV sentinel surveillance in high-risk groups in the Russian Federation, Azerbaijan Republic and the Republic of Moldova: report on a WHO project 1 April 2003 - 31 March 2004. Copenhagen: WHO Regional Office for Europe,; 2004.
6. AIDS Projects Management Group. Assessment of Phase I harm reduction projects funded by Global Fund to fight AIDS, Tuberculosis and Malaria HIV/AIDS grant in Belarus. Sydney: AIDS Projects Management Group; 2006.
7. The Country Coordinating Mechanism for the Global Fund in Bosnia-Herzegovina. Coordinated National Response to HIV/AIDS & Tuberculosis in a war-torn and highly stigmatised setting. Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria; 2005. p. 89.
8. United Nations Office on Drugs and Crime. Audit on the number of injecting drug users in Central and Eastern Europe and Central Asia. New York; 2003.
9. National Focal Point for Drugs and Drug Addictions. Annual Report on the state of the drugs problem in Bulgaria 2006. Sofia: National Drug Council; 2006 October 2006.
10. European Monitoring Centre for Drugs and Drug Addiction. 2007 Annual Report: The State of the Drugs Problem In Europe. Lisbon: EMCDDA; 2007.
11. European Monitoring Centre for Drugs and Drug Addiction. Estimates of Injecting Drug use in Europe. 2008.
12. Akhobadze T. Email "Drug use prevalence data for Georgia". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Tbilisi: IHRD: Open Society Georgia Foundation,; 2008.
13. Stvilia K, Tsertsvadze T, Sharvadze L, Aladashvili M, del Rio C, Kuniholm MH, et al. Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia,. J Urban Health,. 2006 Mar;83(2):289-98.
14. Drug Control Department. 2007 National Report (2006 data) to the EMCDDA by the Reitox National Focal Point: Lithuania New Development, Trends and In-depth Information on Selected Issues: Government of the Republic of Lithuania,; 2007.
15. Kelly JA, Amirkhanian YA. The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe. International Journal of STD & AIDS. 2003 Jun;14(6):361-71.
16. Iliuta C, Bocioc F, Militaru C. Demonstrating the impact of civil society involvement in the target setting process for universal access. Vilnius: Central and Eastern European Harm Reduction Network; 2007.
17. European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point. Romania: Drug Situation 2001. Bucharest: EMCDDA; 2002.
18. Borschevskaya V, Tumano M. Country Report of the Russian Federation on the Implementation of the Declaration of Commitment on HIV/AIDS (UNGASS) January-

December 2005. Moscow: Federal Services for Surveillance of Consumer Rights and Welfare of Russian Federation,; 2006 March 15 2006.
19. Holt E. Slovakia has kept AIDS out despite money problems. The Lancet. 2004 May 22, 2004;363:4.
20. Kiššová Le. Report for the EMCDDA – the REITOX1 National Focal Point in the Slovak Republic: The State of Drug Addiction and Drug Control in the Slovak Republic Developments, trends, and selected issues concerning the drug problem in the Slovak Republic. In: The Government Office of the Slovak Republic, The General Secretariat of the Ministerial Board for Drug Addiction and Drug Control, National Monitoring Centre for Drugs, editors.; 2005. p. 227.
21. Balakiryeva OM, Gusak LM, Dovbakh HV, Lavryenov OO, Paniotto VI, Petrenko TV, et al. Evaluation of the size of most-at-risk-populations vulnerable to HIV infection in Ukraine: analytical report based on the research results. Kyiv: International HIV/AIDS Alliance in Ukraine; 2006.
22. Ministry of Health of Ukraine. Ukraine: National Report on Monitoring Progress Towards the UNGASS Declaration of Commitment on HIV/AIDS - Reporting Period: January 2006 - December 2007. Kyiv: Ministry of Health, Ukraine.; 2008.
23. Donoghoea MC, Bollerup AR, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002–2004. International Journal of Drug Policy. 2007;18(4):271–80.
24. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint Maurice: Institut de Veille sanitaire/French Institute for Public Health Surveillance, European Centre for the Epidemiological Monitoring of AIDS (EuroHIV); 2007 December 2007. Report No.: 76.
25. European Monitoring Centre for Drugs and Drug Addiction. National Prevalence Estimates of Problem Drug Use in the European Union, 1995-2000. . Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA); 2003.
26. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2006. Saint Maurice: Institut de veille sanitaire; 2007. Report No.: 76.
27. Bretteville-Jensen A, Amundsen E. Quantification of intravenous drug use in Norway. Oslo: Norwegian Institute for Alcohol and Drug Research; 2006.
28. Wiessing L. Email "HIV prevalence in the UK". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Lisbon: European Monitoring Centre for Drugs and Drug Addiction 2008.
29. United Nations Office on Drugs and Crime. Patterns and Trends of Amphetamine-Type Stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2006. Bangkok; 2007 June 2007.
30. Ball AL, Rana S, Dehne KL. HIV Prevention among Injecting Drug Users: Responses in Developing and Transitional Countries. Public Health Reports. 1998 June;113(1):12.
31. National Authority for Combating Drugs. Report on Illicit Drug Data and Routine Surveillance Systems in Cambodia 2006. Phnom Penh: Royal Government of Cambodia; 2007.
32. Lu F, Wang N, Wu Z, Sun X, Rehnstrom J, Poundstone K, et al. Estimating the number of people at risk for and living with HIV in China in 2005: methods and results. Sexually Transmitted Infections. 2006 Jun;82(S3):S87-91.
33. Komisi Penanggulangan AIDS. National report on estimates of adults vulnerable to HIV and infection in Indonesia, 2006. Jakarta: National AIDS Commission Indonesia; 2007.
34. United Nations Office on Drugs and Crime. Patterns and Trends of Amphetamine-Type Stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2005. Bangkok; 2006 June 2006.

35. Hidalgo E. Establishing the LCDC Drug Information System: Lao People's Democratic Republic 2005. Vientiane: UNODC Lao Country Office/Lao National Commission for Drug Abuse and Control and Supervision; 2005.
36. The United Nation Office for Control Drug and Crime, The Lao National Commission for the Drug Control and Supervision, The Centre for HIV/AIDS and STI, The Burnet Institute. Drug use and HIV risk: Khamkeuth District (Bolikhamxay), Sing District (Luang Namtha), Khua District (Phongsaly), Lao PDR. Vientiane: The United Nation Office for Control Drug and Crime,The Lao National Commission for the Drug Control and Supervision,The Centre for HIV/AIDS and STI,The Burnet Institute, ; 2005 23 June-27 July 2005.
37. Family Health International. Lao People's Democratic Republic Final Report 1997-2007: USAID,; 2007 July 2007.
38. Phimphachanh C, Sayabounthavong K. The HIV/AIDS/STI situation in Lao People's Democratic Republic. AIDS Education and Prevention. 2004 Jun;16(SA):91-9.
39. Reid G, Kamarulzaman A, Sran SK. Rapid Situation Assessment of Malaysia: The Centre for Harm Reduction; 2004.
40. Government Malaysia. Country Report Malaysia: United Nations General Assembly Special Session on HIV/AIDS Monitoring the Declaration of Commitment on HIV/AIDS 2005.
41. World Health Organization. A Rapid Assesment and Response to HIV and Drug Use in Mongolia - Draft report. Manila: WHO Regional Office for the Western Pacific,; 2006.
42. Miller A. Email "IDU figures Myanmar". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Rangoon: Resource Mobilization and Technical Assistance Coordination Officer, UNAIDS Myanmar,; 2008.
43. United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific. Myanmar – United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific Baseline Assessment Dec 2006
2006.
44. Reid G, Costigan G. Revisiting "The Hidden Epidemic": A Situation Assessment of Drug Use in Asia in the context of HIV/AIDS,. Melbourne: The Centre for Harm Reduction, The Burnet Institute Australia; 2002 January 2002.
45. National Epidemiology Center. 2005 Integrated HIV Behavioral and Serologic Surveillance Findings Summary Report. Manila: Department of Health,; 2005.
46. Global Fund. Proposal Form, Scaling Up HIV Prevention, Treatment, Care and Support Through Enhanced Voluntary Counselling and Testing and Improved Blood Safety Strategies. Phillippines; 2006. p. 153.
47. Philippine National AIDS Council. Country Report of the Philippines. Manilla: Philippine National AIDS Council (PNAC),; 2005.
48. Centres for Disease Control R.O.C. (Taiwan). Populations Vulnerable to HIV Infection. CDC Taiwan 2007 23 November 2007 [cited 2007 24 November]; Available from: http://www.cdc.gov.tw/content.asp?CuItem=7423
49. Cheng SH, Chu F-Y, Chiang S-C, Liu Y-R, Wu Z-Y. Prevalence of hepatitis B, C, D, and human immunodeficiency virus infections among substance users in Taiwan. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney; 2007.
50. Global Fund. Grant Performance Report Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand, : Raks Thai Foundation; 2007. p. 22.
51. Global Fund. Proposal Form: Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand: Raks Thai Foundation; 2003. p. 46.

52. Human Rights Watch. Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights. New York; 2004.
53. World Health Organization. Scaling up Antiretroviral Treatment: Lessons Learnt from Thailand. Report of an external evaluation, 12-19 October 2004. New Delhi: WHO; 2007.
54. Devaney M, Reid G, Baldwin S. Situational analysis of illicit drug issues and responses in the Asia-Pacific region. Canberra: Burnet Institute: Centre for Harm Reduction and Turning Point Alcohol and Drug Centre; 2006.
55. Global Fund. Proposal Form Sixth Call for Proposals. Viet Nam; 2006. p. 123.
56. Ministry of Health. Results from the HIV/STI Intergrated Biological and Behavioral Surveillence (IBBS) in Viet Nam 2005-2006. Hanoi; 2007.
57. United Nations Office on Drugs and Crime. Afghanistan drug use survey 2005. Kabul; 2005 2005.
58. Todd CS, Abed AMS, Strathdee SA, Scott PT, Botros BA, Safi N, et al. HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users, Kabul, Afghanistan,. Emerging Infectious Diseases,. 2007 September 2007,;13(9):5.
59. Reddy A. Size Estimation of IDU in Bangladesh. Dhaka: Family Health International 2005.
60. Azim T, Chowdhury EI, Reza M, Faruque MO, Ahmed G, Khan R, et al. Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh. in press.
61. Azim T, Rahman M, Alam MS, Chowdhury IA, Khan R, Reza M, et al. Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users. International Journal of STD & AIDS. 2008;19(May):327-31.
62. United Nations Office on Drugs and Crime: Regional Office for South Asia. Rapid Situation Response Assesment Bhutan Report - Draft. New Delhi,: UNODC Regional Office for South Asia; 2007.
63. Resource Centre for Sexual Health and AIDS (RCSHA). Report of the Expert Group on Size Estimation of Population with High Risk Behaviour for NACP-III Planning. New Delhi; 2006.
64. National AIDS Control Organization. HIV/AIDS epidemiological Surveillance & Estimation report for the year 2005: National AIDS Control Organization (NACO), Ministry of Health & Family Welfare, Government of India; 2006 April 2006.
65. Mokri A, Schottenfeld R. Drug Abuse and HIV Transmission in Iran—Responding to the Public Health Challenges. Tehran: Tehran University of Medical Sciences and the Iranian National Center for Addiction Studies and Yale University School of Medicine; 2007.
66. Centre for Diseases Management. Islamic Rebublicof Iran Country Report on Monitoring of the United Nations General Assembly Special Session on HIV and AIDS: Office of the Under-secretary for Health, Ministry of Health and Medical Education,Centre for Diseases Management.; 2006.
67. The Foundation for Advancement of Self Help in Attaining Needs (FASHAN), Narcotics Control Board (NCB) of Maldives. Rapid Situation Assessment of Drug Abuse in Maldives 2003,. Male': Narcotics Control Board (NCB) of Maldives,; 2003.
68. National Centre for AIDS and STD Control. National Estimates of Adult HIV Infections, Nepal 2003. Kathmandu, Nepal Ministry of Health, His Majesty's Government of Nepal; 2004 March.
69. Ministry of Narcotics Control, Anti-Narcotics Force, United Nations Office on Drugs and Crime. Problem Drug Use in Pakistan: Results from the National Assesment: United Nations Office of Drugs and Crime,; 2007.

70. National AIDS Control Program. HIV Second Generation Surveillance in Pakistan: National Report Round 1. Islamabad: National AIDS control Program, Ministry of Health; 2005.
71. Kumar S. Injecting of pharmaceutical drugs in the South-Asia: A Review. Chennai; 2006. p. 8.
72. Fernando T, Bridger D. Email "re: Request for data on IDU and HIV prevalance". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Colombo: UNAIDS Sri Lanka and the Maldives; 2008.
73. Niaz K. Email "re: Request for prevalence estimates and Sentinel Surveillance data". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Tashkent: Regional Office in Central Asia, United Nations Office on Drugs and Crime; 2008.
74. Niaz K. Assessment of Problem Drug Use in Central Asia: UNODC/WHO Technical Consultation on Setting Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users (IDU) in Azerbaijan, Kazakhstan, Kyrgyzstan, Taijikistan, Turkmenistan and Uzbekistan. Tashkent: UNODC, WHO; 2007 28 -30 May.
75. Niaz K. Re: Request for prevalence estimates and Sentinel Surveillance data. In: Secretariat of the Reference Group to the United Nations on HIV and injecting drug use, editor. Response to request for data ed. Tashkent, Uzbekistan: Regional Office in Central Asia, United Nations Office on Drugs and Crime; 2008.
76. Sanchez JL, Todd CS, Bautista CT, Botros BAE, Khakimov MM, Giyasova GM, et al. High HIV prevalence and risk factors among injection drug users in Tashkent, Uzbekistan, 2003-2004. Drug and Alcohol Dependence. 2006;82(S1):S15-S22.
77. CAREC. The Caribbean HIV/AIDS Epidemic and the Situation in Member Countries of the Caribbean Epidemiology Centre (CAREC): Caribbean Epidemiology Centre (CAREC) and Pan American Health Organization; 2007 February 2007.
78. World Health Organization. Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections: Barbados. Geneva: WHO; 2006.
79. Brady JE, Friedman SR, Cooper LF, Flom PL, Tempalski B, Gostnell K. Estimating the Prevalence of Injection Drug Users in the U.S. and in Large U.S. Metropolitan Areas from 1992 to 2002. Journal of Urban Health: Bulletin of the New York Academy of Medicine,. 2008;83(3):1099-3460.
80. Reyes J, C., Robles R, R., Colon H, M., Marrero C, A., Matos T, D., Calderon J, M., et al. Severe anxiety symptomatology and HIV risk behavior among Hispanic injection drug users in Puerto Rico. AIDS & Behavior. 2007 January;11(1):145-50.
81. World Health Organization. Approaches to the management of HIV/AIDS in Cuba. Geneva: World Health Organisation; 2004.
82. Inter-American Observatory on Drugs. Qualitative Research on Drug Use: Assessing Emerging Drug Trends in the Caribbean. Washington D.C.: Inter-American Observatory on Drugs (OID); 2004.
83. Hepburn MJ, Lawitz EJ. Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti. BMC Gastroenterology. 2004 Dec 14;4:31.
84. World Health Organization. Access to Antiretroviral Treament and Care: The Experience of the HIV Equity Initiative, Cange, Haiti. Port-au-Prince: WHO; 2003.
85. Gaillard EM, Boulos LM, Andre Cayemittes MP, Eustache L, Van Onacker JD, Duval N, et al. Understanding the reasons for decline of HIV prevalence in Haiti. Sexually Transmitted Infections. 2006 Apr;82(S1):14-20.
86. Figueroa JP. An overview of HIV/AIDS in Jamaica: strengthening the response. West Indian Medical Journal. 2004 Oct;53(5):277-82.
87. Vickers IE, Alveranga H, Smikle MF. Clinical and epidemiological characteristics of adult and adolescent patients newly diagnosed with the human

immunodeficiency virus at a Jamaican clinic for sexually transmitted infections. West Indian Medical Journal. 2005 Dec;54(6):360-3.
88. National HIV/STD Control Programme. National HIV/STI prevention and control program - Facts and figures - HIV/AIDS Epidemic Update January to December 2006. Kingston, Jamaica: Ministry of Health, Health Promotion and Protection Division; 2006 January to December 2006,.
89. Djumalieva D, Imamshah W, Wagner U, Razum O. Drug use and HIV risk in Trinidad and Tobago: qualitative study. International Journal of STD & AIDS. 2002 Sep;13(9):633-9.
90. Rodriguez C, M., Marques L, F., Touze G. HIV and injection drug use in Latin America. AIDS. 2002;16 Suppl 3:S34-41.
91. Sosa-Estani S, Rossi D, Weissenbacher M. Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: high seroprevalence of HIV infection. Clinical Infectious Diseases. 2003 Dec 15;37 Suppl 5:S338-42.
92. Weissenbacher M, Rossi D, Radulich G, Sosa-Estani S, Vila M, Vivas E, et al. High Seroprevalence of Bloodborne Viruses among Street-Recruited Injection Drug Users from Buenos Aires, Argentina. Clinical Infectious Diseases. 2003;37:S348-52.
93. Manzanero M. Email "IVDU Information Belize". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Reponse to request for data ed. Belmopan: National TB, HIV/AIDS and other STIs Programme: Belize; 2008.
94. Pan American Health Organization. AIDS Surveillance in the Americas: Annual Report 2004. Washington, D.C.; 2004.
95. Coordenação Nacional de DST e AIDS. A Política do Ministério da Saúde Para a Atenção Integral a Usuários de Álcool e Outras Drogas. Brasília: Ministério da Saúde; 2003.
96. Hacker MA, Malta M, Enriquez M, Bastos FI. Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic. Revista Panamericana de Salud Pública. 2005;18(4-5):303-13.
97. Pechansky F, Kessler F, Von Diemen L, Inciardi JA, Surratt H. Substance use, risk situations, and HIV seroprevalence among individuals seeking free HIV testing in Porto Alegre, Brazil. Pan American Journal of Public Health. 2005 Oct-Nov;18(4-5):249-55.
98. Pechansky F, Woody G, Inciardi J, Surratt H, Kessler F, Von Diemen L, et al. HIV seroprevalence among drug users: An analysis of selected variables based on 10 years of data collection in Porto Alegre, Brazil. (22 refs.). Drug and Alcohol Dependence. 2006;82(S1):S109-S13.
99. Consejo Nacional Para El Control De Estupefacients (CONACE). Septimo Estudio Nacional De Drogas En Poblacion General De Chile 2006,: Minsterio Del Interior, Gobierno De Chile, ; 2006.
100. Global Fund. Acceleration and Improvement of the National, Intersectoral, Participative and Descentralized Response to the HIV/AIDS epidemic in Chile. Chile: Country Coordinating Mechanism Chile,; 2002. p. 51.
101. Comision Nacional de Sida-Conasida. Epidemiology of HIV/AIDS in Chile. December 2003. Revista Chilena de Infectologia. 2005 Jun;22(2):169-202.
102. Soto RJ, Ghee AE, Nunez CA, Mayorga R, Tapia KA, Astete SG, et al. Sentinel Surveillance of Sexually Transmitted Infection/HIV and Risk Behaviors in Vulnerable Populations in 5 Central American Countries,. Journal of Acquired Immune Deficiency Syndromes,. 2007 September 46(1):101-11.

103. Persaud NE, Klaskala W, Tewari T, Shultz J, Baum M. Drug use and syphilis: Co-factors for HIV transmission among commercial sex workers in Guyana. West Indian Medical Journal. 1999 Jun;48(2):52-6.
104. Ramon JS, Alvarenga M, Walker N, Garcia-Calleja JM, Zacarias F. Estimating HIV/AIDS prevalence in countries with low-level and concentrated epidemics: the example of Honduras. AIDS. 2002 Dec;16(S3):S18-S22.
105. Bravo-García E, Magis-Rodríguez C, Saavedra J. New estimates in Mexico: more than 180,000 people living with HIV. XVI International AIDS Conference. Vancouver; 2006.
106. Frost SDW, Brouwer KC, Firestone Cruz MA, Ramos R, Ramos ME, Lozada RM, et al. Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence,. Journal of Urban Health: Bulletin of the New York Academy of Medicine. 2006 Nov;83(S1):83-97.
107. Strathdee SA, Morgan MP, Semple S, Pu M, Orozovich P, Martinez G, et al. Correlates of injection drug use among female sex workers in two Mexico–U.S. border cities,. Drug and Alcohol Dependence,. 2007:9.
108. Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA). Estudio de ITSS (Infecciones de Transmisión Sexual Sanguínea) y Prácticas de riesgo en UDIs. 2006.
109. Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA). Estudio de Infecciones de Transmision sanguinea y sexual y Practicas de riesgo en Usuarios de Drogas inyectables en Paraguay Informe final.: Organización Panamericana de la Salud/Organización Mundial de la Salud; 2006.
110. National Anti-Drug Council Suriname. SURIDIN Suriname Drug Information Network. Annual National Report 2002,. Paramaribo: National Anti-Drug Council Suriname,; 2002 December 2002.
111. Woratanarat T. Global HIV cohort studies among injecting drug users and future vaccine trials. J Med Assoc Thai. 2006 Jul;89(7):1064-79.
112. UNAIDS. Report on the Global HIV/AIDS epidemic 2002. Geneva: Joint United Nations Programme on HIV/AIDS; 2002.
113. Ialomiteanu A. Email "Estimates of lifetime injecting drug use 15-64 years from the Canadian Addiction Survey 2004" In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Toronto: Centre for Addiction and Mental Health; 2008.
114. Public Health Agency of Canada. HIV/AIDS Epi Updates. August 2006. Ottowa: Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control Public Health Agency of Canada 2006 August 2006.
115. Glynn M, Rhodes P. Estimated HIV Prevelence in the United States at the end of 2003. National HIV Prevention Conference. Atlanta; 2005.
116. UNGASS. Country Report: Federated States of Micronesia: UNGASS; 2006.
117. World Health Organization. Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries (2004-2005). Manila, Philippines: World Health Organisation (WHO), Regional Office for the Western Pacific.; 2006 2006.
118. Pontali E. Email "Info for your Global report". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Response to request for data ed. Genoa: Galliera Hospital and Prison of Genoa; 2008.
119. Wang YA, Cliffe S, Toatu T, Tiban K, Black D, Sullivan E. Prevalence of STI, HIV and risk behaviors among seafarers in Kiribati 2005. XIV International AIDS Conference. Toronto; 2006.
120. McDonald D. A rapid situation assessment of drug use in Papua New Guinea. Drug and Alcohol Review. 2005;24(1):79-82.

121. AusAID. Impacts of HIV/AIDS 2005-2025 in Papua New Guinea, Indonesia and East Timor: Final Report of HIV Epidemiological Modelling and Impact Study. Canberra: Department of Foreign Affairs and Trade; 2006.
122. McBride W. HIV/AIDS in Papua New Guinea: An unfolding disaster? Emergency Medicine Australasia. 2005;17(4):304-6.
123. Razali K, Thein H, Bell J, Cooper-Stanbury M, Dolan K, Dore G, et al. Modelling the hepatitis C virus epidemic in Australia. Drug and Alcohol Dependence. 2007;91(2-3):228-35.
124. National Centre in HIV Epidemiology and Clinical Research. Australian NSP Survey National Data Report 2003-2007: Prevalence of HIV, HCV and Injecting and Sexual Behaviour among IDUs at needle and syringe programs. Sydney: The University of New South Wales,; 2008.
125. Wilkins C, Girling M, Sweetsur P. Recents trends in drug use in New Zealand: 2006. Auckland: Massey University; 2006.
126. UNAIDS. 2006 AIDS Epidemic Update: Middle East and North Africa. Geneva: Joint United Nations Programme on HIV/AIDS; 2006.
127. MESRS. Etude du lien potentiel entre usage problématique de drogues et VIH/SIDA en Algérie. Algeria: UNAIDS; 2006.
128. Jenkins C, Robalino DA. HIV/AIDS in the Middle East and North Africa: The Costs of Inaction. Washington, D.C.: The World Bank; 2003.
129. World Bank. Preventing HIV/AIDS in the Middle East and North Africa: A Window of Opportunity to Act. Washington, D.C.: World Bank; 2005.
130. European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point. Cyprus: New Developments, Trends and in-depth information on selected issues. Lisbon: EMCDDA; 2006.
131. Dewing S, Plüddemann A, Myers B, J., Parry CDH. Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania. Drugs: Education, Prevention and Policy. 2006;13(2):121-37.
132. Grotherath A. Drug abuse and HIV/AIDS in the Middle East and North Africa: a situation assessment: UNODCCP, UNAIDS; 2002.
133. Elshimi T, Warner-Smith M, Aon M. HIV risk-behaviours of problem drug users in greater Cairo Cario: United Nations Office of Drugs and Crime,; 2004.
134. Peles E, Schreiber S, Adelson M. Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel. Drug & Alcohol Dependence. 2006 May 20;82(3):211-7.
135. AIDS Projects Management Group. Recommendations for interventions addressing injecting drug use and related HIV infection in Egypt. Sydney: AIDS Projects Management Group,; 2007. p. 25.
136. Isralowitz R, Reznik A, Spear SE, Brecht ML, Rawson RA. Severity of heroin use in Israel: Comparisons between native Israelis and former Soviet Union immigrants. 2007;102(4):630-7.
137. Gelkopf M, Weizman T, Melamed Y, Adelson M, Bleich A. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Israel Journal of Psychiatry and Related Sciences. 2006;43(2):126-36.
138. Global Fund. Grant Performance Report: Maintaining low HIV prevalence among the population and all vulnerable subpopulations it Jordan. Jordan; 2007. p. 11.
139. Global Fund. Proposal Form Sixth Call for Propsals: Maintaining Low HIV prevalence among the population and all vulnerable sub-populations in Jordan. Jordan; 2006. p. 77.
140. United Nations Office on Drugs and Crime & Institute for Development Research and Applied Care. Substance Use and Misuse in Lebanon. Beirut: UNODC & IDRAC; 2003 May 2003.

141. Toufik A. VIH/Drogues MENA. Paris, France: Observatoire français des drogues et des toxicomanies; 2006.
142. Global Fund. Sixth Call for Proposals of the Global Fund to fight AIDS, Tuberculosis and Malaria: Proposal of the CCM for Morocco. HIV/AIDS and Tuberculosis Components. Kingdom of Morocco; 2006. p. 119.
143. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Al Huzaim NS. Epidemiology of the human immunodeficiency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective. BMC Infectious Diseases. 2004 Aug 6;4:25.
144. Global Fund. Sixth Call for Proposals: Support for Partnership and Strengthening of the Response to the Threat of the Spread of HIV/AIDS in Tunisia. Republic of Tunisia, Ministry of Health. Country Coordinating Mechanism; 2006. p. 122.
145. Kavasoglu E. Email "YNT: Annual Reports Questionnaires (ARQ)". In: Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW, editor. Reponse to request for data ed. Ankara: Ministry of Health; 2008.
146. Beckerleg S, Telfer M, Sadiq A. A Rapid Assessment of Heroin Use in Mombasa, Kenya. Substance Use & Misuse. 2006;41(6-7):1029-44.
147. Beckerleg S, Lewando Hundt G. The characteristics and recent growth of heroin injecting in a Kenyan coastal town. Addiction Research & Theory. 2004;12(1):41-53.
148. AIDS Projects Management Group. Is There Anyone Left in the General Population: A Scan of Information Available on the Context of HIV Transmission and Risk for Vulnerable Groups in Seventeen Countries with Concentrated HIV Epidemics. Sydney: AIDS Projects Management Group, ; 2005 20 August 2005.
149. Odek-Ogunde M, Okoth FA, Lore W, Owiti FR. Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II findings,. International Conference on AIDS July 11-14 2004. Bangkok, Thailand; 2004.
150. Ndetei DM. A study on the linkages between drug abuse, injecting drug abuse and HIV/AIDS in Kenya: A rapid situation assessment 2004: United Nations Office on Drugs and Crime 2004.
151. Bisika T, Konyani S, Chamangwana I. Rapid Situation Assessment of Drug Abuse and HIV/AIDS in Malawi. Malawi: The Ministry of Home Affairs and Internal Security, Inter-Ministerial Committee on Capacity Building for Drug Control Project; 2004.
152. Abdool R, Sulliman FT, Dhannos MI. The injecting drug use and HIV/AIDS nexus in the Republic of Mauritius African Journal of Drug & Alcohol Studies,. 2006;5(2):9.
153. Sulliman F, Ameerberg SAG, Dhannoo MI. Report of the Rapid Situation Assessment and Resonses on Drug Use in Mauritius & Rodrigues. Port Louis: Ministry of Health, Mauritius.; 2004.
154. Adelekan ML, Lawal RA. Drug Use and HIV Infection in Nigeria: A review of recent findings. African Journal of Drug & Alcohol Studies,. 2006;5(2):12.
155. Lawal RA. A rapid situation assessment and response study of drug use, injecting drug use, HIV/AIDS and other risk behaviors among drug users targeting five Nigerian cities. Vienna: UNODC; 2006.
156. Kalichman SC, Simbayi LC, Kagee A, Toefy Y, Jooste S, Cain D, et al. Associations of poverty, substance use, and HIV transmission risk behaviors in three South African communities. Social Science and Medicine. 2006 Apr;62(7):1641-9.
157. Parry CDH, Carney T, Petersen P, Dewing S, Needle R. HIV risk behavior in South African drug users: A tale of three cities. Alcohol & Drug Abuse Research Unit, Medical Research Council South Africa.; 2007. p. 30.
158. Parry C, Nwanyanwu O, Needle R, Achrekar A. HIV and Drug Use Among Injection Drug Users (IDUs), Commercial Sex Workers (CSWs), and Men who have Sex

with Men (MSM) in South Africa. The President's Emergency Plan for AIDS Relief Annual Meeting: The 2006 HIV/AIDS Implementers' Meeting. Durban; 2006.
159. Williams ML, McCurdy SA, Atkinson JS, Kilonzo GP, Leshabari MT, Ross MW. Differences in HIV Risk Behaviors by Gender in a Sample of Tanzanian Injection Drug Users. AIDS and Behavior. 2007;11(1):137-44.
160. Timpson S, et al. Substance Abuse, HIV Risk and HIV/AIDS in Tanzania. African Journal of Drug & Alcohol Studies. 2006;5(2):158-69.
161. McCurdy SA, Ross MW, Gad PK, Leshabari MT, Williams ML. HIV/AIDS and injection drug use in the neighborhoods of Dar es Salaam, Tanzania. Drug and Alcohol Dependence. 2006;82(S1):S23-S7.
162. Dahoma M, Salim A, Abdool R, Othman A, Makame H, Ali S, et al. HIV and Substance Abuse: the dual epidemics challenging Zanzibar. African Journal of Drug & Alcohol Studies. 2006;5(2):130-9.
163. McCurdy A, Williams M, Kilonzo G, Ross M, Leshabari M. Heroin and HIV risk in Dar es Salaam, Tanzania: Youth hangouts, mageto and injecting practices. AIDS Care. 2005;17(1):65-78.

Appendix E: Details of data included in the estimates of the prevalence of injecting drug use and HIV among IDUs

Eastern Europe

Armenia

Prevalence of injecting drug use

Year	2000		
Method	Govt estimate – method not detailed		
N=			
Area	National		
Estimate	2000 IDU, with 50% of these in the capital city Yerevan		
Reference	(Markosyan, Kocharyan et al. 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D1

Calculation

Prevalence (15-64 years) in 2000 = 2,000/1,975,000 = 0.1013%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	not detailed		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	National		
Estimate	6.8%		
Reference	(Markosyan, Kocharyan et al. 2006) (Republic of Armenia 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D1

High:

Year	2002		
Method	Second Generation HIV surveillance		
Sample type	not detailed		
Seroprev/self rpt	not detailed		
N=	not detailed		
Area	National		
Estimate	approx 15% (range 11-20%)[use 20% as the high]		
Reference	(Republic of Armenia 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Azerbaijan

Prevalence of injecting drug use

Mid:

Year	2006		
Method	Indirect prevalence estimate		
N=	-		
Area	National		
Estimate	From 2004 rapid assessment – survey of IDU: 4.8 of IDU surveyed were officially registered 17 714 officially registered drug users estimated 87% (15 411)of these are IDU - **If** there are 15 411 registered IDU **and if** 4.8% of IDU are registered – assuming rates of registration are the same in 2004 and 2006 use multiplier of 20 to determine total number of IDU both registered and unregistered = 300 000 IDU		
Reference	(AIDS Projects Management Group 2007) This reference cites: Abdullayev A., Nasibov R. 2004. Rapid Assessment of the situation on the spread of intravenous drug use and HIV/AIDS. Final report. Baku, Azerbaijan. (Nasibov 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Low-High:

Year	2004		
Method	Sentinel Surveillance – multiple sites/different samples		
Sample type	Street sample (snowball method) and treatment sample		
Seroprev/self rpt	sero-sampling		
N=	Baku: 100 treatment sample; 100 street sample Lenkoran: 200 street sample		
Area	2 cities Baku and Lenkoran		
Estimate	Baku treatment sample – 2% **[use as low]** Baku street sample – 24% **[use as high]** Lenkoran street sample – 19.5%**[within range]**		
Reference	(World Health Organization. Regional Office for Europe 2004)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Belarus

Prevalence of injecting drug use

Year	2005		
Method	Registered drug users		
N=			
Area	National		
Estimate	9 872 registered drug users 63.9% are IDU = 6 308		
Reference	(AIDS Projects Management Group 2006)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Government: Belarus Ministry of Health		
Sample type	Government testing		
Seroprev/self rpt	Seroprevalence		
N=	3 477		
Area	assume national		
Estimate	1.5%		
Reference	(AIDS Projects Management Group 2006)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Bosnia and Herzegovina

Prevalence of injecting drug use

Year	2005		
Method	Not given		
N=	-		
Area	National		
Estimate	IDU reported to occur – extent not known (Low: 6 000 and High: 10 000 provided but no method given and)		
Reference	(The Country Coordinating Mechanism for the Global Fund in Bosnia-Herzegovina 2005)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	D2

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	National		
Estimate	HIV has been reported among IDU		
Reference	(United Nations Office on Drugs and Crime 2003)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	

Year	2005		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	National		
Estimate	HIV prevalence in specific vulnerable groups (IDUs, CSWs, and MSM) <5%		
Reference	(United Nations Office on Drugs and Crime 2003)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	

Bulgaria

Prevalence of injecting drug use

Year	2005		
Method	Indirect prevalence estimate: Multiplier Method Using Treatment Data and a study using the Capture-recapture method, also experts estimations are used and long term observations		
N=			
Area	National		
Estimate	Problem drug users: L: 20 000 H: 30 000 Capital city Sofia: 11 993 IDU: Capital city Sofia: 9686		
Reference	(National Focal Point for Drugs and Drug Addictions 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation:

Assume proportion of IDU/DU is the same nationally as in Sofia = 9 686 / 11 993 = 0.81

- → National IDU Low = 0.81 x 20 000 = 16 200
- → National IDU High = 0.81 x 30 000 = 24 300

Prevalence (15-64) 2005 Low = 16,200/5,346,000 = 0.3030%
High = 24,300/5,346,000 = 0.4545%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2006		
Method	Sentinel surveillance		
Sample type	Prison only – 6 sites		
Seroprev/self rpt	sero sample		
N=	2006: 613		
Area	National (prison only)		
Estimate	2006: 0.0		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2006		
Method	Sentinel surveillance - multisite		
Sample type	Drug treatment centres, out patient, drug detox, NSP, HIV testing centre, low threshold service,		
Seroprev/self rpt	sero sample		
N=	2006: 487		
Area	Capital city only		
Estimate	2006: 0.8		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Croatia

Prevalence of injecting drug use

Year	2001		
Method	-		
N=	-		
Area	National		
Estimate	215/100 000 in total population		
Reference	(United Nations Office on Drugs and Crime 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D2

Calculation
If total population in 2001 = 4 599 000 → 9888 IDU in total in 2001

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	323		
Area	National (multicity including: Zagreb, Rikeka,Split, Zadar, Slavonski Brod, Osijek & Dubrovnik		
Estimate	0.6		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

Czech Republic

Prevalence of injecting drug use

Year	2006		
Method	Data sources: Low-threshold facilities. HCV national study – in treatment rate (portion of above mentioned persons in contact with low-threshold facilities, nomination technique used)		
N=			
Area	National		
Estimate	age range 15-64 29,000 Interval from sensitivity analysis (SI): 25,494-33,823		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2008)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Low:

Year	2006		
Method	sentinel surveillance		
Sample type	NSP and low threshold service		
Seroprev/self rpt	Seroprevalence		
N=	728		
Area	National		
Estimate	0.0		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

High:

Year	2006		
Method	Sentinel surveillance		
Sample type	STI clinics other hospitals of clinics prisons HIV testing centres		
Seroprev/self rpt	Seroprevalence		
N=	994		
Area	National		
Estimate	0.1%		
Reference	As cited in (European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Estonia

Prevalence of injecting drug use

Year	2004		
Method	Estonian Police Database. Health Insurance Fund. State HIV Reference Laboratory. Capture-recapture.		
N=			
Area	National		
Estimate	total number of users: median 13801 (95% CI: 8178-34732) prevalence 15-64years old: 1.51% 95% CI: 0.89-3.79% The original age range of study was 15-44, rates have been adjusted to 15-64.		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	surveillance – single site		
Sample type	drug treatment		
Seroprev/self rpt	sero – dried blood spot		
N=	350		
Area	Tallin		
Estimate	54.3%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2005		
Method	surveillance		
Sample type	drug treatment		
Seroprev/self rpt	sero – dried blood spot		
N=	99		
Area	Kohtla-Jarve		
Estimate	89.9%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Georgia

Prevalence of injecting drug use

Low:

Year	2004		
Method	Registration of drug users by Ministry of Health – Narcologic Register		
N=			
Area	National		
Estimate	14,400 IDU		
Reference	(Akhobadze 2008) Personal communication		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Calculation:

Prevalence (15-64years) in 2004 = 14,400/3,004,000 = 0.4793%

High:

Year	2002		
Method	representative community sample – outpatient clinics		
N=	2000		
Area	T'bilisi		
Estimate	8.1% lifetime injecting (n=162) 7.9% current injecting [definition not given] (n=158)		
Reference	(Stvilia, Tsertsvadze et al. 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	yes	**Grade**	B

Prevalence of HIV amongst people who inject drugs

Low:

Year	2004		
Method	Sentinel surveillance – number of sites and sample types not given		
Sample type			
Seroprev/self rpt			
N=			
Area	National		
Estimate	1.4% among IDU		
Reference	(Akhobadze 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2001-2002		
Method	representative community sample – outpatient clinics		
Sample type	general outpatient clinic		
Seroprev/self rpt	Seroprevalence		
N=	number of IDU among sample 162		
Area	T'bilisi		
Estimate	3/162 = 1.85%		
Reference	(Stvilia, Tsertsvadze et al. 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Hungary

Prevalence of injecting drug use

Year	2005		
Method	IDUs. Treatment and police data. Capture-recapture.		
N=	-		
Area	National		
Estimate	Median: 3941 Low: 2069 High: 5813		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Diagnostic testing, 4 sites		
Sample type	Public Health Laboratories, IDU status not known, prevalence in IDU likely to be underestimated		
Seroprev/self rpt	sero		
N=	69		
Area	National		
Estimate	0.0		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Year	2006		
Method	Specific prevalence study, 10 sites		
Sample type	NSP, drug treatment centre		
Seroprev/self rpt	Seroprevalence – dried blood spots		
N=	69		
Area	National		
Estimate	0.0		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Latvia

Prevalence of injecting drug use

Year	2002		
Method	Mortality Multiplier		
N=			
Area	National		
Estimate	***Estimates on problematic drug use available only*** IDU reported to occur but extent not known		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Low:

Year	2003		
Method	diagnostic testing 2 sites		
Sample type	other hospital or clinics arrest data		
Seroprev/self rpt	serum		
N=	93		
Area	National		
Estimate	9.7%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

High:

Year	2003		
Method	diagnostic testing		
Sample type	Drug treatment centre other hospital or clinic		
Seroprev/self rpt	-		
N=	987		
Area	National		
Estimate	6.6%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Lithuania

Prevalence of injecting drug use

Year	2006		
Method	Registration – drug addicted cases		
N=			
Area	National		
Estimate	5,123 IDU		
Reference	(Drug Control Department 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	C

Calculation

2006 Prevalence (15-64%) of registered IDU = 5,123/2,327,000 = 0.2201%

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method	Diagnostic testing		
Sample type	Drug treatment centre, NSP, other hospital or clinic		
Seroprev/self rpt	Seroprevalence		
N=	1112		
Area	National		
Estimate	2.4%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Moldova

Prevalence of injecting drug use

Year	2001		
Method	Registered drug users		
N=			
Area	National		
Estimate	0.092% in the general population		
Reference	(United Nations Office on Drugs and Crime 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Calculation

0.092% in total population of 4,142,000 = 3,810 IDU in 2001

Prevalence among 15-64 year olds in 2001= 3810/2,715,000 = 0.14%

Prevalence of HIV amongst people who inject drugs

Year	2001		
Method	surveillance study		
Sample type	drug treatment		
Seroprev/self rpt			
N=			
Area			
Estimate	17%		
Reference	*UNAIDS/UNDP Moldova Project. HIV/AIDS/STIs: situational analysis in Moldova. Chisinau: UNAIDS, 2001* As cited in (Kelly and Amirkhanian 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	B

Poland

Prevalence of injecting drug use

Year	2002		
Method			
N=			
Area	National		
Estimate	**NB: Estimate of *problematic drug users* only** median: 0.19% (52 000) low: 0.12% (33 000) high: 0.27% (71 000) Injecting drug use known to occur but extent unknown		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	**-**

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Diagnostic testing		
Sample type	Public Health Laboratories HIV Testing Centres		
Seroprev/self rpt	serum		
N=	910		
Area	National		
Estimate	8.9%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Romania

Prevalence of injecting drug use

Year	2004		
Method	population survey		
N=			
Area	Bucharest		
Estimate	Injecting drug use reported to occur but extent not known		
Reference	(Iliuta, Bocioc et al. 2007)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	

Year	2001		
Method	Rapid assessment data from NGOs, treatment centres, police double counting possible		
N=			
Area	Bucharest, Constanta, Iasi, Timisoara		
Estimate	**IDU reported** but extent nationally not known (25,000-40,000 in Bucharest only)		
Reference	(European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point 2002)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	diagnostic testing; 2 sites		
Sample type	drug treatment centres including: out/inpatient, maintenance, drug free/detox centres		
Seroprev/self rpt	serum		
N=	136		
Area	Bucharest		
Estimate	1.44%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Russian Federation

Prevalence of injecting drug use

Year	2007		
Method	-		
N=	-		
Area	National		
Estimate	2.5 million DU and 73% are IDU = 1,825,000 IDU		
Reference	(AIDS Projects Management Group 2007) This reference cites: Ministry of Public Health and the National Research Centre on Addictions		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D1

Prevalence of HIV amongst people who inject drugs

Year	2003-2005		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	multicity		
Estimate	Moscow Pskov Velikiy Novgorod Cherepovets Biysk Barnaul St. Petersburg	12.41% 0.3% 14.9% 11.5% 74% 3.5% 32%	2003 2003 **USE AS LOW** 2004 2004 2005 **USE AS HIGH** 2005 2005
Reference	(Borschevskaya and Tumano 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	B

Slovakia

Prevalence of injecting drug use

Year	2006		
Method	Unpublished data		
N=			
Area	National		
Estimate	Low: 13,732 Mid: 18,841 High: 34,343		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	specific prevalence study		
Sample type	Drug treatment centre		
Seroprev/self rpt	serum		
N=	79		
Area	Bratislava and surroundings		
Estimate	0.0%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007) Negligible prevalence of HIV among IDU also confirmed in (Holt 2004) and (Kiššová 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Ukraine

Prevalence of injecting drug use

Year	2006		
Method	Multiple indirect estimation methods: Multiplier methods and respondent driven sampling		
N=	-		
Area	National		
Estimate	Low: 325,000 High: 425,000		
Reference	(Balakiryeva, Gusak et al. 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Sentinel surveillance		
Sample type			
Seroprev/self rpt	serum		
N=			
Area	National		
Estimate	41.8%		
Reference	(Ministry of Health of Ukraine 2008)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	B

Central Asia

Kazakhstan

Prevalence of injecting drug use

Year	2006		
Method	indirect prevalence estimate Multipliers at province level: percentage of interviewed IDU registered with Narcological Services; provincial estimates added together to produce total country estimate		
N=	200 people per province [assumed all 14 provinces were included]		
Area	National		
Estimate	**100 000 injecting drug users.**		
Reference	(AIDS Projects Management Group 2007; Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation

Prevalence (15-64y) in 2006 = 100,000/10,439,000 = 0.96%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	CDC Sentinel Surveillance		
Sample type			
Seroprev/self rpt			
N=			
Area	Shimkent		
Estimate	HIV prevalence among IDU 8%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2005		
Method	CDC Sentinel Surveillance		
Sample type			
Seroprev/self rpt			
N=			
Area	Pavlodar [uncertain if province or city referred to]		
Estimate	HIV prevalence among IDU 10.4%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Kyrgyzstan

Prevalence of injecting drug use

MID:

Year	2006		
Method	Indirect prevalence estimate Multipliers at province level: percentage of interviewed IDU registered with Narcological Services; Provincial estimates added together to produce total country estimate		
N=	200 people per province [assumed all 7 provinces were included];		
Area	National		
Estimate	25 000 injecting drug users		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation

Prevalence (15-64y) in 2006 = 25,000/33,573,000 = 0.74%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type			
Seroprev/self rpt			
N=			
Area	Bishkek [uncertain if province or city referred to]		
Estimate	HIV prevalence among IDU 2.4%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type			
Seroprev/self rpt			
N=			
Area	Osh City		
Estimate	HIV prevalence among IDU 13.6%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Tajikistan

Prevalence of injecting drug use

Year	2006		
Method	Indirect prevalence estimate Multipliers at province level: percentage of interviewed IDU registered with Narcological Services; Provincial estimates added together to produce total country estimate		
N=	200 people per province [assumed all 7 provinces were included];		
Area	National		
Estimate	17 000 injecting drug users		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation

Prevalence (15-64y) in 2006 = 17,000/3,814,000 = 0.45%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type			
Seroprev/self rpt			
N=			
Area	Khujant City		
Estimate	HIV prevalence among IDU 11.5%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type			
Seroprev/self rpt			
N=			
Area	Dushanbe City		
Estimate	HIV prevalence among IDU 17.9%		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Turkmenistan

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	IDU reported to occur		
Reference	(AIDS Projects Management Group 2007) This reference cites: *Report No. 32495-KZ Republic of Turkmenistan- Evaluation of National Tuberculosis and HIV/AIDS Programs, World Bank Human Development Sector Unit Central Asia Country Unit Europe and Central Asia Region, June 2005, Accessed 19 July 2007*		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2007		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(AIDS Projects Management Group 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Uzbekistan

Prevalence of injecting drug use

Year	2006		
Method	Indirect prevalence estimate Multipliers at province level: percentage of interviewed IDU registered with Narcological Services; Provincial estimates added together to produce total country estimate		
N=	200 people per province [assumed all 7 provinces were included];		
Area	National		
Estimate	80 000 injecting drug users		
Reference	(AIDS Projects Management Group 2007; Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation

Prevalence (15-64y) in 2006 = 80,000/16,977,000 = 0.47%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	Samarkand City		
Estimate	HIV prevalence among IDU 11.7% in		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2005		
Method	CDC Sentinel Surveillance for 2005		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	Tashkent City		
Estimate	HIV prevalence among IDU 19.5% in		
Reference	(Niaz 2007; Niaz 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

East and South East Asia

Brunei Darussalam

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(United Nations Office on Drugs and Crime 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Cambodia

Prevalence of injecting drug use

Year	2004		
Method	Expert consensus estimate; Delphi technique		
N=	-		
Area	National		
Estimate	1,750 IDU (90% CI:1,000-7,000)		
Reference	(National Authority for Combating Drugs 2007) This reference cites: *2005 Family Health International (2004). "Consensus Estimates of the Number of Problem Drug Users in Cambodia, 2004."*		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Prevalence of HIV amongst people who inject drugs

Low:

Year	2006		
Method	surveillance – two treatment sites		
Sample type	treatment/harm reduction centre		
Seroprev/self rpt			
N=	63		
Area	-		
Estimate	14.3%		
Reference	(National Authority for Combating Drugs 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2004		
Method	surveillance – two treatment sites		
Sample type	treatment/harm reduction centre		
Seroprev/self rpt			
N=	32		
Area			
Estimate	31.3%		
Reference	(National Authority for Combating Drugs 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	B

- Even though these estimates were for three different years because each of these sample sizes were small it was decided to use these as a range rather than take the most recent estimate.

Within range:

Year	2005		
Method	surveillance – two treatment sites		
Sample type	treatment/harm reduction centre		
Seroprev/self rpt			
N=	31		
Area			
Estimate	16.1%		
Reference	(National Authority for Combating Drugs 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	B

China

Prevalence of injecting drug use

Year	2005		
Method	Indirect prevalence estimate		
N=			
Area			
Estimate	Low: 1.8 Million High: 2.9 Million		
Reference	(Lu, Wang et al. 2006)		
1˚ or 2˚ source			
Peer reviewed	Yes	**Grade**	A

Calculation

Prevalence (15-64 years) in 2005 = low: 1,800,000/928,743,000 = 0.1938%
= high 2,900,000/928,743,000 = 0.3122%

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	UNAIDS Workbook method		
Sample type			
Seroprev/self rpt			
N=			
Area	National		
Estimate	Low: 230,800 High: 344,900		
Reference	(Lu, Wang et al. 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	Yes	**Grade**	A

Calculation:

Low= (low number of IDU living with HIV) / (high number of IDU) = 7.96%
High= (high number of IDU living with HIV) / (low number of IDU) = 19.16%
Mid= (mid number of IDU living with HIV) / ((High number of IDU + low number of IDU)/2) = 12.25%

Democratic People's Republic of Korea

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data available		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data available		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Indonesia

Prevalence of injecting drug use

Year	2006		
Method	Indirect prevalence estimates: Three different multiplier methods		
N=			
Area			
Estimate	Mid: 219,130 Low: 190,460 High: 247,800		
Reference	(Komisi Penanggulangan AIDS 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Calculation

Prevalence (15-64 years) in 2006 = low: 190,460/151,820,000 = 0.1255%
= high 247,800/151,820,000 = 0.1632%

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type	Multi site, multi samples		
Seroprev/self rpt			
N=			
Area			
Estimate	Low: 31.73% High: 53.26% Within range: 41.09%		
Reference	(Komisi Penanggulangan AIDS 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Japan

Prevalence of injecting drug use

Year	2004		
Method	Ministry of Health estimate- not detailed		
N=			
Area			
Estimate	400,000		
Reference	(United Nations Office on Drugs and Crime 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	D1

Calculation

Prevalence (15-64 years) in 2004 = low: 400,000/85,315,000 = 0.4689%

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported: 34 PLWHA known to be IDU		
Reference	(United Nations Office on Drugs and Crime 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	-

Lao PDR

Prevalence of injecting drug use

Year	2002; 2004; 2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Hidalgo 2005)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Year	2002; 2004; 2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(United Nations Office on Drugs and Crime, The Lao National Commission for the Drug Control and Supervision et al. 2005) (Family Health International 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU known to occur (0.09% of reported HIV is due to IDU)		
Reference	(Phimphachanh and Sayabounthavong 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Malaysia

Prevalence of injecting drug use

Low:

Year	2002		
Method	Multiplier methods using self-reported HIV transmission methods from rehabilitation centres, police roundups and mandatory testing, premarital mandatory testing and VCT centres		
N=			
Area			
Estimate	170,000		
Reference	(Huang and Hussein 2004) As cited in (Reid, Kamarulzaman et al. 2004)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	C

Low:

Year	2002		
Method	WHO and Ministry of Health consensus meeting		
N=			
Area			
Estimate	170,000		
Reference	*Futures Group 2003* As cited in (Reid, Kamarulzaman et al. 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

Calculation

Prevalence (15-64 years) in 2002 = 170,000/15,370,000 = 1.1061%

High:

Year	2002		
Method	Multiplier methods using self-reported HIV transmission methods from rehabilitation centres, police roundups and mandatory testing, premarital mandatory testing and VCT centres		
N=			
Area			
Estimate	240,000		
Reference	(Huang and Hussein 2004) As cited in (Reid, Kamarulzaman et al. 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

High:

Year	2002		
Method	WHO and Ministry of Health consensus meeting		
N=			
Area			
Estimate	240,000		
Reference	*Futures Group 2003* As cited in (Reid, Kamarulzaman et al. 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

Calculation

Prevalence (15-64 years) in 2004 = 240,000/15,370,000 = 1.5614%

Prevalence of HIV amongst people who inject drugs
MID

Year	2002		
Method	Sentinel surveillance		
Sample type	27 drug rehabilitation centres and 33 prisons		
Seroprev/self rpt			
N=	50,351		
Area	National		
Estimate	10.3% In 2000- 19.6% (N=9,500) In 2001- 13.2% (N=35,763)		
Reference	(Government Malaysia 2005)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Mongolia

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	Limited amount of injecting reported to occur		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

Myanmar

Prevalence of injecting drug use

Low & High

Year	2007		
Method	Consensus estimates from a Multi-stakeholder estimation workshop involving Ministry of Health, WHO, UNAIDS, and NGOs working in Myanmar		
N=			
Area			
Estimate	Low: 60,000 High: 90,000		
Reference	(Miller 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	C

Year	2006		
Method	Department of Health estimate		
N=			
Area			
Estimate	60,000		
Reference	(United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	D1

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Consensus estimates from a Multi-stakeholder estimation workshop involving Ministry of Health, WHO, UNAIDS, and NGOs working in Myanmar		
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	42.6%		
Reference	(Miller 2008)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	C

Republic of Korea

Prevalence of injecting drug use

Year	2002		
Method			
N=			
Area			
Estimate	IDU reported, extent unknown		
Reference	(Reid and Costigan 2002)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2002		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported (2 known cases in 2002)		
Reference	(Reid and Costigan 2002)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Philippines

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur		
Reference	(National Epidemiology Center 2005) (Global Fund 2006) (Philippine National AIDS Council 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	sentinel surveillance,		
Sample type	purposive sampling – recruitment otherwise not detailed		
Seroprev/self rpt	sero		
N=	243		
Area	Cebu City		
Estimate	1%		
Reference	(National Epidemiology Center 2005)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	B

Singapore

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known. Heroin and buprenorphine injection known to occur		
Reference	(United Nations Office on Drugs and Crime 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Taiwan

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	IDU reported		
Reference	(Centres for Disease Control R.O.C. (Taiwan) 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

LOW:

Year	2004		
Method	None detailed		
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	2%		
Reference	(Centres for Disease Control R.O.C. (Taiwan) 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	D1

HIGH:

Year	2006		
Method			
Sample type	Single population- 1 site (detox center)		
Seroprev/self rpt			
N=	192		
Area			
Estimate	25.6%		
Reference	(Cheng, Chu et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	B

Thailand

Prevalence of injecting drug use

Year	2001		
Method	None described		
N=			
Area			
Estimate	160,528		
Reference	(Global Fund 2007) (Global Fund 2003) (Human Rights Watch 2004) All these references cite *Thai Epidemiology Working Group*		
1˚ or 2˚ source			
Peer reviewed		**Grade**	D1

Calculation

Prevalence (15-64 years) in 2001= 160,528/42,796,000 = 0.3751%

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method	Sentinel surveillance		
Sample type	Single population- treatment centres		
Seroprev/self rpt			
N=			
Area			
Estimate	42.5%		
Reference	(World Health Organization 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	B

Timor Leste

Prevalence of injecting drug use

Year	2005		
Method			
N=			
Area			
Estimate	IDU reported to occur but no estimate of extent (use among university sample reported).		
Reference	(Devaney, Reid et al. 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Viet Nam

Prevalence of injecting drug use

Year	2005		
Method			
N=			
Area			
Estimate	180,406 drug users were reported, 75% will be IDUs. = 135,305 IDU		
Reference	(Global Fund 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	no	**Grade**	D1

Calculation

Prevalence (15-64 years) in 2005= 135,305/55,102,000 = 0.2456%

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Sentinel surveillance		
Sample type	Rehabilitation center populations		
Seroprev/self rpt			
N=	Hanoi (N= 296) Hai Phong (N=301) Quang Ninh (N=266) Da Nang (N=274) HCMC (N=296) Can Tho (N=299) An Giang(N=300)		
Area	Multi-city		
Estimate	Hanoi- 23.9% Hai Phong- 65.8% **USE AS HIGH** Quang Ninh- 58.7% Da Nang- 1.9% **USE AS LOW** HCMC- 34.0% Can Tho- 36.6% An Giang-13.3%		
Reference	(Ministry of Health 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	B

South Asia

Afghanistan

Prevalence of injecting drug use

Year	2005		
Method	Comparison between estimates of drug use provided by key informants and estimates provided by drug users		
N=	1480 key informants and 1393 drug users were interviewed in provincial capitals, district centres and villages		
Area	National		
Estimate	▪ 49,536 heroin users in the country in total ▪ Urban male: 19698(40%); Urban female: 1968(4%); Urban child: 13(<1%) ▪ Rural Male: 26103(53%); Rural female: 1500(3%); Rural child: 256(1%) ▪ 15% of male heroin users inject ▪ <1% of female heroin users in Kabul inject		
Reference	(United Nations Office on Drugs and Crime 2005)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation:

Heroin injectors based on figures in ***(United Nations Office on Drugs and Crime 2005)***:

- *Assuming 15% of 45,801 male heroin users inject= 6870*
- *Assuming 15% of 269 'child' heroin users inject = 40*
- *Assuming 1% of 1,968 female heroin users inject = 20*
- *Assuming 0% of rural female heroin users inject*

→ **High = 6,930**

- *Assuming 0% of 'child' and female heroin users inject*

→ **Low = 6,870**

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005-2006		
Method	cross sectional study convenience sample-accessed via outreach workers IDUs who had injected in the past 6 months		
Sample type	street outreach, male IDU		
Seroprev/self rpt	Seroprevalence		
N=	464		
Area	Kabul		
Estimate	3% 95% CI: 1.7% - 5.1%		
Reference	(Todd, Abed et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	B

Bangladesh

Prevalence of injecting drug use

Low:

Year	2005		
Method	consensus estimate		
N=			
Area	National		
Estimate	20,000 – 40,000		
Reference	(Reddy 2005) (Azim, Chowdhury et al. in press)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	C

Calculations:

Prevalence (15-64 years) = 20,000/93,941,000 = 0.0213%
Prevalence (15-64 years) = 40,000/93,941,000 = 0.0426%

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	sentinel surveillance IDU from 18 cities IDU = those who injected in the past year all 15 years or older		
Sample type	Drop in centres, Out reach		
Seroprev/self rpt	serum		
N=	4,095 male IDU 121 female IDU		
Area	National		
Estimate	National: male 1.9% Use as HIGH National: female 0.8% Use as LOW (Dhaka overall 7%)		
Reference	(Azim, Rahman et al. 2008)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	A

HIV epidemic among IDU is concentrated in one area in Central Dhaka.

Bhutan

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	Injection of heroin, propoxyphene and buprenorphine reported. 37/200 DU reported ever having injected		
Reference	(United Nations Office on Drugs and Crime: Regional Office for South Asia 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU not reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

India

Prevalence of injecting drug use

Low:

Year	2006		
Method	Indirect prevalence estimate Mapping and size estimation exercise		
N=	-		
Area	National		
Estimate	Total: 106,518 (male: 96,463) (female: 10,055)		
Reference	(Resource Centre for Sexual Health and AIDS (RCSHA) 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculations

Prevalence (15-64 years) = 106,518/718,877,000 = 0.0148%

High:

Year	2006		
Method	Indirect prevalence estimate		
N=	-		
Area	National		
Estimate	Total: 223,121 (male: 189,729) (female: 33,392)		
Reference	(Resource Centre for Sexual Health and AIDS (RCSHA) 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculations

Prevalence (15-64 years) = 223,121/718,877,000 = 0.0310%

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method	Sentinel surveillance		
Sample type	treatment centres (drug de-addiction centres), targeted intervention sites		
Seroprev/self rpt	serum		
N=	4,978 (male= 4550 female=428)		
Area	National		
Estimate	11.15% (male= 11.65 female= 5.84)		
Reference	(National AIDS Control Organization 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Iran

Prevalence of injecting drug use

Use as Mid:

Year	2004		
Method	indirect prevalence estimate from Rapid situation assessment - looked at street drug users only		
N=	-		
Area	National		
Estimate	180,000 [→ prev (15-64y 2004) = 0.39922%]		
Reference	(Mokri and Schottenfeld 2007) This reference sites: *Narenjiha, H. (2005) Rapid Situation Assessment of Drug Abuse and Drug Dependence in Iran. Unpublished manuscript [in Persian], Darius Institute.*		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Excluded: More recent data of equal grade is available

Year	1998		
Method	indirect prevalence estimate from Rapid situation assessment - number of receiving drug treatment - multiplier: percentage of registered drug users reporting participation in drug treatment - 16% of DU = IDU		
N=	-		
Area	National		
Estimate	166,000 [→ prev (15-64y 1998) = 0.44705%]		
Reference	(Mokri and Schottenfeld 2007) This reference sites: *Razzaghi, E. M., Rahimi, A., Hosseini, M., Madani, S., & Chatterjee, A. (1999). Rapid Situation Assessment (RSA) of Drug Abuse in Iran (1998-1999). Prevention Department, State Welfare Organization, Ministry of Health, I. R. of Iran, and United Nations International Drug Control Program.*		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Excluded as higher grade data available

Year	2001		
Method	Adjusted population estimate Ministry of health Based on emergency room visits		
N=	-		
Area	National		
Estimate	137,000 [→ prev (15-64y 2001) = 0.33178%]		
Reference	(Mokri and Schottenfeld 2007) This reference sites: *Yassami, M. T. (2002) Epidemiology of Drug Abuse in the Islamic Republic of Iran. Unpublished manuscript [in Persian]. Islamic Republic of Iran Ministry of Health and Medical Education; Drug Control Headquarters.*		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	Surveillance		
Sample type	unknown		
Seroprev/self rpt	Seroprevalence		
N=	-		
Area	National		
Estimate	5%-25% regional variation		
Reference	(Centre for Diseases Management 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Maldives

Prevalence of injecting drug use

Year	2003, 2006		
Method			
N=			
Area			
Estimate	IDU reported to occur (8% of drug users reported injecting) - extent not known		
Reference	(The Foundation for Advancement of Self Help in Attaining Needs (FASHAN) and Narcotics Control Board (NCB) of Maldives 2003)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Nepal

Prevalence of injecting drug use

Low:

Year	2003		
Method	indirect estimate mapping exercise		
N=			
Area	National		
Estimate	16,100		
Reference	(National Centre for AIDS and STD Control 2004)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculations:

Prevalence (15-64years) = 16,100/14,717,000 = 0.1094%

High:

Year	2003		
Method	indirect estimate mapping exercise		
N=	-		
Area	National		
Estimate	28,000		
Reference	(National Centre for AIDS and STD Control 2004)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Calculations:

Prevalence (15-64years) = 28,000/14,717,000 = 0.1903%

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method	Sentinel surveillance population weighted prevalence		
Sample type			
Seroprev/self rpt			
N=			
Area	National		
Estimate	30.22%-52.56%		
Reference	(National Centre for AIDS and STD Control 2004)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Pakistan

Prevalence of injecting drug use

Year	2006		
Method	Indirect prevalence estimate		
N=			
Area	National		
Estimate	0.14% among 15-64 year olds 125,000 – 150,000 (NWFP = 0.06 = 7,000 Punjab = 0.2 = 100,000 Sind = 0.2 = 42,000 Baluchistan = 0.1 = 4,400)		
Reference	(Ministry of Narcotics Control, Anti-Narcotics Force et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	sentinel surveillance		
Sample type	time location cluster sampling		
Seroprev/self rpt	sero		
N=	1779		
Area	National		
Estimate	10.8% (not weighted for population or regional variation see below) 95% CI = 9.6-12.1%		
Reference	(National AIDS Control Program 2005; Ministry of Narcotics Control, Anti-Narcotics Force et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Sri Lanka

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Reid and Costigan 2002) (Kumar 2006) (Fernando and Bridger 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Fernando and Bridger 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Caribbean

Antigua and Barbuda

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Bahamas

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998) (CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Barbados

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007) (World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Bermuda

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Commonwealth of Puerto Rico

Prevalence of injecting drug use

Year	2002		
Method	Multiple Indirect Prevalence Estimation Method		
N=			
Area			
Estimate	1.15%		
Reference	(Brady, Friedman et al. 2008)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	1998-2001		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	12.9%		
Reference	(Reyes, Robles et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	A

Cuba

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(World Health Organization 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Dominica

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(Inter-American Observatory on Drugs 2004) (CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Dominican Republic

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Grenada

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Haiti

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(CAREC 2007) (Inter-American Observatory on Drugs 2004) (Hepburn and Lawitz 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007) (World Health Organization 2003) (Gaillard, Boulos et al. 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Jamaica

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004, 2005, 2006, 2007		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(CAREC 2007) (Figueroa 2004) (Vickers, Alveranga et al. 2005) (National HIV/STD Control Programme 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Saint Kitts and Nevis

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(Inter-American Observatory on Drugs 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Saint Lucia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(Inter-American Observatory on Drugs 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Saint Vincent & Grenadines

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Trinidad and Tobago

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No Data		
Reference	(Djumalieva, Imamshah et al. 2002)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No Data		
Reference	(CAREC 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Latin America

Argentina

Prevalence of injecting drug use

***Low*:**

Year	1999		
Method	Government estimate		
N=			
Area			
Estimate	64,500		
Reference	*Bloch C, Procupet A, Kaufmann R, Tecilla E. Perfil epidemiológico de los usuarios de drogas inyectables enfermos de SIDA en laArgentina. In: Boletín sobre el SIDA en la República Argentina Año VII, no. 19. Ministerio de Salud, Unidad Coordinadora Ejecutora VIH/SIDA y ETS, Setiembre 2000.* As cited in (Rodriguez, Marques et al. 2002)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	D1

Calculation

Prevalence (15-64years) = 64,500/22,611,000 = 0.2853%

High:

Year	1999		
Method	Government estimate- not detailed		
N=			
Area			
Estimate	67,158		
Reference	*Estudio nacional sobre sustancias adictivas, Argentina. Buenos Aires: Secretaría de Programación para la Prevención de la Drogadicción y Lucha contra el Narcotrófico, 1999.* As cited in (Sosa-Estani, Rossi et al. 2003)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	D1

Prevalence (15-64years) = 67,158/22,611,000 = 0.2970%

Prevalence of HIV amongst people who inject drugs

Year	1987-1999		
Method	Literature review		
Sample type	Multi sample- Outpatient, Prisoner, Children in rehabilitation centres, hospitals and treatment samples		
Seroprev/self rpt	Seroprevalence		
N=			
Area			
Estimate	High: 64% (Outpatient sample) Low: 35.4% (Prisoner sample)		
Reference	(Sosa-Estani, Rossi et al. 2003)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	A

Within range:

Year	2001		
Method	Street recruited snowball sample		
Sample type	Single population- street IDU		
Seroprev/self rpt			
N=	174		
Area	Buenos Aires		
Estimate	44.25%		
Reference	(Weissenbacher, Rossi et al. 2003)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	B

Belize

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No reports of IDU		
Reference	(Manzanero 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference	(Pan American Health Organization 2004) (CAREC 2007) (Manzanero 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Bolivia

Prevalence of injecting drug use

Year	2003		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Pan American Health Organization 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference	(Pan American Health Organization 2004)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Brazil

Prevalence of injecting drug use

Year	2003		
Method	Government estimate		
N=	-		
Area	National		
Estimate	800,000 IDU = use in the last 12 months		
Reference	(Coordenação Nacional de DST e AIDS 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D1

Calculation:
Prevalence of IDU (15-64 years) = 800,000/119,476,000 = 0.6696%

HIV amongst people who inject drugs

Year	2000		
Method	Multicentre survey		
Sample type	multiple		
Seroprev/self rpt			
N=			
Area	multicity		
Estimate	Regional differences pronounced 18-34% in cites in Sao Paulo 48.5-78% in cities in far south USE 78% as HIGH USE 18% as LOW		
Reference	*Caiaffa TW, Proietti AF, Marques LF, Doneda D, Proietti AB, Mingotti S, Deslandes S. Prevenção do HIV em Populações em UDs e Projeto Ajude-Brasil. In: Consumo de drogas desafios e perspectivas. Mesquita F, Seibel S (editors). São Paulo, Brazil Hucitec; 2000.* As cited in (Rodriguez, Marques et al. 2002)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	A

Within range:

Year	2000-2001		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area	Port Alergre, Itajai		
Estimate	High: 64.3% Low: 31.0%		
Reference	*Caiaffa WT, Proietti FA, Carneiro-Proietti AB, Mingoti SA, Doneda D, Gandolfi D, et al. Epidemiological Study of Injection Drug Users in Brazil (AjUDE-Brasil Project). The dynamics of the Human Immunodeficiency Virus epidemics in the south of Brazil: Increasing role of injection drug users. Clinical Infectious Diseases. 2003; 37(Suppl 5):S376–81.* As cited in (Hacker, Malta et al. 2005)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	D

Year	1995-1997		
Method	State testing site, drug treatment centres, outpatient services		
Sample type	Multisite		
Seroprev/self rpt			
N=	203		
Area			
Estimate	57.1%		
Reference	(Pechansky, Kessler et al. 2005) (Pechansky, Woody et al. 2006)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	A

Chile

Prevalence of injecting drug use

Year	2006		
Method	-		
N=	-		
Area	National		
Estimate	Lifetime injection 0.38% 15-64 year olds		
Reference	(Consejo Nacional Para El Control De Estupefacients (CONACE) 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D1

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	-		
Estimate	HIV among IDU reported – extent not known		
Reference	(Global Fund 2002) (Comision Nacional de Sida-Conasida 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	-	**Grade**	-

Colombia

Prevalence of injecting drug use

Year	1999		
Method	-		
N=	-		
Area	Bogotá		
Estimate	IDU reported to occur – extent not known		
Reference	*Mejía Motta, IE. La Inyección de Drogas en Bogotá: una realidad oculta. Santa Fe de Bogotá: Presidencia de la República de Colombia; 2003. (Part of the WHO Multicentre Study)* As cited in (Hacker, Malta et al. 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1999		
Method	survey of IDU		
Sample type			
Seroprev/self rpt	Seroprevalence		
N=			
Area	Bogotá		
Estimate	<2% **used zero as lower and 2% as upper limit – median 1%**		
Reference	*Mejía Motta, IE. La inyección de drogas en Bogotá: una realidad oculta. Santa Fe de Bogotá: Presidencia de la República de Colombia; 2003. (Part of the WHO Multicentre Study)* As cited in (Hacker, Malta et al. 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	B

Costa Rica

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Ecuador

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

El Salvador

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent no known		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Guatemala

Prevalence of injecting drug use

Year	2004, 2007		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known (1.3% MSM past year IDU; 1.3% FSW past year IDU)		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent no known		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Guyana

Prevalence of injecting drug use

Year	1999		
Method			
N=			
Area			
Estimate	IDU not reported		
Reference	(Persaud, Klaskala et al. 1999)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No data		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Honduras

Prevalence of injecting drug use

Year	2002		
Method	-		
N=	-		
Area	-		
Estimate	IDU reported to occur – extent not known (1.2% MSM past year IDU; 3.3% FSW past year IDU)		
Reference	(Ramon, Alvarenga et al. 2002)		
1˚ or 2˚ source	-		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent no known		
Reference	(Ramon, Alvarenga et al. 2002) (Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Mexico

Prevalence of injecting drug use

Year	2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Rodriguez, Marques et al. 2002) (Bravo-García, Magis-Rodríguez et al. 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	Respondent driven sampling		
Sample type			
Seroprev/self rpt	Serum		
N=	207		
Area	Tijuana		
Estimate	1.9%		
Reference	(Frost, Brouwer et al. 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	B

High:

Year	2005		
Method	Respondent driven sampling		
Sample type			
Seroprev/self rpt	-		
N=	197		
Area	Cd Juarez		
Estimate	4.1%		
Reference	(Frost, Brouwer et al. 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	B

Within range:

Year	2007		
Method	Respondent driven sampling		
Sample type			
Seroprev/self rpt	Serum		
N=	1052		
Area	Tijuana		
Estimate	4%→ adjusted for potential effect from sampling strategy = 2.3%		
Reference	(Strathdee, Morgan et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	B

Nicaragua

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2000 [by default using the year of publication of source article]		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	25		
Area	Managua		
Estimate	6.0%		
Reference	*Díaz RMM, Salgado ZG. Sífilis, hepatitis B y VIH em um cartel de expendio de drogas em Manágua, Nicarágua. In: Anais do Fórum 2000, Vol I. Conferencia Latinoamericana y del Caribe-Forum 2000: 2000 Nov 6–10; Rio de Janeiro; 2000. P. 234*. As cited in (Hacker, Malta et al. 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	Yes	**Grade**	D1

Panama

Prevalence of injecting drug use

Year	2004, 2007		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004, 2007		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent no known		
Reference	(Pan American Health Organization 2004) (Soto, Ghee et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Paraguay

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur –extent not known		
Reference	(Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) (Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Low

Year	2006		
Method	-		
Sample type	current and former IDU		
Seroprev/self rpt	Serum		
N=	164		
Area	Central Region and Asuncion,		
Estimate	3.7%		
Reference	(Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) (Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) This reference cites other studies but no details		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High

Year	2006		
Method			
Sample type			
Seroprev/self rpt	serum		
N=	70		
Area	Asuncion (city)		
Estimate	15%		
Reference	(Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) (Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) This reference cites other studies but no details		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Within Range:

Year	2006		
Method	-		
Sample type	-		
Seroprev/self rpt	serum		
N=	99		
Area	-		
Estimate	9.1%		
Reference	(Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006) (Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Peru

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Hacker, Malta et al. 2005)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1994-1995		
Method	Part of a national survey (all the detail that is given)		
Sample type			
Seroprev/self rpt			
N=			
Area	National		
Estimate	13%		
Reference	(Hacker, Malta et al. 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D

Suriname

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Mid

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference	(National Anti-Drug Council Suriname 2002)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Uruguay

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Woratanarat 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2002		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Rodriguez, Marques et al. 2002) (UNAIDS 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	

Venezuela

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Oceania

American Samoa

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No data		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Australia

Prevalence of injecting drug use

Year	2005		
Method	Indirect: IDU estimated through a mathematical model of HCV transmissions based on a standard percentage increase in IDU annually		
N=			
Area	National		
Estimate	Absolute number: High-204,564 Low-89,253 Median-149,591 Prevalence: 1.07% (0.67-1.46)		
Reference	(Razali, Thein et al. 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	A

Calculations Prevalence (15-64years) Low = 89,253/ 13,683,000 = 0.6523%
Median = 149,591/ 13,683,000 = 1.0933%
High = 204,564/ 13,683,000 = 1.4950%

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Sentinel surveillance- multi-site treatment centres		
Sample type	Single population- treatment centre		
Seroprev/self rpt	Seroprevalence		
N=	1,897		
Area	National		
Estimate	1.5% Prevalence Absolute number of IDUs with HIV: 2,245		
Reference	(National Centre in HIV Epidemiology and Clinical Research 2008)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Federated States of Micronesia

Prevalence of injecting drug use

Year	2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(UNGASS 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method	Sentinel surveillance		
Sample type	General population surveillance		
Seroprev/self rpt	Seroprevalence		
N=			
Area	National		
Estimate	1 case of HIV from IDU but little HIV in the country		
Reference	(UNGASS 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	No	**Grade**	

Fiji

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur (among male high risk populations) – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area	(World Health Organization 2006)		
Estimate	1 case of HIV from IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	

Year	2005		
Method	Expert opinion		
Sample type			
Seroprev/self rpt			
N=			
Area	National		
Estimate	IDU listed as a marginal route of transmission with no clear estimates possible		
Reference	(Pontali 2008)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	

French Polynesia

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Guam

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Kiribati

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur (among male high risk populations) – extent not known		
Reference	(World Health Organization 2006) (Wang, Cliffe et al. 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Marshall Islands

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Nauru

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

New Caledonia

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

New Zealand

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	Absolute number: High- 26,792 Low- 13,535 Median- 20,163 Prevalence: 0.72 (0.49, 0.96)		
Reference	(Wilkins, Girling et al. 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	B

Calculations Prevalence (15-64 years) Median = 20,163/ 2,754,000 = 0.7321%
Low = 13,535/ 2,754,000 = 0.4915%
High = 26,792/ 2,754,000 = 0.9728%

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt	Self report		
N=			
Area			
Estimate	1.6%		
Reference	(Wilkins, Girling et al. 2006)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	B

Palau

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV as yet unreported among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Papua New Guinea

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known (thought to be very low)		
Reference	(McDonald 2005) (AusAID 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported to occur – extent unknown		
Reference	(McBride 2005)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Samoa

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004-2005		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	0.0		
Reference	(Ministries of Health: Fiji Kiribati Samoa Solomon Islands Tonga and Vanuatu 2006) (World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	D1

Solomon Islands

Prevalence of injecting drug use

Year	2004-2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004-2005		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	0		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	D

Tonga

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur (among young people) – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004-2005		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	0.0		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	D

Tuvalu

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate			
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Vanuatu

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	IDU reported to occur (among young people) – extent not known		
Reference	(World Health Organization 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate			
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Canada and the United States

Canada

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	1.3% Lifetime IDU for 15-64 age group Lower estimate: 1.0% Upper estimate: 1.7%		
Reference	(Ialomiteanu 2008)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	B

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	Sentinel Surveillance		
Sample type			
Seroprev/self rpt	Seroprevalence		
N=			
Area			
Estimate	Lower estimate: 2.9% Higher estimate: 23.8%		
Reference	(Public Health Agency of Canada 2006)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	A

United States

Prevalence of injecting drug use

Year	2002		
Method	Multiple indirect prevalence estimation methods		
N=			
Area			
Estimate	0.961% among those 15-64 years Lower range: 0.67% Upper range: 1.34%		
Reference	(Brady, Friedman et al. 2008)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method	Indirect prevalence estimate		
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	(1)Estimate of HIV positive persons in US: 925,000-1,185,000 (2) Estimated persons living with HIV through IDU as at 2005: 24.8% (117,843) -Assume 24.8% of all HIV positive persons are IDU= 229,400-293,800 HIV+IDU -Inferred HIV prevalence among IDU from % past year IDU (6) and total estimated IDU with HIV Lower Estimate: 8.7% Upper Estimate: 22.4%		
Reference	(Glynn and Rhodes 2005) (Brady, Friedman et al. 2008)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Western Europe

Albania

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2007		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Andorra

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2007		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Austria

Prevalence of injecting drug use

Year	2000		
Method	Multiplier methods from police, treatment and mortality data; Back calculations, methadone consumption		
N=	NA		
Area	National		
Estimate	17,500 (range 12,000-23,000)		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	112		
Area			
Estimate	7.1%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Belgium

Prevalence of injecting drug use

Year	1997		
Method	Multiplier methods from police, treatment and mortality data; Back calculations, methadone consumption		
N=			
Area	National		
Estimate	Absolute number: 25,800 (range 23,200-28,400)		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No national data available; regional data ranged from 5.7% in Antwerp (Ref 8) to 2.9% in 'Flemish Community'		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Denmark

Prevalence of injecting drug use

Year	1996		
Method			
N=			
Area	National		
Estimate	Low: 12,372 High: 18,460		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	188		
Area	5 site study		
Estimate	2.1%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Finland

Prevalence of injecting drug use

Year	2002		
Method			
N=			
Area	National		
Estimate	Mid: 15,650 Low: 12,200 High: 19,700		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	1486		
Area			
Estimate	0.2		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

France

Prevalence of injecting drug use

Year	1999		
Method			
N=			
Area			
Estimate	Absolute number: 122,000		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method			
Sample type			
Seroprev/self rpt			
N=	8385		
Area	National		
Estimate	12.2%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Former Yugoslav Republic of Macedonia

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Germany

Prevalence of injecting drug use

Year	2005		
Method			
N=			
Area			
Estimate	Mid: 94,250 Low: 78,000 High: 110,500		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	1296		
Area			
Estimate	2.9%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Greece

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	Mid: 9,720 Low: 8,542 High: 11,134		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2008)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	(1) n=761 (2) n=1259		
Area	National		
Estimate	(1)0.3- (2)0.7 range		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Iceland

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Ireland

Prevalence of injecting drug use

Year	1996		
Method			
N=			
Area			
Estimate	Mid: 6,289 Low: 4,694 High: 7,884		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	1999		
Method			
Sample type			
Seroprev/self rpt			
N=	173		
Area	National		
Estimate	5.8%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Italy

Prevalence of injecting drug use

Year	1996		
Method			
N=			
Area			
Estimate	326,000		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	12.1%		
Reference	(EuroHIV 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	A

Liechtenstein

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No reports of IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Luxembourg

Prevalence of injecting drug use

Year	2000		
Method			
N=			
Area			
Estimate	1,715		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	254		
Area	National (8 sites)		
Estimate	2.8%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Malta

Prevalence of injecting drug use

Year	2005		
Method	Registers		
N=	NA		
Area	Specific treatment sites		
Estimate	IDU reported to occur – extent not known		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	175 (1 site)		
Area	National		
Estimate	0.0%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	B

Monaco

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Montenegro

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Netherlands

Prevalence of injecting drug use

Year	2001		
Method	Treatment multiplier		
N=	NA- problem drug users currently injecting		
Area	National		
Estimate	Mid: 3,115 Low: 2,211 High: 4,321		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed		**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2002		
Method	Sentinel surveillance		
Sample type	IDU		
Seroprev/self rpt	Seroprevalence		
N=	452		
Area	Rotterdam		
Estimate	9.5%		
Reference	(EuroHIV 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Norway

Prevalence of injecting drug use

Year	2005		
Method	Mortality Multiplier method, Municipal survey (with), Multiple Indicator Method		
N=	NA- IDU		
Area	National		
Estimate	Mid: 10,049 Low: 8,374 High: 11,724		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	3349		
Area	National (14 sites)		
Estimate	3.2%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Portugal

Prevalence of injecting drug use

Year	2000		
Method	Three multiplier methods based on police data, treatment data and mortality rates, Capture-recapture		
N=	NA: 'Problem Drug Users'		
Area	National		
Estimate	Mid: 32,287 Low: 15,900 High: 48,673)		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	No	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	(1)n=1520 (2)n=4128		
Area	National (1) 77 sites (2)71 sites		
Estimate	Low: 10.9 Mid: 15.6 High: 20.2		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

San Marino

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Serbia

Prevalence of injecting drug use

Year	2004		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Donoghoea, Bollerup et al. 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Slovenia

Prevalence of injecting drug use

Year	2001		
Method	Indirect (capture-recapture)		
N=			
Area			
Estimate	Estimates of *problematic drug use*: Absolute number: 7,399 Prevalence: 0.53 Proportion of heroin users injecting= 0.988		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary (Primary source unpublished)		
Peer reviewed	non peer reviewed	**Grade**	A

Calculation:
Use proportion of heroin users who inject to adjust for IDU among PDU:
7399*0.988= 7310 (prevalence= 0.52)

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=	476		
Area	National (19 sites)		
Estimate	0.4%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Spain

Prevalence of injecting drug use

Year	1998		
Method	Indirect- treatment centre registers		
N=	15,711 'opiate addicts' aged 15-44		
Area	Regional (Catalonia)- Subjects from treatment centres and hospital registries		
Estimate	83,972		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	1194		
Area	National (66 sites)		
Estimate	39.7%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Sweden

Prevalence of injecting drug use

Year	2003		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	Secondary source- Primary source in Swedish		
Peer reviewed		**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2007		
Method			
Sample type			
Seroprev/self rpt			
N=	203		
Area	Stockholm's county (207 sites)		
Estimate	5.4%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Switzerland

Prevalence of injecting drug use

Year	1997		
Method			
N=			
Area	National		
Estimate	Low: 24,907 High: 38,399		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	1.4%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed	no	**Grade**	A

United Kingdom

Prevalence of injecting drug use

Year	2005		
Method	The UK estimate is the England estimate for 2004/05, Northern Ireland estimate for 2004, Scotland estimate for 2003 and Wales is assumed the same prevalence as England (No methodological details provided)		
N=			
Area			
Estimate	Low: 151,032 Mid: 156,398 High: 165,696		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2008)		
1˚ or 2˚ source	Primary		
Peer reviewed	No	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Low:

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	(1) n= 2482		
Area	England and Wales excluding London		
Estimate	0.6%		
Reference	(Wiessing 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

High:

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=	n= 593		
Area	London		
Estimate	4.0%		
Reference	(EuroHIV 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	A

Middle East and North Africa

Algeria

Prevalence of injecting drug use

Year	2006		
Method	Snowball sample		
N=	285		
Area	Multicity (Alger, Oran, Annaba)		
Estimate	IDU reported to occur – extent not known		
Reference	(MESRS 2006) (UNAIDS 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	-		
Estimate	HIV among IDU reported – extent not known		
Reference	(Woratanarat 2006) (MESRS 2006) (Jenkins and Robalino 2003)		
1˚ or 2˚ source	Secondary		
Peer reviewed	Yes	**Grade**	-

Bahrain

Prevalence of injecting drug use

Mid:

Year	2005		
Method			
N=			
Area			
Estimate	IDU reported to occur but no estimate of prevalence		
Reference	(World Bank 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2000		
Method	-		
Sample type	-		
Seroprev/self rpt			
N=	291		
Area	-		
Estimate	0.3%		
Reference	(World Bank 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Cyprus

Prevalence of injecting drug use

Mid:

Year	2006		
Method	*Unpublished report- details unavailable*		
N=			
Area	National		
Estimate	Low: 257 Mid: 305 High: 382		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	A

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method	sentinel surveillance – 6 sites		
Sample type	drug treatment sites		
Seroprev/self rpt	-		
N=	96		
Area	National		
Estimate	0.0%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Egypt

Prevalence of injecting drug use

Year	2002, 2004, 2006		
Method	-		
N=	-		
Area	-		
Estimate	IDU reported to occur – extent not known		
Reference	(Dewing, Plüddemann et al. 2006) (Jenkins and Robalino 2003) (Grotherath 2002) (Elshimi, Warner-Smith et al. 2004)		
1˚ or 2˚ source	Primary and secondary		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2006		
Method	sentinel surveillance		
Sample type	male IDU		
Seroprev/self rpt	-		
N=	-		
Area	-		
Estimate	0.6%		
Reference	*Ministry of Health and Population National AIDS Program Arab Republic of Egypt/ Family Health International HIV/AIDS Biological and Behavioural Surveillance Survey: Summary Report. Cairo 2006* As cited by (AIDS Projects Management Group 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2006		
Method	sentinel surveillance		
Sample type	-		
Seroprev/self rpt	-		
N=	100		
Area	Alexandria		
Estimate	4.5% (5/100)		
Reference	*Ministry of Health and Population National AIDS Program Arab Republic of Egypt/ Family Health International HIV/AIDS Biological and Behavioural Surveillance Survey: Summary Report. Cairo 2006* As cited by (AIDS Projects Management Group 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Iraq

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	no reports of HIV among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Israel

Prevalence of injecting drug use

Year	2002 - 2006		
Method	treatment samples (MMT clinic, intake centre, day treatment facility) heroin users		
N=	native Israeli heroin users = 272 immigrants to Israel from former Soviet Union heroin users= 300		
Area	Negev region		
Estimate	IDU reported to occur – extent not known		
Reference	(Isralowitz, Reznik et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	-

Year	2004		
Method	-		
N=	-		
Area	National		
Estimate	IDU reported to occur – extent not known (approximately 20 000 heroin users in Israel)		
Reference	*Israel Anti-drug Authority update 6 July 2004* http://www.antidrugs.gov.il/ - [NB data cited could not be found on this website by us]. As cited by (Peles, Schreiber et al. 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	cross sectional		
Sample type	Treatment sample: MMT		
Seroprev/self rpt	seroprevalence		
N=	145 – not certain if all were injectors		
Area			
Estimate	2.07%		
Reference	(Gelkopf, Weizman et al. 2006)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	B

High:

Year	2002 - 2006		
Method	treatment samples heroin users		
Sample type	treatment samples (MMT clinic, intake centre, day treatment facility) heroin users		
Seroprev/self rpt	sero samples		
N=	native Israeli heroin IDU = 173 immigrants to Israel from former Soviet Union heroin users= 300 (including 19 non injectors among fSU sample)		
Area	Negev region		
Estimate	fSU immigrants = 6.0%; native Israeli = 0.0% overall = 3.81%		
Reference	(Isralowitz, Reznik et al. 2007)		
1˚ or 2˚ source	primary		
Peer reviewed	yes	**Grade**	A

Jordan

Prevalence of injecting drug use

Year	2007		
Method			
N=			
Area			
Estimate	IDU reported to occur		
Reference	(Global Fund 2007) (Jenkins and Robalino 2003) (Global Fund 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported		
Reference	(Global Fund 2006) (World Bank 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Kuwait

Prevalence of injecting drug use

Year	2005		
Method	-		
N=	-		
Area	-		
Estimate	IDU reported to occur – extent not known		
Reference	(World Bank 2005) (Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D

Prevalence of HIV amongst people who inject drugs

Year	2000		
Method	Registry		
Sample type			
Seroprev/self rpt	sero sample		
N=			
Area	National		
Estimate	HIV among IDU reported – extent not known		
Reference	(World Bank 2005)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Lebanon

Prevalence of injecting drug use

Year	2003		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(United Nations Office on Drugs and Crime & Institute for Development Research and Applied Care 2003)		
1˚ or 2˚ source			
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1984-2000		
Method	Registry		
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Jenkins and Robalino 2003) (United Nations Office on Drugs and Crime & Institute for Development Research and Applied Care 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Libyan Arab Jamahiriya

Prevalence of injecting drug use

Year	2001		
Method	police registration		
N=	-		
Area	National		
Estimate	1 685 registered IDU		
Reference	(Grotherath 2002)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Calculation

Prevalence (15-64years) of registered IDU = 1,685/3,817,000 = 0.0441%

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method	Seroprevalence		
Sample type	Treatment sample and snowball (community)		
Seroprev/self rpt	Seroprevalence		
N=	169		
Area	Single city (Tripoli)		
Estimate	22%		
Reference	(Toufik 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Morocco

Prevalence of injecting drug use

Year	2006		
Method	-		
N=	-		
Area	-		
Estimate	IDU reported to occur		
Reference	(Toufik 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Year	2006		
Method	Snowball sample from street; Prison sample; Treatment sample		
N=	495		
Area	Multicity (Tangier, Tetouan, Rabat, Casablanca)		
Estimate	IDU reported to occur		
Reference	(Global Fund 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2006		
Method			
Sample type			
Seroprev/self rpt	self report		
N=	61		
Area	Multicity (Tangier, Tetouan, Rabat, Casablanca)		
Estimate	6.5% (4/61)		
Reference	(Toufik 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Occupied Palestinian Territories

Prevalence of injecting drug use

Year	2002, 2003		
Method	Registry		
N=	-		
Area	-		
Estimate	IDU reported to occur – extent not known		
Reference	(Grotherath 2002)		
1˚ or 2˚ source	secondary		
Peer reviewed	no	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2002		
Method	Registry		
Sample type	-		
Seroprev/self rpt	sero		
N=	-		
Area	-		
Estimate	HIV among IDU reported		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	no	**Grade**	-

Oman

Prevalence of injecting drug use

Year	1997-2005		
Method	Registry and other		
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	primary and secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2000		
Method	WHO UNAIDS assessment [assume registry from police records]		
Sample type	arrested IDU		
Seroprev/self rpt			
N=	135		
Area			
Estimate	5%		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2000-2005		
Method	-		
Sample type	treatment sample		
Seroprev/self rpt	sero		
N=	129		
Area	-		
Estimate	18.6%		
Reference	(Toufik 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Within range:

Year	2000		
Method	-		
Sample type	-		
Seroprev/self rpt	-		
N=	60		
Area	-		
Estimate	8.3%		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	D

Qatar

Prevalence of injecting drug use

Year	1998		
Method	Registry		
N=			
Area			
Estimate	IDU reported to occur – (1.2% of AIDS cases IDU)		
Reference	(Grotherath 2002) (Ball, Rana et al. 1998)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method	Registry		
Sample type	-		
Seroprev/self rpt	Seroprevalence		
N=	-		
Area	-		
Estimate	HIV among IDU reported		
Reference	(Grotherath 2002) (Ball, Rana et al. 1998)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Saudi Arabia

Prevalence of injecting drug use

Year	1984-2001		
Method	Registry		
N=	-		
Area	-		
Estimate	IDU reported to occur – extent not known		
Reference	(Jenkins and Robalino 2003) (Madani, Al-Mazrou et al. 2004)		
1˚ or 2˚ source	secondary		
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1997		
Method	-		
Sample type	IDU		
Seroprev/self rpt	-		
N=	2102		
Area	-		
Estimate	0.14% (3/2102)		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Sudan

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	2003		
Method	-		
Sample type	Registry		
Seroprev/self rpt	-		
N=	-		
Area	-		
Estimate	0% HIV among IDU reported		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Syrian Arab Republic

Prevalence of injecting drug use

Year	1997-2000, 2001		
Method	Registry and other		
N=	-		
Area	-		
Estimate	IDU reported to occur		
Reference	(Grotherath 2002)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	1997-2000		
Method	Registry		
Sample type	-		
Seroprev/self rpt	-		
N=	-		
Area	-		
Estimate	HIV among IDU reported		
Reference	(Jenkins and Robalino 2003)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Tunisia

Prevalence of injecting drug use

Year	2002, 2003		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known (many IDU thought to be expatriates returning home to Tunisia from abroad).		
Reference	(Grotherath 2002) (Jenkins and Robalino 2003) (Global Fund 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Mid:

Year	1997		
Method	Sentinel surveillance		
Sample type	IDU		
Seroprev/self rp-t	seroprevalence		
N=	-		
Area	-		
Estimate	1997 0.3%		
Reference	(Global Fund 2006)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Turkey

Prevalence of injecting drug use

Year	2005		
Method	Registry – treatment centres		
N=			
Area			
Estimate	IDU reported to occur – extent not known (in 2005 there were 549 IDUs in treatment centres)		
Reference	(Kavasoglu 2008)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Year	2005		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	Registry		
Sample type	treatment centre		
Seroprev/self rpt	-		
N=	549		
Area	-		
Estimate	12/549 = 2.3%		
Reference	(Kavasoglu 2008)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2001		
Method	surveillance		
Sample type	Treatment sample		
Seroprev/self rpt	-		
N=	99		
Area	Ankara		
Estimate	3%		
Reference	(European Monitoring Centre for Drugs and Drug Addiction 2007)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	B

United Arab Emirates

Prevalence of injecting drug use

Year	2002		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known (very strict penalties and very little drug use recorded. However Some IDU is believed to occur)		
Reference	(Grotherath 2002)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Yemen

Prevalence of injecting drug use

Year	2002		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known (little evidence that "hard drugs" have penetrated the Yemeni market. The National AIDS Program believes there is drug injection in the elite group of Yemeni society – but this is the exception.)		
Reference	(Grotherath 2002)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rp-t			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Sub-Saharan Africa

Angola

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Benin

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Botswana

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Burkina Faso

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Burundi

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Cameroon

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Cape Verde

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Central African Republic

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Chad

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Comoros

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Côte d'Ivoire

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Democratic Republic of the Congo

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Djibouti

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year	1998		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Equatorial Guinea

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Eritrea

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Ethiopia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Gabon

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Gambia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Ghana

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Guinea

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Guinea-Bissau

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Kenya

Prevalence of injecting drug use

Low:

Year	2004		
Method	Mapping, key informant guidance, questionnaire for recruited participants-recruiting based on presence in identified gather places for heroin dealing/use, informal interview, group discussion, expert opinion		
N=	496 heroin users		
Area	Single site- Mombasa		
Estimate	15% of heroin users had 'ever injected' (76/496), 7% had injected in the last week (37/496) Estimate (expert opinion with method outlined): 10,000 heroin users in Greater Mombasa in March 2004 Population "exceeds one million"		
Reference	(Beckerleg, Telfer et al. 2006)		
1˚ or 2˚ source	Primary source		
Peer reviewed	Yes	**Grade**	C

Calculation:

10,000 heroin users in Mombasa and between 7% and 15% of these are past year IDU: 1,500 – 700 injectors. Projected population of Mombasa in 2004: 787,280 (Statistics and Development 2007) 15-64 year olds make up 54.35% of the population in Kenya in 2004 (Kenyan Bureau of Statistics 2007)

Assuming similar age distribution in Mombasa as the rest of the country then 54.35% of 787,280 = 427,887 15-64 year olds in Mombasa in 2004.

2004 prevalence of IDU among 15-64 year olds: 0.16% - 0.35% **[use 0.16% as low]**

High:

Year	2000-2002		
Method	Rapid assessment: snowball sample of female IDUs.		
N=	26 Female IDU involved in the snowball, 4 informants underwent nomination techniques, 21 interviews with community members		
Area	Single city		
Estimate	600 IDU (30 female) in an estimated population of 85,000		
Reference	(Beckerleg and Lewando Hundt 2004)		
1˚ or 2˚ source	Primary source		
Peer reviewed	Yes	**Grade**	C

15-64 year olds make up 53.85% of the population in Kenya in 2002 (Division 2007)

Assuming similar age distribution in this city as in the rest of the country 53.85% of 85,000 = 45,773 15-64 year olds in this city in 2002

2002 Prevalence of IDU among 15-64 year olds: 1.3% **[use as high]**

Within range:

Year	2001		
Method	Rapid Assessment and Response		
N=	Unknown		
Area	Single city (Nairobi)		
Estimate	13,000 heroin users 50% of which cite injection as their preferred route		
Reference	*M. Odek-Ogunde, WHO, Rapid assessment and response study Kenya 2001, Nairobi*. As cited by (AIDS Projects Management Group 2005)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	C

Calculation

Assume 50% of 13,000 IDU = 6,500 IDU in Nairobi in 2001

Population in Nairobi in 2001: 2,470,850 (Statistics and Development 2007)

53.51% of population in Kenya aged 15-64 years in 2001 (Division 2007)therefore 1,322,151 in Nairobi

2001 prevalence of IDU among 15-64 year olds: 0.49%

Prevalence of HIV amongst people who inject drugs

Low:

Year	2004		
Method	Not described		
Sample type	Not described		
Seroprev/self rpt	Seroprevalence		
N=	146 IDU		
Area	Single city- Nairobi		
Estimate	36.30% (53/146 IDU tested)		
Reference	(Odek-Ogunde, Okoth et al. 2004)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2003		
Method	Sentinel surveillance- multi site (areas within the city known as converging places for drug users)		
Sample type	Single population- snowball technique within the community		
Seroprev/self rpt	Sero sample		
N=	101 IDU		
Area	Single city- Mombasa		
Estimate	49.5% (50/101)		
Reference	(Ndetei 2004)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

Lesotho

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Liberia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Madagascar

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Malawi

Prevalence of injecting drug use

Year	2004		
Method			
N=	1,185 Drug users		
Area	National		
Estimate	IDU reported to occur – extent not known (2.2% (26/1,185) of drug users were injecting drug users)		
Reference	(Bisika, Konyani et al. 2004)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No reports of HIV among IDU		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Mali

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Mauritania

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Mauritius

Prevalence of injecting drug use

Low:

Year	2004		
Method	Rapid Situation Assessment- Indirect: Consensus and indirect multiplier methods		
N=			
Area	National/ multi-population study (prison, treatment centres, street IDUs)		
Estimate	17,000 IDU		
Reference	(Sulliman, Ameerberg et al. 2004) (Abdool, Sulliman et al. 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	A

Calculations:

Prevalence (15-64years) = 17,000/ 846,000 = 2.009%

High:

Year	2004		
Method	Rapid Situation Assessment- Indirect: Consensus and indirect multiplier methods		
N=	NA		
Area	National/ multi-population study (prison, treatment centres, street IDUs)		
Estimate	18,000 IDU		
Reference	(Sulliman, Ameerberg et al. 2004) (Abdool, Sulliman et al. 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	A

Calculations:

Prevalence (15-64years) = 18,000/ 846,000 = 2.1277%

Prevalence of HIV amongst people who inject drugs

Year	2004		
Method	Registry		
Sample type			
Seroprev/self rpt	seroprevalence		
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Abdool, Sulliman et al. 2006) (Sulliman, Ameerberg et al. 2004)		
1˚ or 2˚ source	secondary		
Peer reviewed	non peer reviewed	**Grade**	-

Mozambique

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Namibia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Niger

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Nigeria

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Adelekan and Lawal 2006) (Lawal 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Low:

Year	2003		
Method	Rapid Assessment and Response		
Sample type	Single population- Snowball sampling of community IDU		
Seroprev/self rpt	Seroprevalence		
N=	11		
Area	Multi city study (Kano and Port Harcourt)		
Estimate	0% of those having 'ever injected'		
Reference	(Adelekan and Lawal 2006)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

High:

Year	2000		
Method	Rapid Assessment and Response		
Sample type	Single population- Snowball sampling of community IDU		
Seroprev/self rpt	Seroprevalence		
N=	79		
Area	Single city- Lagos		
Estimate	8.9% (7/79) 'ever injected', **11% (6/54) 'current injectors' [use as high]**		
Reference	(Adelekan and Lawal 2006)		
1˚ or 2˚ source	Secondary		
Peer reviewed	non peer reviewed	**Grade**	B

Within range:

Year	2005		
Method	Seroprevalence study as part of Rapid Assessment and Response		
Sample type	Single population- Snowball sampling of community IDU – all		
Seroprev/self rpt	Seroprevalence		
N=	127 IDU		
Area	5 city study (Benin, Calabar, Ibadan, Kaduna, Maiduguri)		
Estimate	7.9% (10/127) of those ever injected drugs		
Reference	(Lawal 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	non peer reviewed	**Grade**	B

NB: Because these three studies were each from 3 different geographic areas they were all considered and the range was reported.

Republic of the Congo

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Rwanda

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Sao Tome and Principe

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Senegal

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Seychelles

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Sierra Leone

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Somalia

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

South Africa

Prevalence of injecting drug

Mid**:**

Year	2004		
Method	Population survey Community interviews- carried out in public places		
N=	2172		
Area	Three communities in one city (Cape Town) all with different ethnic/socioeconomic makeup		
Estimate	**19 (0.87%) reported ever having injected-** (range of 1.31%, 1.00%, 0.15% in each of the townships)		
Reference	(Kalichman, Simbayi et al. 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	B

Prevalence of HIV amongst people who inject drugs

Low:

Year	2005		
Method	Sentinel surveillance		
Sample type	Single population- community		
Seroprev/self rpt	Seroprevalence		
N=	40 IDU		
Area	Multi city- Cape Town, Durban, Pretoria		
Estimate	4.8%		
Reference	(Parry, Carney et al. 2007)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	B

High:

Year	2006		
Method	Sentinel Surveillance		
Sample type	Single population- Snowball sampling of community members		
Seroprev/self rpt	Seroprevalance		
N=	55 IDU		
Area	Multi city (Durban, Cape Town, Pretoria)		
Estimate	20%		
Reference	(Parry, Nwanyanwu et al. 2006)		
1˚ or 2˚ source	Primary		
Peer reviewed	Yes	**Grade**	B

Swaziland

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Togo

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Uganda

Prevalence of injecting drug use

Year	1988		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed	yes	**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

United Republic of Tanzania

Prevalence of injecting drug use

Year	2006		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Williams, McCurdy et al. 2007) (Timpson and et al 2006) (McCurdy, Ross et al. 2006) (Dewing, Plüddemann et al. 2006) (Dahoma, Salim et al. 2006)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year	2005		
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	HIV among IDU reported – extent not known		
Reference	(Williams, McCurdy et al. 2007) (Timpson and et al 2006) (McCurdy, Williams et al. 2005)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Zambia

Prevalence of injecting drug use

Year	1998		
Method			
N=			
Area			
Estimate	IDU reported to occur – extent not known		
Reference	(Ball, Rana et al. 1998)		
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	-

Zimbabwe

Prevalence of injecting drug use

Year			
Method			
N=			
Area			
Estimate	No IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

Prevalence of HIV amongst people who inject drugs

Year			
Method			
Sample type			
Seroprev/self rpt			
N=			
Area			
Estimate	No HIV among IDU reported		
Reference			
1˚ or 2˚ source			
Peer reviewed		**Grade**	

References

Abdool, R., F. T. Sulliman, et al. (2006). "The injecting drug use and HIV/AIDS nexus in the Republic of Mauritius " African Journal of Drug & Alcohol Studies, **5**(2): 9.

Adelekan, M. L. and R. A. Lawal (2006). "Drug Use and HIV Infection in Nigeria: A review of recent findings." African Journal of Drug & Alcohol Studies, **5**(2): 12.

AIDS Projects Management Group (2005). Is There Anyone Left in the General Population: A Scan of Information Available on the Context of HIV Transmission and Risk for Vulnerable Groups in Seventeen Countries with Concentrated HIV Epidemics. Sydney, AIDS Projects Management Group, **:** 97.

AIDS Projects Management Group (2006). Assessment of Phase I harm reduction projects funded by Global Fund to fight AIDS, Tuberculosis and Malaria HIV/AIDS grant in Belarus. Sydney, AIDS Projects Management Group**:** 54.

AIDS Projects Management Group (2007). Measuring Coverage of HIV Prevention and Care for Injecting Drug Users: Draft Final Report. Sydney, AIDS Project Management Group,.

AIDS Projects Management Group (2007). Recommendations for interventions addressing injecting drug use and related HIV infection in Egypt. Sydney, AIDS Projects Management Group,**:** 25.

Akhobadze, T. (2008). Email "Drug use prevalence data for Georgia". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Tbilisi, IHRD: Open Society Georgia Foundation,.

AusAID (2006). Impacts of HIV/AIDS 2005-2025 in Papua New Guinea, Indonesia and East Timor: Final Report of HIV Epidemiological Modelling and Impact Study. A. Government. Canberra, Department of Foreign Affairs and Trade**:** 169.

Azim, T., E. I. Chowdhury, et al. (in press). Prevalence of infections, HIV risk behaviors and factors associated with HIV infection among male injecting drug users attending a needle/syringe exchange program in Dhaka, Bangladesh.

Azim, T., M. Rahman, et al. (2008). "Bangladesh moves from being a low-prevalence nation for HIV to one with a concentrated epidemic in injecting drug users." International Journal of STD & AIDS **19**(May): 327-331.

Balakiryeva, O. M., L. M. Gusak, et al. (2006). Evaluation of the size of most-at-risk-populations vulnerable to HIV infection in Ukraine: analytical report based on the research results. Kyiv, International HIV/AIDS Alliance in Ukraine.

Ball, A. L., S. Rana, et al. (1998). "HIV Prevention among Injecting Drug Users: Responses in Developing and Transitional Countries." Public Health Reports **113**(1): 12.

Beckerleg, S. and G. Lewando Hundt (2004). "The characteristics and recent growth of heroin injecting in a Kenyan coastal town." Addiction Research & Theory **12**(1): 41-53.

Beckerleg, S., M. Telfer, et al. (2006). "A Rapid Assessment of Heroin Use in Mombasa, Kenya." Substance Use & Misuse **41**(6-7): 1029-1044.

Bisika, T., S. Konyani, et al. (2004). Rapid Situation Assessment of Drug Abuse and HIV/AIDS in Malawi. Malawi, The Ministry of Home Affairs and Internal Security, Inter-Ministerial Committee on Capacity Building for Drug Control Project**:** 56

Borschevskaya, V. and M. Tumano (2006). Country Report of the Russian Federation on the Implementation of the Declaration of Commitment on HIV/AIDS (UNGASS) January-December 2005. Analytical Group for Monitoring and Evaluation of Projects and Programs Targeted at Countering the HIVAIDS Epidemic in the Russian Federation. Moscow, Federal Services for Surveillance of Consumer Rights and Welfare of Russian Federation,**:** 60.

Brady, J. E., S. R. Friedman, et al. (2008). "Estimating the Prevalence of Injection Drug Users in the U.S. and in Large U.S. Metropolitan Areas from 1992 to 2002." Journal of Urban Health: Bulletin of the New York Academy of Medicine, **83**(3): 1099-3460.

Bravo-García, E., C. Magis-Rodríguez, et al. (2006). New estimates in Mexico: more than 180,000 people living with HIV. XVI International AIDS Conference. Vancouver.

CAREC (2007). The Caribbean HIV/AIDS Epidemic and the Situation in Member Countries of the Caribbean Epidemiology Centre (CAREC). Caribbean Epidemiology Centre (CAREC): Special Programme on Sexually Transmitted Infections, Caribbean Epidemiology Centre (CAREC) and Pan American Health Organization.

Centre for Diseases Management (2006). Islamic Rebublicof Iran Country Report on Monitoring of the United Nations General Assembly Special Session on HIV and AIDS, Office of

the Under-secretary for Health, Ministry of Health and Medical Education,Centre for Diseases Management.**:** 56.

Centres for Disease Control R.O.C. (Taiwan). (2007, 23 November 2007). "Populations Vulnerable to HIV Infection." CDC Taiwan Retrieved 24 November, 2007, from http://www.cdc.gov.tw/content.asp?CuItem=7423.

Cheng, S. H., F.-Y. Chu, et al. (2007). Prevalence of hepatitis B, C, D, and human immunodeficiency virus infections among substance users in Taiwan. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. Sydney.

Comision Nacional de Sida-Conasida (2005). "Epidemiology of HIV/AIDS in Chile. December 2003." Revista Chilena de Infectologia **22**(2): 169-202.

Consejo Nacional Para El Control De Estupefacients (CONACE) (2006). Septimo Estudio Nacional De Drogas En Poblacion General De Chile 2006,, Minsterio Del Interior, Gobierno De Chile, **:** 256.

Coordenação Nacional de DST e AIDS (2003). A Política do Ministério da Saúde Para a Atenção Integral a Usuários de Álcool e Outras Drogas. Série B. Textos Básicos de Saúde. Brasília, Ministério da Saúde.

Dahoma, M., A. Salim, et al. (2006). "HIV and Substance Abuse: the dual epidemics challenging Zanzibar." African Journal of Drug & Alcohol Studies **5**(2): 130-139.

Devaney, M., G. Reid, et al. (2006). Situational analysis of illicit drug issues and responses in the Asia-Pacific region. ANCD Research Paper, No. 12. Australian National Council on Drugs. Canberra, Burnet Institute: Centre for Harm Reduction and Turning Point Alcohol and Drug Centre.

Dewing, S., A. Plüddemann, et al. (2006). "Review of injection drug use in six African countries: Egypt, Kenya, Mauritius, Nigeria, South Africa and Tanzania." Drugs: Education, Prevention and Policy **13**(2): 121-137.

Division, U. N. P. (2007). World Population Prospects: The 2006 Revision.

Djumalieva, D., W. Imamshah, et al. (2002). "Drug use and HIV risk in Trinidad and Tobago: qualitative study." International Journal of STD & AIDS **13**(9): 633-9.

Donoghoea, M. C., A. R. Bollerup, et al. (2007). "Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002–2004." International Journal of Drug Policy **18**(4): 271–280.

Drug Control Department (2007). 2007 National Report (2006 data) to the EMCDDA by the Reitox National Focal Point: Lithuania New Development, Trends and In-depth Information on Selected Issues, Government of the Republic of Lithuania,**:** 67.

Elshimi, T., M. Warner-Smith, et al. (2004). HIV risk-behaviours of problem drug users in greater Cairo Cario, United Nations Office of Drugs and Crime,.

EuroHIV (2007). HIV/AIDS Surveillance in Europe. End-year report 2006. Saint Maurice, Institut de Veille sanitaire/French Institute for Public Health Surveillance, European Centre for the Epidemiological Monitoring of AIDS (EuroHIV).

European Monitoring Centre for Drugs and Drug Addiction (2007). 2007 Annual Report: The State of the Drugs Problem In Europe. Lisbon, EMCDDA**:** 100.

European Monitoring Centre for Drugs and Drug Addiction (2008). Estimates of Injecting Drug use in Europe.

European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point (2002). Romania: Drug Situation 2001. Bucharest, EMCDDA**:** 80.

European Monitoring Centre for Drugs and Drug Addiction & Reitox National Focal Point (2006). Cyprus: New Developments, Trends and in-depth information on selected issues. Lisbon, EMCDDA**:** 100.

Family Health International (2007). Lao People's Democratic Republic Final Report 1997-2007, USAID,**:** 74.

Fernando, T. and D. Bridger (2008). Email "re: Request for data on IDU and HIV prevalance". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Colombo, UNAIDS Sri Lanka and the Maldives.

Figueroa, J. P. (2004). "An overview of HIV/AIDS in Jamaica: strengthening the response." West Indian Medical Journal **53**(5): 277-282.

Frost, S. D. W., K. C. Brouwer, et al. (2006). "Respondent-driven sampling of injection drug users in two U.S.-Mexico border cities: recruitment dynamics and impact on estimates of HIV and syphilis prevalence,." Journal of Urban Health: Bulletin of the New York Academy of Medicine **83**(S1): 83-97.

Gaillard, E. M., L. M. Boulos, et al. (2006). "Understanding the reasons for decline of HIV prevalence in Haiti." Sexually Transmitted Infections **82**(S1): 14-20.
Gelkopf, M., T. Weizman, et al. (2006). "Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic." Israel Journal of Psychiatry and Related Sciences **43**(2): 126-136.
Global Fund (2002). Acceleration and Improvement of the National, Intersectoral, Participative and Descentralized Response to the HIV/AIDS epidemic in Chile. Chile, Country Coordinating Mechanism Chile,**:** 51.
Global Fund (2003). Proposal Form: Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand, Raks Thai Foundation**:** 46.
Global Fund (2006). Proposal Form Sixth Call for Proposals. Viet Nam**:** 123.
Global Fund (2006). Proposal Form Sixth Call for Propsals: Maintaining Low HIV prevalence among the population and all vulnerable sub-populations in Jordan. Jordan**:** 77.
Global Fund (2006). Proposal Form, Scaling Up HIV Prevention, Treatment, Care and Support Through Enhanced Voluntary Counselling and Testing and Improved Blood Safety Strategies. Phillippines**:** 153.
Global Fund (2006). Sixth Call for Proposals of the Global Fund to fight AIDS, Tuberculosis and Malaria: Proposal of the CCM for Morocco. HIV/AIDS and Tuberculosis Components. Kingdom of Morocco**:** 119.
Global Fund (2006). Sixth Call for Proposals: Support for Partnership and Strengthening of the Response to the Threat of the Spread of HIV/AIDS in Tunisia. Republic of Tunisia, Ministry of Health. Country Coordinating Mechanism**:** 122.
Global Fund (2007). Grant Performance Report Preventing HIV/AIDS and Increasing Care and Support for Injection Drug Users in Thailand. Thailand, , Raks Thai Foundation**:** 22.
Global Fund (2007). Grant Performance Report: Maintaining low HIV prevalence among the population and all vulnerable subpopulations it Jordan. Jordan**:** 11.
Glynn, M. and P. Rhodes (2005). Estimated HIV Prevelence in the United States at the end of 2003. National HIV Prevention Conference. Atlanta.
Government Malaysia (2005). Country Report Malaysia, United Nations General Assembly Special Session on HIV/AIDS Monitoring the Declaration of Commitment on HIV/AIDS 61.
Grotherath, A. (2002). Drug abuse and HIV/AIDS in the Middle East and North Africa: a situation assessment, UNODCCP, UNAIDS.
Hacker, M. A., M. Malta, et al. (2005). "Human immunodeficiency virus, AIDS, and drug consumption in South America and the Caribbean: epidemiological evidence and initiatives to curb the epidemic." Revista Panamericana de Salud Pública **18**(4-5): 303-313.
Hepburn, M. J. and E. J. Lawitz (2004). "Seroprevalence of hepatitis C and associated risk factors among an urban population in Haiti." BMC Gastroenterology **4**: 31.
Hidalgo, E. (2005). Establishing the LCDC Drug Information System: Lao People's Democratic Republic 2005. Vientiane, UNODC Lao Country Office/Lao National Commission for Drug Abuse and Control and Supervision**:** 138.
Holt, E. (2004). "Slovakia has kept AIDS out despite money problems." The Lancet **363**: 4.
Huang, M. and H. Hussein (2004). "The HIV/AIDS Epidemic Country Paper: Malaysia." AIDS Education and Prevention **June 16**(Supp A): 100-109.
Human Rights Watch (2004). Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights. HRW. New York. **16:** 60.
Ialomiteanu, A. (2008). Email "Estimates of lifetime injecting drug use 15-64 years from the Canadian Addiction Survey 2004" Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Toronto, Centre for Addiction and Mental Health.
Iliuta, C., F. Bocioc, et al. (2007). Demonstrating the impact of civil society involvement in the target setting process for universal access. Vilnius, Central and Eastern European Harm Reduction Network**:** 16.
Inter-American Observatory on Drugs (2004). Qualitative Research on Drug Use: Assessing Emerging Drug Trends in the Caribbean. Washington D.C., Inter-American Observatory on Drugs (OID)**:** 272.
Isralowitz, R., A. Reznik, et al. (2007). "Severity of heroin use in Israel: Comparisons between native Israelis and former Soviet Union immigrants." **102**(4): 630-637.

Jenkins, C. and D. A. Robalino (2003). HIV/AIDS in the Middle East and North Africa: The Costs of Inaction. Orientations in Development Series. Washington, D.C., The World Bank: 169.
Kalichman, S. C., L. C. Simbayi, et al. (2006). "Associations of poverty, substance use, and HIV transmission risk behaviors in three South African communities." Social Science and Medicine **62**(7): 1641-9.
Kavasoglu, E. (2008). Email "YNT: Annual Reports Questionnaires (ARQ)". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Ankara, Ministry of Health.
Kelly, J. A. and Y. A. Amirkhanian (2003). "The newest epidemic: a review of HIV/AIDS in Central and Eastern Europe." International Journal of STD & AIDS **14**(6): 361-371.
Kenyan Bureau of Statistics. (2007). "National Statistics Profile." Ministry of Planning and National Development Retrieved 30 November, 2007, from http://www.knbs.go.ke/#.
Kiššová, L. e. (2005). Report for the EMCDDA – the REITOX1 National Focal Point in the Slovak Republic: The State of Drug Addiction and Drug Control in the Slovak Republic Developments, trends, and selected issues concerning the drug problem in the Slovak Republic. The Government Office of the Slovak Republic, The General Secretariat of the Ministerial Board for Drug Addiction and Drug Control and National Monitoring Centre for Drugs: 227.
Komisi Penanggulangan AIDS (2007). National report on estimates of adults vulnerable to HIV and infection in Indonesia, 2006. Jakarta, National AIDS Commission Indonesia.
Kumar, S. (2006). Injecting of pharmaceutical drugs in the South-Asia: A Review. Chennai: 8.
Lawal, R. A. (2006). A rapid situation assessment and response study of drug use, injecting drug use, HIV/AIDS and other risk behaviors among drug users targeting five Nigerian cities. Vienna, UNODC.
Lu, F., N. Wang, et al. (2006). "Estimating the number of people at risk for and living with HIV in China in 2005: methods and results." Sexually Transmitted Infections **82**(S3): S87-91.
Madani, T. A., Y. Y. Al-Mazrou, et al. (2004). "Epidemiology of the human immunodeficiency virus in Saudi Arabia; 18-year surveillance results and prevention from an Islamic perspective." BMC Infectious Diseases **4**: 25.
Manzanero, M. (2008). Email "IVDU Information Belize". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Belmopan, National TB, HIV/AIDS and other STIs Programme: Belize.
Markosyan, K. M., A. Kocharyan, et al. (2006). "Meeting the challenge of injection drug use and HIV in Armenia." Health & Human Rights **9**(1): 128-51.
McBride, W. (2005). "HIV/AIDS in Papua New Guinea: An unfolding disaster?" Emergency Medicine Australasia **17**(4): 304-306.
McCurdy, A., M. Williams, et al. (2005). "Heroin and HIV risk in Dar es Salaam, Tanzania: Youth hangouts, mageto and injecting practices." AIDS Care **17**(1): 65-78.
McCurdy, S. A., M. W. Ross, et al. (2006). "HIV/AIDS and injection drug use in the neighborhoods of Dar es Salaam, Tanzania." Drug and Alcohol Dependence **82**(S1): S23-S27.
McDonald, D. (2005). "A rapid situation assessment of drug use in Papua New Guinea." Drug and Alcohol Review **24**(1): 79-82.
MESRS (2006). Etude du lien potentiel entre usage problématique de drogues et VIH/SIDA en Algérie. Algeria, UNAIDS: 151.
Miller, A. (2008). Email "IDU figures Myanmar". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Rangoon, Resource Mobilization and Technical Assistance Coordination Officer, UNAIDS Myanmar,.
Ministries of Health: Fiji Kiribati Samoa Solomon Islands Tonga and Vanuatu (2006). Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries (2004-2005), World Health Organization.
Ministry of Health (2007). Results from the HIV/STI Intergrated Biological and Behavioral Surveillence (IBBS) in Viet Nam 2005-2006. F. H. I. National Institute of Hygiene and Epidemiology, Viet Nam Administration of HIV / AIDS Control (VAAC), US Centers for Disease Control (CDC), United States Agency for International Development (USAID),. Hanoi: 76.
Ministry of Health of Ukraine (2008). Ukraine: National Report on Monitoring Progress Towards the UNGASS Declaration of Commitment on HIV/AIDS - Reporting Period: January 2006 - December 2007. Kyiv, Ministry of Health, Ukraine.

Ministry of Narcotics Control, Anti-Narcotics Force, et al. (2007). Problem Drug Use in Pakistan: Results from the National Assesment, United Nations Office of Drugs and Crime,.

Mokri, A. and R. Schottenfeld (2007). Drug Abuse and HIV Transmission in Iran—Responding to the Public Health Challenges. Tehran, Tehran University of Medical Sciences and the Iranian National Center for Addiction Studies and Yale University School of Medicine.

Nasibov, R. (2005). Rapid assessment of situation on intravenous drug use related HIV/AIDS in Azerbaijan. The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. Rio de Janeiro.

National AIDS Control Organization (2006). HIV/AIDS epidemiological Surveillance & Estimation report for the year 2005, National AIDS Control Organization (NACO), Ministry of Health & Family Welfare, Government of India.

National AIDS Control Program (2005). HIV Second Generation Surveillance in Pakistan: National Report Round 1. Islamabad, National AIDS control Program, Ministry of Health**:** 89.

National Anti-Drug Council Suriname (2002). SURIDIN Suriname Drug Information Network. Annual National Report 2002,. Paramaribo, National Anti-Drug Council Suriname,**:** 25.

National Authority for Combating Drugs (2007). Report on Illicit Drug Data and Routine Surveillance Systems in Cambodia 2006. Phnom Penh, Royal Government of Cambodia**:** 63.

National Centre for AIDS and STD Control (2004). National Estimates of Adult HIV Infections, Nepal 2003. Kathmandu, Nepal Ministry of Health, His Majesty's Government of Nepal**:** 40.

National Centre in HIV Epidemiology and Clinical Research (2008). Australian NSP Survey National Data Report 2003-2007: Prevalence of HIV, HCV and Injecting and Sexual Behaviour among IDUs at needle and syringe programs. Sydney, The University of New South Wales,**:** 220.

National Epidemiology Center (2005). 2005 Integrated HIV Behavioral and Serologic Surveillance Findings Summary Report. Manila, Department of Health,**:** 26.

National Focal Point for Drugs and Drug Addictions (2006). Annual Report on the state of the drugs problem in Bulgaria 2006. Sofia, National Drug Council.

National HIV/STD Control Programme (2006). National HIV/STI prevention and control program - Facts and figures - HIV/AIDS Epidemic Update January to December 2006. Kingston, Jamaica, Ministry of Health, Health Promotion and Protection Division**:** 10.

Ndetei, D. M. (2004). A study on the linkages between drug abuse, injecting drug abuse and HIV/AIDS in Kenya: A rapid situation assessment 2004, United Nations Office on Drugs and Crime

Niaz, K. (2007). Assessment of Problem Drug Use in Central Asia: UNODC/WHO Technical Consultation on Setting Targets for Universal Access to HIV Prevention, Treatment and Care for Injecting Drug Users (IDU) in Azerbaijan, Kazakhstan, Kyrgyzstan, Taijikistan, Turkmenistan and Uzbekistan. Tashkent, UNODC,

WHO.

Niaz, K. (2008). Email "re: Request for prevalence estimates and Sentinel Surveillance data". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Tashkent, Regional Office in Central Asia, United Nations Office on Drugs and Crime.

Odek-Ogunde, M., F. A. Okoth, et al. (2004). Seroprevalence of HIV, HBC and HCV in injecting drug users in Nairobi, Kenya: World Health Organization Drug Injecting Study Phase II findings,. International Conference on AIDS July 11-14 2004. Bangkok, Thailand. **Abstract No. WePeC6001**.

Pan American Health Organization (2004). AIDS Surveillance in the Americas: Annual Report 2004. PAHO. Washington, D.C.**:** 21.

Parry, C., O. Nwanyanwu, et al. (2006). HIV and Drug Use Among Injection Drug Users (IDUs), Commercial Sex Workers (CSWs), and Men who have Sex with Men (MSM) in South Africa. The President's Emergency Plan for AIDS Relief Annual Meeting: The 2006 HIV/AIDS Implementers' Meeting. Durban.

Parry, C. D. H., T. Carney, et al. (2007). HIV risk behavior in South African drug users: A tale of three cities, Alcohol & Drug Abuse Research Unit, Medical Research Council South Africa.**:** 30.

Pechansky, F., F. Kessler, et al. (2005). "Substance use, risk situations, and HIV seroprevalence among individuals seeking free HIV testing in Porto Alegre, Brazil." Pan American Journal of Public Health **18**(4-5): 249-55.
Pechansky, F., G. Woody, et al. (2006). "HIV seroprevalence among drug users: An analysis of selected variables based on 10 years of data collection in Porto Alegre, Brazil. (22 refs.)." Drug and Alcohol Dependence **82**(S1): S109-S113.
Peles, E., S. Schreiber, et al. (2006). "Factors predicting retention in treatment: 10-year experience of a methadone maintenance treatment (MMT) clinic in Israel." Drug & Alcohol Dependence **82**(3): 211-217.
Persaud, N. E., W. Klaskala, et al. (1999). "Drug use and syphilis: Co-factors for HIV transmission among commercial sex workers in Guyana." West Indian Medical Journal **48**(2): 52-56.
Philippine National AIDS Council (2005). Country Report of the Philippines. Manilla, Philippine National AIDS Council (PNAC),**:** 46.
Phimphachanh, C. and K. Sayabounthavong (2004). "The HIV/AIDS/STI situation in Lao People's Democratic Republic." AIDS Education and Prevention **16**(SA): 91-99.
Pontali, E. (2008). Email "Info for your Global report". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Genoa, Galliera Hospital and Prison of Genoa.
Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) (2006). Estudio de Infecciones de Transmision sanguinea y sexual y Practicas de riesgo en Usuarios de Drogas inyectables en Paraguay Informe final., Organización Panamericana de la Salud/Organización Mundial de la Salud.
Programa nacional de Control de SIDA/ITS Paraguay (PRONASIDA) (2006). Estudio de ITSS (Infecciones de Transmisión Sexual Sanguínea) y Prácticas de riesgo en UDIs.
Public Health Agency of Canada (2006). HIV/AIDS Epi Updates. August 2006. Ottowa, Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control Public Health Agency of Canada 126.
Ramon, J. S., M. Alvarenga, et al. (2002). "Estimating HIV/AIDS prevalence in countries with low-level and concentrated epidemics: the example of Honduras." AIDS **16**(S3): S18-S22.
Razali, K., H. Thein, et al. (2007). "Modelling the hepatitis C virus epidemic in Australia." Drug and Alcohol Dependence **91**(2-3): 228-235.
Reddy, A. (2005). Size Estimation of IDU in Bangladesh. Dhaka, Family Health International
Reid, G. and G. Costigan (2002). Revisiting "The Hidden Epidemic": A Situation Assessment of Drug Use in Asia in the context of HIV/AIDS,. Melbourne, The Centre for Harm Reduction, The Burnet Institute Australia**:** 240.
Reid, G., A. Kamarulzaman, et al. (2004). Rapid Situation Assessment of Malaysia, The Centre for Harm Reduction**:** 44.
Republic of Armenia (2007). HIV/AIDS Epidemic in the Republic of Armenia. National Centre for AIDS Prevention.
Resource Centre for Sexual Health and AIDS (RCSHA) (2006). Report of the Expert Group on Size Estimation of Population with High Risk Behaviour for NACP-III Planning. New Delhi.
Reyes, J., C., R. Robles, R., et al. (2007). "Severe anxiety symptomatology and HIV risk behavior among Hispanic injection drug users in Puerto Rico." AIDS & Behavior **11**(1): 145-50.
Rodriguez, C., M., L. Marques, F., et al. (2002). "HIV and injection drug use in Latin America." AIDS **16 Suppl 3**: S34-41.
Sosa-Estani, S., D. Rossi, et al. (2003). "Epidemiology of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome in injection drug users in Argentina: high seroprevalence of HIV infection." Clinical Infectious Diseases **37 Suppl 5**: S338-42.
Soto, R. J., A. E. Ghee, et al. (2007). "Sentinel Surveillance of Sexually Transmitted Infection/HIV and Risk Behaviors in Vulnerable Populations in 5 Central American Countries,." Journal of Acquired Immune Deficiency Syndromes, **46**(1): 101-111.
Statistics, K. B. o. and M. o. P. a. N. Development. (2007). from http://www.knbs.go.ke/#.
Strathdee, S. A., M. P. Morgan, et al. (2007). "Correlates of injection drug use among female sex workers in two Mexico–U.S. border cities,." Drug and Alcohol Dependence,: 9.
Stvilia, K., T. Tsertsvadze, et al. (2006). "Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia,." J Urban Health, **83**(2): 289-98.

Sulliman, F., S. A. G. Ameerberg, et al. (2004). Report of the Rapid Situation Assessment and Resonses on Drug Use in Mauritius & Rodrigues. Port Louis, Ministry of Health, Mauritius.

The Country Coordinating Mechanism for the Global Fund in Bosnia-Herzegovina (2005). Coordinated National Response to HIV/AIDS & Tuberculosis in a war-torn and highly stigmatised setting, Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria**:** 89.

The Foundation for Advancement of Self Help in Attaining Needs (FASHAN) and Narcotics Control Board (NCB) of Maldives (2003). Rapid Situation Assessment of Drug Abuse in Maldives 2003,. Male', Narcotics Control Board (NCB) of Maldives,**:** 74.

Timpson, S. and et al (2006). "Substance Abuse, HIV Risk and HIV/AIDS in Tanzania." African Journal of Drug & Alcohol Studies **5**(2): 158-169.

Todd, C. S., A. M. S. Abed, et al. (2007). "HIV, Hepatitis C, and Hepatitis B Infections and Associated Risk Behavior in Injection Drug Users, Kabul, Afghanistan,." Emerging Infectious Diseases, **13**(9): 5.

Toufik, A. (2006). VIH/Drogues MENA. Paris, France, Observatoire français des drogues et des toxicomanies.

UNAIDS (2006). 2006 AIDS Epidemic Update: Middle East and North Africa. Geneva, Joint United Nations Programme on HIV/AIDS**:** 2.

UNAIDS (2006). 2006 Report on the global AIDS epidemic. Geneva, Joint United Nations Programme on HIV/AIDS,**:** 629.

UNGASS (2006). Country Report: Federated States of Micronesia. United Nations General Assembly Special Session on HIV/AIDS, UNGASS.

United Nations Office on Drugs and Crime (2003). Audit on the number of injecting drug users in Central and Eastern Europe and Central Asia. UNODC. New York.

United Nations Office on Drugs and Crime (2005). Afghanistan drug use survey 2005. UNODC & Government of Afghanistan - Ministry of Counter Narcotics. Kabul.

United Nations Office on Drugs and Crime (2006). Patterns and Trends of Amphetamine-Type Stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2005. United Nations Office on Drugs and Crime Regional Centre for East Asia and the Pacific. Bangkok**:** 146.

United Nations Office on Drugs and Crime, The Lao National Commission for the Drug Control and Supervision, et al. (2005). Drug use and HIV risk: Khamkeuth District (Bolikhamxay), Sing District (Luang Namtha), Khua District (Phongsaly), Lao PDR. Vientiane, United Nations Office on Drugs and Crime, The Lao National Commission for the Drug Control and Supervision, The Centre for HIV/AIDS and STI, The Burnet Institute, .

United Nations Office on Drugs and Crime & Institute for Development Research and Applied Care (2003). Substance Use and Misuse in Lebanon. The Lebanon Rapid Situation Assessment and Responses Study. Beirut, UNODC & IDRAC**:** 131.

United Nations Office on Drugs and Crime: Regional Office for South Asia (2007). Rapid Situation Response Assesment Bhutan Report - Draft. New Delhi,, UNODC Regional Office for South Asia.

United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific (2006). Myanmar – United Nations Regional Task Force on Injecting Drug Use and HIV/AIDS in Asia and the Pacific Baseline Assessment Dec 2006

Vickers, I. E., H. Alveranga, et al. (2005). "Clinical and epidemiological characteristics of adult and adolescent patients newly diagnosed with the human immunodeficiency virus at a Jamaican clinic for sexually transmitted infections." West Indian Medical Journal **54**(6): 360-363.

Wang, Y. A., S. Cliffe, et al. (2006). Prevalence of STI, HIV and risk behaviors among seafarers in Kiribati 2005. XIV International AIDS Conference. Toronto.

Weissenbacher, M., D. Rossi, et al. (2003). "High Seroprevalence of Bloodborne Viruses among Street-Recruited Injection Drug Users from Buenos Aires, Argentina." Clinical Infectious Diseases **37**: S348-352.

Wiessing, L. (2008). Email "HIV prevalence in the UK". Secretariat to the UN Reference Group on HIV and injecting drug use: University of NSW. Lisbon, European Monitoring Centre for Drugs and Drug Addiction

Wilkins, C., M. Girling, et al. (2006). Recents trends in drug use in New Zealand: 2006. Findings from the Illicit Drug Monitoring System (IDMS). Centre for Social and Health Outcomes Research and Evaluation. Auckland, Massey University.

Williams, M. L., S. A. McCurdy, et al. (2007). "Differences in HIV Risk Behaviors by Gender in a Sample of Tanzanian Injection Drug Users." AIDS and Behavior **11**(1): 137-144.

Woratanarat, T. (2006). "Global HIV cohort studies among injecting drug users and future vaccine trials." J Med Assoc Thai **89**(7): 1064-79.

World Bank (2005). Preventing HIV/AIDS in the Middle East and North Africa: A Window of Opportunity to Act. Orientations in Development Series. Washington, D.C., World Bank**:** 110.

World Health Organization (2003). Access to Antiretroviral Treament and Care: The Experience of the HIV Equity Initiative, Cange, Haiti. Port-au-Prince, WHO**:** 16.

World Health Organization (2004). Approaches to the management of HIV/AIDS in Cuba. Perspectives and Practice in Antiretroviral Treatment. J. Pérez, D. Pérez, I. Gonzalezet al. Geneva, World Health Organisation**:** 19.

World Health Organization (2006). Epidemiological Fact Sheets on HIV/AIDS and Sexually Transmitted Infections: Barbados. Geneva, WHO**:** 18.

World Health Organization (2006). A Rapid Assesment and Response to HIV and Drug Use in Mongolia - Draft report. Manila, WHO Regional Office for the Western Pacific,.

World Health Organization (2006). Second generation surveillance surveys of HIV, other STIs and risk behaviours in 6 Pacific Island countries (2004-2005). S. Cliffe, Y. Wang and E. Sullivan. Manila, Philippines, World Health Organisation (WHO), Regional Office for the Western Pacific.**:** 123.

World Health Organization (2007). Scaling up Antiretroviral Treatment: Lessons Learnt from Thailand. Report of an external evaluation, 12-19 October 2004. World Health Organization Regional Office for South-East Asia. New Delhi, WHO**:** 90.

World Health Organization. Regional Office for Europe (2004). HIV sentinel surveillance in high-risk groups in the Russian Federation, Azerbaijan Republic and the Republic of Moldova: report on a WHO project 1 April 2003 - 31 March 2004. Copenhagen, WHO Regional Office for Europe,**:** 146.

Appendix F: 2007 estimated number of people who inject drugs

The following tables present estimates of the number of people who inject drugs per country for 2007. In deriving these estimates it was assumed that IDU prevalence was the same in 2007 as in the year of the estimate as reported in the literature. United Nations Population Division estimates of 2007 general population (15-64 years of age) were used (2).
2007

Table (F) 2a: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Eastern Europe

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Armenia	2000	--	0.10	--		2,091		D1	CIDU	2005,2002	6.8	13.4	20	D1, B
Azerbaijan	2006	--	5.21	--		306,145		A	CIDU	2004	2	13	24	A
Belarus	2005	--	0.09	--		6,327		C	REG	2006	--	1.5	--	B
Bosnia & Herzegovina	--	--	NK	--		NK		--	--	--	--	NK	--	--
Bulgaria	2005	0.30	0.38	0.45	16,033	20,042	24,050	A	CIDU	2006	0.0	0.4	0.8	B, A
Croatia	--	--	NK			NK		--	--	2006	--	0.6	--	A
Czech Republic	2006	0.35	0.40	0.47	25,501	29,008	33,832	A	CIDU	2006	0.0	0.05	0.1	A
Estonia	2004	0.89	1.51	3.79	8,151	13,756	34,618	A	CIDU	2005	54.3	72.1	89.9	B
Georgia	2004,02	0.48	4.19	7.90	14,290	124,894	235,499	C, B	CIDU	2004, 2001-02	1.4	1.63	1.85	B
Hungary	2005	0.03	0.06	0.08	2,064	3,931	5,799	A	CIDU	2006	--	0.0	--	A
Latvia	--	--	NK	--		NK		--	CIDU	2003	6.6	8.15	9.7	A
Lithuania	2006	--	0.22	--		5,116		C	REG	2003	--	2.4	--	A
Moldova	2001	--	0.14	--		3,730		C	REG	2001	--	17	--	B
Poland	--	--	NK	--		NK		--	CIDU	2006	--	8.9	--	A
Romania	--	--	NK	--		NK		--	--	2006	--	1.44	--	B
Russia	2007	--	1.78	--		1,825,000		D1	CIDU	2003	0.3	37.15	74.0	B
Slovakia	2005	0.35	0.49	0.89	13,796	18,929	34,503	A	CIDU	2006	--	0.0	--	B
Ukraine	2006	1.00	1.16	1.31	324,167	374,038	423,910	A	CIDU	2006	--	41.8	--	B
Observed population-weighted prevalence**			**1.50**									**27.03**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors"
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 2b: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Western Europe

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Albania	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Andorra	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Austria	2000	0.22	0.32	0.42	12,399	18,082	23,765	A	CIDU	2006	--	7.1	--	A
Belgium	1997	0.35	0.39	0.43	23,958	26,643	29,328	A	CIDU	2006	2.9	4.3	5.7	A
Denmark	1996	0.35	0.44	0.52	12,554	15,643	18,732	A	CIDU	2006	--	2.1	--	A
Finland	2002	0.35	0.45	0.57	12,347	15,839	19,938	A	CIDU	2006	--	0.2	--	A
France	1999	--	0.32	--	--	128,348	--	A	CIDU	2003	--	12.2	--	A
Germany	2005	0.14	0.17	0.20	77,435	93,568	109,700	A	CIDU	2006	--	2.9	--	A
Greece	2005	0.11	0.13	0.15	8,572	9,754	11,173	A	CIDU	2006	0.3	0.5	0.7	A
Iceland	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Ireland	1996	0.20	0.27	0.33	5,820	7,798	9,776	A	CIDU	1999	--	5.8	--	A
Italy	1996	--	0.83	--	--	323,362	--	A	CIDU	2006	--	12.1	--	A
Liechtenstein	--	--	--	--	--		--	--	--		--	--	--	--
Luxembourg	2000	--	0.59	--	--	1,850	--	A	CIDU	2006	--	2.8	--	A
Macedonia	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Malta	--	--	NK	--	--	NK	--	C	REG	2006	--	0	--	B
Monaco	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Montenegro	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Netherlands	2001	0.02	0.03	0.04	2,254	3,176	4,406	A	CIDU	2002	--	9.5	--	B
Norway	2005	0.27	0.33	0.38	8,517	10,220	11,924	A	CIDU	2006	--	3.2		A
Portugal	2000	0.23	0.47	0.70	16,419	33,341	50,262	A	CIDU	2006	10.9	15.6	20.2	A
San Marino	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Serbia	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Slovenia	2001	--	0.52	--	--	7,378	--	A	CIDU	2004	--	0.4	--	A
Spain	1998	--	0.31	--	--	93,948	--	A	CIDU	2006	--	39.7	--	A
Sweden	--	--	NK	--	--	NK	--	A	CIDU	2007	--	5.4	--	A
Switzerland	1997	0.51	0.65	0.78	25,849	32,850	39,851	A	**	2004	--	1.4	--	A
UK	2005	0.38	0.39	0.42	152,773	158,201	167,606	A	CIDU	2006	0.6	2.3	4	A
Observed population-weighted prevalence**			**0.37**									**11.14**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors";
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 3a: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in East and South East Asia

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Brunei	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	
Burma	2007	0.18	0.23	0.27	60,000	75,000	90,000	C	CIDU	2006	--	42.6	--	C
Cambodia	2004	0.01	0.02	0.09	1,096	1,918	7,672	C	CIDU	2006, 04	14.3	22.8	31.3	B
China	2005	0.19	0.25	0.31	1,850,714	2,416,210	2,981,706	A	CIDU	2005	7.96	12.3	19.2	A
Indonesia	2006	0.13	0.14	0.16	193,421	222,536	251,652	A	CIDU	2006	31.7	42.5	53.3	A
Japan	2004	--	0.47	--	--	393,295	--	D1	CIDU	--	--	NK	--	--
Laos	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Malaysia	2002	1.11	1.33	1.56	190,971	230,288	269,606	C	CIDU	2002	--	10.3	--	A
Mongolia	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
North Korea	--	--		--	--		--	--	--	--	--	--	--	--
Philippines	--	--	NK	--	--	NK	--	--	--	2005	--	1	--	B
Singapore	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
South Korea	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Taiwan	--	--	NK	--	--	NK	--	--	--	2004,06	2	13.8	25.6	D1, B
Thailand	2001	--	0.38	--	--	169,347	--	D1	CIDU	2004	--	42.5	--	B
Timor Leste	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Vietnam	2005	--	0.25	--	--	142,222	--	D1	CIDU	2006	1.9	33.85	65.8	B
Observed population-weighted prevalence**			**0.26**									**16.70**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors"
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 3b: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in South Asia

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Afghanistan	2005	0.05	0.05	0.05	7,474	7,507	7,539	A	CIDU	2005-06	1.7	3.4	5.1	B
Bangladesh	2005	0.02	0.03	0.04	20,969	31,453	41,938	C	CIDU	2006	0.8	1.35	1.9	A
Bhutan	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
India	2006	0.01	0.02	0.03	108,787	168,331	227,874	A	CIDU	2004	--	11.15	--	A
Iran	2004	--	0.40	--	--	195,174	--	A	CIDU	2005	5	15	25	B
Maldives	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Nepal	2003	0.11	0.15	0.19	17,989	24,638	31,286	A	CIDU	2003	30.22	41.39	52.56	B
Pakistan	2006	0.13	0.14	0.16	128,707	134,329	154,448	A	CIDU	2005	9.6	10.8	12.1	A
Sri Lanka	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Observed population-weighted prevalence**			**0.05**									**13.07**		

Table (F) 3c: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Central Asia

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Kazakhstan	2006	--	0.96	--	--	101,264	--	A	CIDU	2005	8.0	9.2	10.4	B
Kyrgyzstan	2006	--	0.74	--	--	25,573	--	A	CIDU	2005	2.4	8.0	13.6	B
Tajikistan	2006	--	0.45	--	--	17,468	--	A	CIDU	2005	11.5	14.7	17.9	B
Turkmenistan	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Uzbekistan	2006	--	0.47	--	--	82,281	--	A	CIDU	2005	11.7	15.6	19.5	B
Observed population-weighted prevalence**			**0.64**									**11.81**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors"
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 4a: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Caribbean

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Antigua & Barbuda	--	--	--	--	--	--	--	--	--		--	--	--	--
Bahamas	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Barbados	--	--	--	--	--	--	--	--	--		--	--	--	--
Bermuda	--	--	NK	--	--	--	--	--	--		--	--	--	--
Puerto Rico	2002	--	1.15	--	--	12.9	--	A	CIDU	1998-2001	--	12.9	--	A
Cuba	--	--	--	--	--	--	--	--	--		--	--	--	--
Dominica	--	--	--	--	--	--	--	--	--		--	--	--	--
Dominican Republic	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Grenada	--	--	--	--	--	--	--	--	--		--	--	--	--
Haiti	--	--	NK	--	--	--	--	--	--		--	--	--	--
Jamaica	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Saint Kitts & Nevis	--	--	--	--	--	--	--	--	--		--	--	--	--
Saint Lucia	--	--	--	--	--	--	--	--	--		--	--	--	--
Saint Vincent & Grenadines	--	--	--	--	--	--	--	--	--		--	--	--	--
Trinidad & Tobago	--	--	--	--	--	--	--	--	--		--	--	--	--
Observed population-weighted prevalence**			**1.15**									**12.90**		

CIDU: Estimate made for “current injectors” (indirect estimates were defined as “current IDUs” unless otherwise specified); PYIDU: Estimate of “past year injectors”; LTIDU: Estimate of “lifetime injectors”
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 4b: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Latin America

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Argentina	1999	0.29	0.29	0.30	72,005	73,489	74,972	D1	CIDU	1987-99	35.4	49.7	64.0	A
Belize	--	--	--	--	--	--	--	--	--		--	--	--	--
Bolivia	--	--	NK	--	--	NK	--	--	--		--	--	--	--
Brazil	2003	--	0.67	--	--	850,708	--	D1	CIDU	2000	18	48	78	A
Chile	2006	--	0.38	--	--	42,830	--	D1	LTIDU	--	--	NK	--	--
Colombia	--	--	NK	--	--	NK	--	--	--	1999	0.0	1	2.0	B
Costa Rica	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Ecuador	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
El Salvador	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Guatemala	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Guyana	--	--	--	--	--	--	--	--	--		--	--	--	--
Honduras	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Mexico	--	--	NK	--	--	NK	--	--	--	2005	1.9	3.0	4.1	B
Nicaragua	--	--	NK	--	--	NK	--	--	--	2000	--	6.0	--	D1
Panama	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Paraguay	--	--	NK	--	--	NK	--	--	--	2006	3.7	9.35	15.0	B
Peru	--	--	NK	--	--	NK	--	--	--	1994-95	--	13.0	--	D1
Suriname	--	--	NK	--	--	NK	--	--	--		--	--	--	--
Uruguay	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Venezuela	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Observed population-weighted prevalence**			**0.59**									**28.76**		

Table (F) 4c: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Canada and the United States

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Canada	2004	1.00	1.30	1.70	228,630	297,219	388,671	B	LTIDU	2005	2.9	13.4	23.8	A
USA	2002	0.67	0.96	1.34	1,375,691	1,973,192	2,751,382	A	CIDU	2003	8.74	15.57	22.4	A
Observed population-weighted prevalence**			**0.99**									**15.28**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors";
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 5a: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Pacific Island States and territories

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
American Samoa	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Micronesia	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
Fiji	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
French Polynesia	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
Guam	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
Kiribati	--	--	NK	--	--	--	--	--	--	--	--	--	--	--
Marshall Islands	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Nauru	--	--	--	--	--	--	--	--	--	--	--	--	--	--
New Caledonia	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
Palau	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Papua New Guinea	--	--	NK	--	--	--	--	--	--	--	--	NK	--	--
Samoa	--	--	NK	--	--	--	--	--	--	2004-5	--	0	--	D1
Solomon Islands	--	--	NK	--	--	--	--	--	--	2004-5	--	0	--	D1
Tonga	--	--	NK	--	--	--	--	--	--	2004-5	--	0	--	D1
Tuvalu	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Vanuatu		--	NK	--	--	--	--	--	--	--	--	--	--	--
Observed population-weighted prevalence**			**--**									**--**		

Table (F) 5b: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Australasia

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Australia	2005	0.65	1.09	1.50	91,314	153,046	209,288	A	CIDU	2006	--	1.5	--	A
New Zealand	2006	0.49	0.73	0.97	13,687	20,390	27,094	B	CIDU	2006	--	1.6	--	B
Observed population-weighted prevalence**			**1.03**									**1.51**		

REG: Estimate derived from cumulative registries of drug users

NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.

-- No reports of injecting drug use or HIV among people who inject drugs identified

* Prevalence among 15-64 year olds

** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made.

(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 6a: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in the Middle East and North Africa

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Algeria	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Bahrain	--	--	NK	--	--	NK	--	--	--	2000	--	0.3	--	B
Cyprus	2006	0.04	0.05	0.07	261	310	388	A	CIDU	2006	--	0	--	B
Egypt	--	--	NK	--	--	NK	--	--	--	2006	0.6	2.55	4.5	B
Iraq	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Israel	--	--	NK	--	--	NK	--	--	--	2005, 2002-6	2.07	2.94	3.81	B, A
Jordan	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Kuwait	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Lebanon	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Libya	2001	--	0.05	--	--	1,924	--	C	REG	2004	--	22	--	B
Morocco	--	--	NK	--	--	NK	--	--	--	2006	--	6.5	--	C
Oman	--	--	NK	--	--	NK	--	--	--	2000, 2000-2005	5	11.8	18.6	B
Palestine	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Qatar	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Saudi Arabia	--	--	NK	--	--	NK	--	--	--	1997	--	0.14	--	B
Sudan	--	--	NK	--	--	NK	--	--	--	2003	--	0	--	B
Syria	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Tunisia	--	--	NK	--	--	NK	--	--	--	1997	--	0.3	--	B
Turkey	--	--	NK	--	--	NK	--	--	--	2005, 2001	2.3	2.65	3	B
United Arab Emirates	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Yemen	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Observed population-weighted prevalence**			**0.04**									**2.94**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors";
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Table (F) 6b: Evidence on the prevalence of injecting drug use and HIV among people who inject drugs in Sub-Saharan Africa

Countries and territories	Year of estimate	Prevalence of injecting drug use (%)*			Estimated number of people who inject drugs in 2007			Grade	Type	Year of estimate	HIV prevalence among people who inject drugs (%)			Grade
		Lower	Mid	Upper	Lower	Mid	Upper				Lower	Mid	Upper	
Angola	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Benin	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Botswana	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Burkina Faso	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Burundi	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Cameroon	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Cape Verde	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Central African Republic	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Chad	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Comoros	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Cote d'Ivoire	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Dem Rep of the Congo	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Djibouti	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--
Equatorial Guinea	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Eritrea	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Ethiopia	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Gabon	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Gambia	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Ghana	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Guinea	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Guinea-Bissau	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Kenya	2004, 2000-02	0.16	0.73	1.3	32,835	149,811	266,786	C	CIDU	2003, 2004	36.3	42.9	49.5	B
Lesotho	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Liberia	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Madagascar	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Malawi	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Mali	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Mauritania	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Mauritius	2004	2.01	2.07	2.13	17,663	18,183	18,702	A	CIDU	--	--	NK	--	--
Mozambique	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Namibia	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Niger	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Nigeria	--	--	NK	--	--	NK	--	--	--	2003, 2000	0	5.5	11	B
Republic of the Congo	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Rwanda	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Sao Tome & Principe	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Senegal	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Seychelles	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Sierra Leone	--	--	--	--	--	--	--	--	--	--	--	--	--	--
Somalia	--	--	--	--	--		--	--	--	--	--	--	--	--
South Africa	2004	--	0.87	--	--	269,369	--	B	LTIDU	2005	4.8	12.4	20	B
Swaziland	--	--	--	--	--		--	--	--	--	--	--	--	--
Tanzania	--	--	NK	--	--	NK	--	--	--	--	--	NK	--	--

Togo	--	--	--	--	--		--	--	--	--	--	--	--	--
Uganda	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Zambia	--	--	NK	--	--	NK	--	--	--	--	--	--	--	--
Zimbabwe	--	--	--	--	--		--	--	--	--	--	--	--	--
Observed population-weighted prevalence**			**0.36**				--					**19.23**		

CIDU: Estimate made for "current injectors" (indirect estimates were defined as "current IDUs" unless otherwise specified); PYIDU: Estimate of "past year injectors"; LTIDU: Estimate of "lifetime injectors";
REG: Estimate derived from cumulative registries of drug users
NK: Injecting drug use OR HIV reported among those who inject drugs but a prevalence estimate could not be made.
-- No reports of injecting drug use or HIV among people who inject drugs identified
* Prevalence among 15-64 year olds
** Population-weighted-prevalence of IDU and IDU-population-weighted-prevalence of HIV for region countries based upon countries where a prevalence estimate could be made
(See Appendix D <web link> for source documents for all figures listed in tables and Appendix E <web link> for further information on how country level estimates were determined)

Appendix G: Methods used to derive estimates of regional and global numbers of IDUs and HIV positive IDUs

Estimates of the number of people who inject drugs:

A range of situations existed with respect to the amount of data available on the prevalence of injecting drug use or the number of people who inject drugs. The ways in which uncertainty was estimated around these estimates differed depending upon the amount of country specific data to hand (the calculated regional estimates and global total of the number of people who inject are presented in the paper):

1. Country-specific information available: If a country had a lower and higher estimate of IDU prevalence, the midpoint between these two estimates was taken. The exception to this was in countries where lower, mid and higher estimates were published (this was particularly notable in the case of the EMCDDA figures) in which case the three estimates provided were used.

2. One estimate of IDU prevalence (or IDU population size) available: in the situation where only one estimate of population prevalence or IDU population size was available, then the weighted global uncertainty limits around population prevalence were used. These were derived by estimating the weighted prevalence of low, mid and high IDU prevalence in countries where all three estimates were available (see #1 above). The amount of uncertainty (in terms of % variation less than and greater than the mid estimate) was estimated. For all regions with the exception of Sub Saharan Africa, this global % variation was then applied to each country where only one estimate had been derived in order to estimate an uncertainty range around the estimate. For those countries in Sub Saharan Africa where only one estimate of IDU prevalence was available the *regional* % variation was applied; this was done to better reflect the much greater uncertainty around the observed estimates in that region.

3. No estimate of IDU prevalence (or IDU population size) available but IDU had been reported: In this instance, the weighted regional prevalence was used. The methods for estimating uncertainty ranges described in #2 above were used to estimate uncertainty bounds.

4. No reports of IDU were found for the country: In countries where no documented evidence of injecting drug use occurring could be located, we assumed zero prevalence of injecting. Given this comprised 11% of the world's population aged 15-64 years it is possible that the resulting global estimate of the number of injecting drug users is likely to be an underestimate by assuming that there are no injectors at all in these countries.

For each region, the sum of all country estimates (as derived above) and their ranges was made. The "global" estimate comprised the addition of all regional estimates.

Estimates of the number of people who inject drugs who may be HIV positive

A range of situations existed with respect to the amount of data available on the prevalence of HIV among those who inject drugs. The ways in which uncertainty was estimated around these estimates differed depending upon the amount of country specific data to hand (the calculated regional estimates and global total of the number of people who inject and who may also be HIV positive are presented in the paper):

1. Country-specific information available: If a country had a lower and higher estimate of HIV prevalence, the midpoint between these two estimates was taken. The upper and lower estimates were derived by multiplying the lower estimate of IDU population size by the lower estimate of HIV prevalence; and the upper estimate of IDU population size by the upper estimate of HIV prevalence.

2. One estimate of HIV prevalence available: in the situation where only one estimate of HIV prevalence was available, then the weighted *regional* uncertainty limits around HIV prevalence were used. These were derived by estimating the weighted prevalence of low, mid and high HIV prevalence in countries where low, mid and high estimates were available (see #1 above). The amount of uncertainty (in terms of % variation less than and greater than the mid estimate) was estimated. This % variation was then applied to each country where only one estimate had been derived in order to estimate an uncertainty range around the estimate. For, Australasia, the Pacific Island States and Territories and the Caribbean only single estimates of HIV prevalence were available. To estimate uncertainty bounds for these three regions the weighted *global* uncertainty limits were applied.

3. No estimate of HIV prevalence available: In this instance, with the exception of the Pacific Island States and Territories, the weighted regional HIV prevalence was used for all countries without an estimate of HIV prevalence but where injecting drug use reported to occur. For the Pacific Island States and Territories the combined weighted HIV prevalence for this region and Australasia was applied. The methods for estimating uncertainty ranges described in #2 above were used to estimate uncertainty bounds in all regions.

4. No reports of IDU were found for the country: In countries where no documented evidence of injecting drug use occurring could be located, we assumed zero prevalence of injecting and of HIV among people who inject drugs.

For each region, the sum of all country estimates (as derived above) and their ranges was made. The "global" estimate comprised the addition of all regional estimates.